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Abstract 
Work on the mathematical modeling and data analysis of skin absorption with focus 
on finite dosing is presented within this thesis. It could be shown that correction of 
experimental data based on the area of application should be taken into considera-
tion depending on the drug's lipophilic character. Next, the influence of the lateral 
compartment for finite dose in-vitro skin mass balance was examined with the help 
three mathematical models that could satisfyingly predict or describe the experi-
mental data. Moreover, for two model drugs high amounts of substance could be 
found in the lateral skin compartment. Finally, a diffusion model was developed to 
predict in-vivo concentration-depth profiles (C-DP) with model input parameters 
gathered from in-vitro experiments. In addition, work on prediction of keratin bind-
ing is presented using an extended database. Furthermore, it could be shown that 
skin topography might have a considerable impact on skin absorption. Finally, a 
mathematical equation to correct Raman signal attenuation to improve non-invasive 
C-DPs of human skin is presented. In summary, it can be stated that the concepts 
and investigations at hand could improve experimental data, experimental setups 
and mathematical models in the field of skin absorption. 
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Kurzzusammenfassung 
Arbeiten auf dem Gebiet der mathematischen Modellierung und Analyse von 
Hautabsorption, mit einem Fokus auf finite Dosierung, werden in dieser Arbeit 
vorgestellt. Es konnte gezeigt werden, dass Abhängig von der Lipophilie der Sub-
stanz, die Korrektur experimenteller Daten, basierend auf der Applikationsfläche, in 
Betracht gezogen werden sollte. Der Einfluss des lateralen Kompartiments auf die 
in-vitro Massenbilanz bei finiter Dosierung wurde mit Hilfe dreier mathematischer 
Modelle untersucht, die experimentelle Daten befriedigend vorhersagen oder be-
schreiben konnten. Für zwei Modellsubstanzen konnten hohe Substanzmengen im 
lateralen Hautkompartiment gefunden werden. Zuletzt wurde ein Diffusionsmo-
dell, basierend auf aus in-vitro Experimenten stammenden Modelleingabeparame-
tern, entwickelt, um in-vivo Konzentrations-Schicht-Tiefenprofile (KST) vorherzusa-
gen. In Ergänzung werden Arbeiten auf dem Gebiet der Vorhersage von Keratin-
Bindung mit Hilfe einer erweiterten Datenbank vorgestellt. Außerdem konnte ge-
zeigt werden, dass die Hauttopographie Auswirkungen auf die Hautabsorption ha-
ben kann. Abschließend wird eine mathematische Gleichung zur Signaldämp-
fungskorrektur bei Raman-Spektroskopie vorgestellt, um nichtinvasive Messungen 
von KST der menschlichen Haut zu verbessern. Zusammenfassend lässt sich sa-
gen, dass die hier gezeigten Konzepte und Untersuchungen zur Verbesserung ex-
perimenteller Daten, Versuche und mathematischer Modelle im Bereich der Haut-
absorption beigetragen konnten. 
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Abbreviations 
A Application area 
 c(x,t) Concentration at position x and time t 
C0 Initial concentration 
 CAF Caffeine 
  D Apparent diffusion coefficient  
DSL Deeper skin layers (viable epidermis and parts of the dermis) 
 FD-C Franz diffusion-cell 
 FFA Flufenamic acid 
 FTS Full thickness skin 
 h Height 
  
HSE Heat-separated epidermis 
J Flux 
  Jpeak Peak flux 
  JSS Steady-state flux 
 k Boltzmann’s constant 
 Ki/j Partition coefficient regarding compartment i and j 
Ko/w Octanol-water partition coefficient 
kp Permeability 
 l Length  
  m(t) Accumulated permeated mass at time t 
MW Molecular weight 
 Q(t) Amount released over time t 
RSE Residual standard error 
 SB-M Saarbücken penetration model 
Abbreviations 
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SC Stratum corneum 
 SE Standard error 
 Sv Saturated concentration in layer v 
t Time 
  T Temperature 
 tlag Lag-time 
  V Volume 
  VE Viable epidermis 
 Ωi  Compartment i 
 Гi,j  Interface between compartment i and j 
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1.1 Transdermal absorption 
1.1.1 Skin morphology 
The human skin is by far the largest visible organ of the body (approximately 2 m2). 
On the one hand it forms an effective barrier between the organism and the envi-
ronment, preventing invasion of pathogens and impeding the absorption of chemi-
cals, on the other hand it prevents the unregulated loss of water and solutes from 
inside. 
Furthermore, the skin is responsible for metabolism and several other functions 
like the regulation of heat balance, sense of touch and protection against injuries. 
The outer skin can roughly be divided into three layers of epithelial tissue: 
• Epidermis 
• Dermis 
• Subcutis 
For in-depth information about the structure and function of the human skin the 
reader is kindly referred to [1, 2]. 
1.1.1.1 Epidermis 
The epidermis is the outermost layer and is responsible for the protective and wa-
terproofing properties of the skin. It features a thickness of about 100 – 150 µm. 
One specialty is the lack of blood vessels so that the deepest layers are nourished by 
diffusion from capillaries from the upper layers of the subjacent dermis. The main 
types of cells that are located inside the epidermis are Langerhans cells, Merkel cells 
and melanocytes, whereas the largest part (90%) ascribes to the keratinocytes [3]. 
The Langerhans cells are responsible for the immune response of the whole skin 
and Merkel cells are associated with the sense of touch. The human epidermis can 
be further subdivided into two main layers, the stratum corneum (SC) and the viable 
epidermis. 
Introduction 
 19 
The stratum corneum is the outermost layer of the epidermis, featuring a thickness 
of usually 10 – 25 µm (depending on body site) under physiological conditions, 
while it may swell to several times this thickness when immersed in water for long-
er periods of time. Despite the fact that it accounts to only a small fraction of total 
skin thickness the SC is by far the most effective barrier of the skin. Applying me-
chanical damage to the skin (e.g. via scalpel blade, sandpaper abrasion, adhesive 
tape stripping and suction blister top removal) showed a strong increase in permea-
bility [4]. The SC is composed of large, nonviable, cornified plate-like envelopes 
(corneocytes) filled with keratin (fibrous structural proteins) which are arranged in 
layers (15 – 25) [5]. They are almost non-permeable, are embedded in a continuous 
lipid matrix and originate from the basal layer of the epidermis, the stratum germina-
tivum. Due to this shape one can model this layer as a bricks and mortar model 
(Figure 1-1) where the bricks are the corneocytes and the mortar is the lipid matrix 
[6]. The keratin helps to provide a certain hydration level (approximately 30% in-vivo 
[7]) by preventing water evaporation. 
 
Figure 1-1  Bricks and mortar model of the stratum corneum (not drawn to scale). 
 
Finally the viable epidermis can be subdivided into several layers (from top to bot-
tom, Figure 1-2): 
• Stratum lucidum (only in palms of hands and bottom of feet) 
• Stratum granulosum 
• Stratum spinosum 
• Basal membrane (stratum germinativum) 
1.2 Structure of the Human Skin
Finally the viable epidermis can be subdivided into several layers (from top to bottom), as depicted
in Figure 1.2:
• Stratum lucidum (only in palms of hands and bottom of feet)
• Stratum granulosum
• Stratum spinosum
• Basal membrane (stratum germinativum)
The viable epidermis provides protection against exposure to ultraviolet light (via production of
melanin – a pigment).
Lipid matrix
Corneocytes
Figure 1.3: The well-known ”Bricks and Mortar” model of SC.
Dermis
The dermis has a thickness of 3 – 5 mm and is thus forms the thickest layer of the skin. It is
mainly composed of fibroblasts which are responsible for the production of collagen and elastin
fibres. Sensoric nerves, blood and lymphatic vessels, hair follicles and sweat glands are also
located inside this thick layer. The elastic fibers are responsible for the flexibility of the skin and
the ability to adap to pressure.
Subcutis
The subcutaneous fat layer acts as a conjunction between the overlying dermis and the underlying
body tissue. The thickness depends highly on the site of the body and physical condition of the
person. It is composed of loose fat, connective tissue, blood vessels and nerves. The main purpose
of this layer is to isolate the body, provide mechanical protection against physical shock and serve
as an energy reservoir.
3
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The viable epidermis provides protection against exposure to ultraviolet light (via 
production of melanin – a pigment). 
1.1.1.2 Dermis 
The dermis has a thickness of 3 – 5 mm and thus forms the thickest layer of the 
skin. It is mainly composed of fibroblasts which are responsible for the production 
of collagen and elastin fibres. Sensory nerves, blood and lymphatic vessels, hair fol-
licles and sweat glands are also located inside this thick layer. The elastic fibers are 
responsible for the flexibility of the skin and the ability to adapt to pressure. 
 
Figure 1-2  Simplified morphology of the epidermis. Adapted from [8]. 
 
1.1.1.3 Subcutis 
The subcutaneous fat layer acts as a conjunction between the overlying dermis and 
the underlying body tissue. The thickness highly depends on the site of the body 
and physical condition of the person. It is composed of loose fat, connective tissue, 
blood vessels and nerves [1]. The main purpose of this layer is to isolate the body, 
provide mechanical protection against physical shock and serve as an energy reser-
voir. 
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Figure 1.1: Schematic illustration of the three main layers of human skin[1].
The stratum corneum (SC) is the outermost layer of the epidermis, featuring a thickness of usually
10 - 25 µm (depending on body site) under physiological conditions, while it may swell to several
times this thickness when immersed in water for longer periods of time. Despite the fact that it is
just a small part (compared to the tot l th ckness of the sk n) the SC is by far the most e↵ective
barrier of the skin. Applying mechanical damage to the skin (e.g. via scalpel blade, sandpaper
abrasion, adhesive tape stripping and suction blister top removal) showed a strong increase in
permeability[3].
The SC is composed of large, nonviable, cornified plate-like envelopes (corneocytes) filled with
keratin (fibrous structural proteins) which are arranged in layers (15 – 25). They are almost
nonpermeable, are embedded in a continous lipd matrix and orginate from the basal layer of the
epidermis, the stratum germinativum. Due to this shape one can model this layer as a ”Bricks
and Mortar model” (Figure 1.3) where the bricks are the corne cytes and the mortar is the
lipid matrix[4]. The keratin helps to provide cert in hydrat on level (only 30% in vivo[5]) by
preventing water evaporation.
Figure 1.2: The five layers of epidermis. Adapted from [6].
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The stratum corneum (SC) is the outermost layer of the epidermis, featuring a thickness of usually
10 - 25 µm (depending on body site) nder physiological conditions, while it may swell to several
times this thickness when immersed in water for longer periods of time. Despite the fact that it is
just a small part (compared to the total thickness of the skin) the SC is by far the most e↵ective
barrier of the skin. Applying mechanical damage to the skin (e.g. via scalpel blade, sandpaper
abrasion, adhesive tape stripping and sucti n blis e top removal) showed a strong increase in
perme bil ty[3].
The SC is composed of large, nonvi ble, cornified plat -li e envelopes (corneocytes) filled with
keratin (fibrous structural proteins) which are arranged in layers (15 – 25). They are almo t
nonpermeable, are embedded in a continous lipd matrix and orginate from the basal layer of the
epidermis, the stratu g rm nativum. Due to th shape one ca model this layer as a ”Bricks
and Mortar model” (Figure 1.3) w ere the bri re the corneocytes and th m r ar is the
lipid matrix[4]. The keratin helps to p ovid a certain hydratio lev l (on y 30% in vivo[5]) by
preventing water evaporatio .
Figure 1.2: The five layers of i fro [6].
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1.1.2 Transport pathways through the skin 
While for healthy skin the barrier function is typically located in the stratum 
corneum, the bottleneck for invasion of very lipophilic substances shifts down to the 
conjunction of stratum corneum and viable epidermis due to their reduced solubility 
in the aqueous epidermis layers [9].  
Based on the anatomical structure of the skin, two basically different pathways for 
substance invasion are to be considered: 
• Diffusion across the intact SC, the outermost layer of the skin. 
• Invasion via skin appendages such as hair follicles or glands. 
Normally, the route through the intact SC accounts for the main pathway of skin 
absorption, especially if small and dissolved molecules are concerned. However, for 
nanoparticles or submicron-sized drug delivery systems, for example liposomes and 
nanoparticles, the appendageal pathway may be predominant [10-12]. An additional 
mechanical rubbing, e.g. a massage, will improve the appendageal delivery. Moreo-
ver, for healthy skin it has been reported that nanoparticles > 10 nm are unlikely to 
overcome the stratum corneum barrier [13].  
Governed by the anatomical structure of the intact stratum corneum the following 
absorption pathways are feasible: The intercellular route and the transcellular route. 
The intercellular route is associated with the lipid bilayer structures in between the 
corneocytes and is considered to be the predominating invasion route, particularly if 
steady state conditions are assumed. It has been shown that transepidermal water 
loss is strongly increased and the permeability is strongly enhanced after lipid ex-
traction of the epidermis [14, 15]. Due to the liquid crystalline structures of the lipid 
matrix surrounding the corneocytes, the intercellular route provides hydrophilic as 
well as lipophilic domains offering the possibility that both lipophilic and hydro-
philic entities diffuse via this pathway. Although the intercellular route is very tortu-
ous and therefore much longer (e.g. a factor of approximately 13 in comparison to 
the macroscopic thickness of the SC for an unexpanded membrane [16]), the diffu-
sion is relatively fast in this region due to an enhanced diffusivity in comparison to 
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the corneocytes. Furthermore, this pathway can easily be modulated by penetration 
enhancers.  
 
Figure 1-3  Illustration of the four possible substance absorption routes in human skin  
    (adapted from [17]). A: Intercellular diffusion, B: Transport pathway trough hair 
    follicles and sweat glands, C: Transcellular pathway, D: Micro-scale holes in  
    the  skin. 
The transcellular route is normally regarded negligible because diffusion in the sol-
id corneocytes is low and the necessity to partition several times between the lipid 
bilayers and the more hydrophilic corneocytes. Both phenomena result in a reduced 
absorption with the exception if penetration enhancers are used which might in-
crease the permeability of the corneocytes.  
As a result of the various possibilities for substance invasion through and into the 
stratum corneum, in-vitro skin absorption experiments must take into account these 
different pathways. 
In diseased skin the barrier function is reduced because of structural changes in the 
stratum corneum. For example, the lipid bilayer structure is partly lost or the number 
of stratum corneum layers may be reduced. An illustrated overview with regard to the 
different transport pathways is given in Figure 1-3. 
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1.2 Experimental methods to investigate transdermal drug 
transport 
As an easy accessible organ, for a long time our skin is used for the application of 
cosmetics and furthermore also for the topical application of drugs [18]. Primarily, 
however, the skin is actually a protective organ hindering the invasion of foreign 
substances from the environment to our body and to maintain homeostasis. There-
fore, different reasons exist to monitor the fate of compounds in contact with the 
skin. For example, to assure that no absorption occurs (cosmetics or hazardous sub-
stances) or vice versa to demonstrate that skin absorption does take place, indeed 
(drug delivery). While the motivation and scope for skin absorption studies might be 
different, the same experimental setups can be used to gather the desired infor-
mation. In contrast to clinical studies or animal experiments, in-vitro skin absorp-
tion studies allow the screening of different formulations, without any ethical re-
strictions, which is a particular problem for cosmetics where animal experiments 
have been banned [19, 20]. Actually, information about xenobiotic in-vitro skin ab-
sorption is requested explicitly by the EU initiative REACH – Registration, Evalua-
tion, Authorization and Restriction of Chemicals [21]. Besides these advantages, the 
major drawback of in-vitro skin absorption studies is the absence of peripheral blood 
flow that cannot be simulated completely. Furthermore, concerning risk assessment 
the acceptance of in-vitro skin absorption data by the authorities are different.  
In the European Union, dermal absorption data for many pesticides has been esti-
mated by in-vitro experiments [22, 23]. In contrast NAFTA countries (the USA, Can-
ada and Mexico [24]) do not accept in-vitro skin absorption data alone for risk as-
sessment. However, most of the skin absorption data published in the field of cos-
metic and pharmaceutical sciences is based on in vitro skin absorption studies. 
The following sections address common in-vitro test systems and analytical methods 
for the two major types of skin absorption experiments: "Skin permeation" and 
"skin penetration" experiments. Skin permeation measurements focus on the 
amount of substance transported across the skin (or parts of the skin) over time. 
This is especially important for questions regarding systemic delivery of drugs or 
risk assessment with respect to exposure to hazardous substances. 
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In contrast, skin penetration measurements deal with the investigation of drug con-
centration distribution in different skin layers over time. These investigations are 
typically important to answer questions regarding local application of drugs. 
1.2.1 Methods to investigate skin permeation 
In-vitro skin permeation experiments are generally performed using diffusion cells, 
whose donor and acceptor compartments are separated by excised skin or one or 
more of its composing layers. The cells are usually made of glass although other 
materials are in use as well. Diffusion cells can be classified into two major types, 
static and flow through cells. In static cells, donor, membrane and acceptor may be 
arranged either vertically as in the well-known Franz diffusion cell (Figure 1-4 A) 
[25] or horizontally (side by side) as in the (Teflon) Bronaugh cell (Figure 1-4 B) [26]. 
Usually, the acceptor solution is stirred by magnetic stir bars and the whole system 
is thermostatically controlled. Side by side cells can be used for measurement of 
permeation from one stirred solution through a membrane into another stirred so-
lution which might be advantageous for, e.g., testing permeation from a saturated 
solution in the presence of excess solid [27]. 
Flow through cells are usually similar to the upright Franz diffusion cells but with 
certain modifications that allow the continuous replacement of the acceptor solution 
with the aid of a pump (Figure 1-4 C). This might be useful for permeants of very 
low solubility as a tool to provide sink conditions such as in the case of highly lipo-
philic drugs that easily saturate the acceptor solution in the static type of cells [28, 
29]. Another possible advantage of the flow through system is achieved by using a 
tissue culture medium as acceptor solution that continuously flows under the skin, 
so that local metabolism can be studied and the system has higher similarity to the 
in-vivo situation [30]. However, care should be taken to avoid high dilution that 
might lead to detection or analytical problems. Furthermore, parameters like flow 
rate or sampling interval can have a considerable impact on the curve shape and 
hence on the estimated parameters [31]. Detailed review of the different types and 
design of diffusion cells are available in literature [32]. 
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When performing permeation experiments, samples from the acceptor solution are 
withdrawn after pre-determined time intervals and assessed for cumulative amount 
of permeant. The amount of substance in the barrier itself is usually not deter-
mined. 
Different preparations and layers of excised skin may be used as the barrier, for ex-
ample stratum corneum sheets or epidermis or dermatomed skin. 
 
A    B  
C    D  
Figure 1-4  Sketch of a static vertical Franz diffusion-cell (A), static side-by-side diffusion 
    cell, flow through cell (C) and Saarbruecken penetration model (D). 
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1.2.2 Methods to investigate skin penetration 
While the total amounts of permeant in the acceptor solution and in the barrier al-
ready allow for assessing the transport process across the skin, the concentration-
depth profile of a permeant in the different skin layers may be even more valuable. 
Concentration-depth profiles are time dependent and vary with the permeant's 
physicochemical properties. 
One of the most commonly performed experiments to evaluate the change in per-
meant concentration within the SC both in-vitro and in-vivo is tape stripping [27]. In 
short, drug formulations are applied to the skin and after a pre-determined time 
tape stripping is performed. Subsequently, the drug may be extracted from the tapes 
to quantify the amount of drug which has penetrated into the SC. 
The removal of sequential layers of the SC using adhesive tapes is considered to be 
minimally invasive and suitable for bioequivalence studies [33, 34]. A good correla-
tion between the amount of drug recovered on the strips and that having entered 
systemic circulation was also found [35, 36]. In-vivo, tape stripping can be performed 
with minimal discomfort and relative ease on the volar forearm of healthy volun-
teers [36]. To improve the contact of the tape to the skin in-vitro, pressure on the 
tape may be applied using a roller [11] or a defined weight [37, 38]. For further in-
formation on the tape stripping procedure, the reader is kindly referred to [39, 40]. 
To establish concentration-depth profiles in the SC, the thickness of the removed 
layer and the location in the skin are required. Here, difficulties arise primarily 
from the change in cohesion between the corneocytes with SC depth. For example, 
the outer layers seem to be less densely bound and therefore can be easily removed 
in comparison to the deeper more intact layers [41]. As a consequence, the amount 
of SC removed per tape strip follows an exponential decay curve [42, 43]. 
1.2.2.1 The Saarbrücken penetration model 
The Saarbrücken penetration model (SB-M) is a model to study the rate and extent 
of drug penetration into the stratum corneum and the deeper skin layers in-vitro [38]. 
In this type of experiment, a semisolid drug formulation or a piece of filter paper 
soaked in a drug solution is applied to the skin surface placed in a Teflon block on a 
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filter paper soaked with Ringer solution to prevent drying of the skin. Subsequently, 
a Teflon punch containing the formulation is placed on the skin and charged with a 
weight for two minutes in order to improve the contact between the skin and the 
drug preparation [38, 44]. Thus, this setup avoids the relatively non-physiologic hy-
dration which may occur when using FD-Cs. The skin itself is the only acceptor for 
the penetrating drug and the penetration of the drug into the different skin layers is 
followed by skin segmentation and further analysis of the drug concentration in 
these segments. Therefore, data obtained from SB-M are mainly related to the drug 
concentration in the different skin layers without giving any details about drug 
permeation or flux through the skin, which can be better investigated using a FD-C. 
However, a direct correlation between the penetration data obtained from SB-M and 
the permeation parameters from FD-Cs for the lipophilic drug flufenamic acid was 
found [45]. 
1.2.2.2 Optical methods 
Optical methods such as confocal laser scanning microscopy (CLSM) or confocal 
Raman spectroscopy may be used as well to obtain semi-quantitative concentration-
depth profiles. Both are non-invasive imaging techniques that can be applied both 
in-vitro and in-vivo. However, until now quantitative measurements are not possible. 
With CLSM, images parallel to the skin surface at different depths are recorded that 
can then be reconstructed to obtain a three dimensional image for different skin 
structures and any permeant that penetrated the skin without any mechanical sec-
tioning of the skin [46]. As CLSM is mainly used to visualize the fate of fluorescent 
substances or carriers through the skin, experiments are mostly performed under 
infinite dose conditions (see next section) [11, 47].  
Raman spectroscopy has long been recognized as a standard method in analytical 
pharmacy and chemistry. In pharmaceutics and biopharmaceutics, it has been wide-
ly used to study biological skin samples [48] and in clinical dermatology, to study, 
e.g. atopic dermatitis [49] and basal cell carcinoma [50]. Similar to CLSM, confocal 
Raman spectroscopy may be used to obtain concentration-depth profiles [51, 52]. An 
advantage of this technique is that it is not necessary to label the diffusing mole-
cules as long as they are Raman-active. 
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Due to the optical density of skin, CLSM and confocal Raman spectroscopy do not 
allow inspection of deeper skin layers. 
1.2.3 Infinite and finite dosing 
Two scenarios may be distinguished according to the amount of substance applied 
to the skin, infinite and finite dosing. In the case of infinite dosing, the applied dose 
is so large that depletion of the permeant in the donor chamber caused by evapora-
tion or diffusion into and through the barrier is negligibly small. Consequently, the 
dose is considered to be constant and infinite [27]. In infinite dose experiments, the 
permeant is often applied in comparatively large volumes, which may exert an oc-
clusive effect and thus lead to an increased permeability, although this effect may 
already be observed for thin layers [53]. 
In contrast to infinite dose experiments with an infinitely large donor, in the finite 
dose regime, only a limited amount of the donor formulation is applied to the skin 
surface. The application of a finite dose supposedly best resembles the in-vivo situa-
tion when applying e.g., an ointment. Furthermore, special effects like the influence 
of evaporation of excipients can be observed. 
Per definition in the Organisation for Economic Co-Operation and Development 
(OECD) guideline 428 [54] and the guidance document 28 [55], finite dose skin ab-
sorption experiments are characterized by the application of ≤ 10 μl/cm2 of a liquid 
formulation to the skin. For semisolid and solid substances, values range from 1 to 
10 mg/cm2 [54-56]. 
For substances with low permeability, it may be difficult to observe donor depletion 
and to obtain the curve shapes characteristic for finite dosing [57]. 
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1.3 Mathematical background of analyzing skin absorption 
processes 
 
It is usually assumed that the travel of molecules through the skin membrane is 
governed simply by passive diffusion due to the absence of active transporters. 
From an atomistic point of view diffusion is based on Brownian motion of particles 
in virtue of their thermal energy. From an empirical and more macroscopic under-
standing the driving force of molecular movement is a concentration gradient of the 
diffusant in a medium and can be mathematically described by laws derived by 
Adolf Fick in 1855. 
Fick’s first law (Equation 1-1) relates the diffusion flux J (e.g. in mol/m2s) to the 
concentration gradient. Here D, the diffusion coefficient, is a proportionality con-
stant usually given in m2/s and c the concentration at point x in space and time t. 
𝐽 𝑥, 𝑡 = −𝐷∇𝑐 𝑥, 𝑡  Equation 1-1 
Assuming conservation of mass one can derive Fick’s second law of diffusion 
(Equation 1-2). 
𝜕𝑐 𝑥, 𝑡𝜕𝑡 = ∇ D  ∇𝑐 𝑥, 𝑡  Equation 1-2 
In this general equation the diffusion coefficient may vary in dependence of location 
and/or concentration. Additional terms can be included to address e.g. binding 
phenomena [58], enzymatic reactions [59], corneocyte desquamation [60] or general 
convective transport to model elimination or clearance of molecules into the sys-
tematic circulation [61]. For the one-dimensional case and a homogenous medium 
(constant diffusivity) Equation 1-2 simplifies to: 
𝛿𝑐 𝑥, 𝑡𝛿𝑡 = 𝛿𝛿𝑥 𝐷 𝛿𝛿𝑥 𝑐 𝑥, 𝑡  Equation 1-3 
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Homogeneity is often a strong simplification but a typical assumption for easy ana-
lytical models to describe transdermal drug transport. These parabolic partial differ-
ential equations can often be solved analytically for various initial and boundary 
conditions and various solutions are presented in Sections 1.3.1 and 1.3.2. As men-
tioned before, these conditions often denote simplifications and are only true for the 
description of a specific experimental setup (e.g. infinite dose or finite dose condi-
tions with certain initial conditions). This is a fundamental issue and must be al-
ways kept in mind when applying mathematical models in general. More flexible 
but complex models that allow the application to a wider range of scenarios can be 
solved by applying numerical concepts and are addressed in section 1.3.4. 
For the inhomogeneous and more general case the diffusion flux at a cross-section x 
at time t is directed from sites of higher chemical potential to sites of lower chemi-
cal potential (Equation 1-4 [62, 63]). Inhomogeneous media transitions change the 
classical diffusion problem to a diffusion-partition problem. 
𝐽 𝑥, 𝑡 = − 𝐷𝑘𝑇 𝑐 𝑥, 𝑡 𝛿𝜑 𝑥, 𝑡𝛿𝑥  Equation 1-4 
Here, ρ(x,t) is the chemical potential of the substance, T the temperature and k is 
Boltzmann’s constant. For the homogeneous case with ρ(x,t) = kT ln(c(x,t) and a 
constant diffusivity Equation 1-4 simplifies to the standard diffusion equation as 
stated in Equation 1-3. 
The general case equation that describes the diffusion-partion problem with the 
chemical potential defined as ρ(x,t) = kT ln((c(x,t)/K(x)) and the position-dependent 
partition coefficient K(x) is given by Equation 1-5 [62]. 
𝛿𝑐 𝑥, 𝑡𝛿𝑡 = 𝛿𝛿𝑥 𝐷 𝛿𝛿𝑥 𝑐 𝑥, 𝑡 − 𝐷 𝑥 𝑐 𝑥, 𝑡 𝛿𝛿𝑥 ln𝐾 𝑥  Equation 1-5 
Besides studies with variable partition and/or diffusion coefficients inside a certain 
skin layer [62] it is more common (especially for more complex multi-layer models) 
to assign specific diffusion coefficients to the different layers and specific partition 
coefficients to the interfaces of two adjacent layers. The presented solutions of the 
diffusion equation and determination of distinctive parameters almost exclusively 
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depend on predicted, fitted or experimentally determined diffusivities and partition 
coefficients. Therefore, at least a basic understanding of the relationship between 
molecular properties and the aforementioned parameters is essential when it comes 
to the preparation, setup and evaluation of transdermal skin transport. 
For spherical particles in a continuous fluid, the diffusion coefficient can be calcu-
lated by using the well-known Stokes-Einstein relation (Equation 1-6) with viscosity 
η of the solvent and particle radius r. 
𝐷 = 𝑘𝑇6𝜋𝜂𝑟 Equation 1-6 
For the diffusion in polymers it could be found empirically that for a small particles 
the following relationship holds [64]: 
𝐷 = 𝐷!!𝑀𝑊!!   
Equation 1-7 
Here, MW is the solute molecular weight and n and D0m are constants characteris-
tics of the membrane at a specific temperature. Other theories derived from poly-
mer research have also been applied successfully to the field of describing diffusivi-
ties in the skin domain. For deeper insight the interested reader is kindly referred to 
[65]. 
Where the diffusivity D denotes the speed of a diffusant through a membrane and is 
inversely related to the weight of the solute, the partition coefficient K accounts for 
jumps in concentrations at the interface of two adjacent skin layers and is often re-
lated to a measure of solute lipophilicity, most commonly the logarithmic octanol-
water partition coefficient. K is a thermodynamic parameter reflecting the relative 
affinity of a solute for a certain phase over another phase. Hence, the partition coef-
ficient between layer m2 and layer m1 can be defined as 
𝐾!!!! = 𝐶!!!"𝐶!!!"  Equation 1-8 
with 𝐶!!!"  and 𝐶!!!"  being the respective solute concentrations at the interface of the 
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two adjacent phases at equilibrium. In general, the partition coefficient is concentra-
tion-dependent but if the solubilities in the two phases are relatively low (which 
holds true for many cases) this effect can be neglected and the partition coefficient 
can be defined by using the saturation concentrations Sm1 and Sm2 in the different 
layers [66] with 
𝐾!!!! = 𝑆!!𝑆!! Equation 1-9 
A typical strategy is to establish a relationship between an easy to observe parameter 
that mimics the membrane properties and the parameter of interest. A prominent 
example is the ocanol/water partition coefficient Ko/w that could be related to the 
stratum corneum lipid phase/water partition coefficient Klip with the help of a linear 
free energy relationship [67]: 
𝐾!"# = 𝑎𝐾!/!!  
Equation 1-10 
Here, the constants a and b correspond to characteristics of the relationship be-
tween aqueous vehicle and lipid phase of the stratum corneum. It is obvious that this 
relationship strongly depends on the physico-chemical properties of the layers at the 
interface (e.g. donor/SC or viable epidermis/stratum corneum). 
It must be noted that representation of diffusivity and partition coefficient in a cer-
tain skin layer by a single number basically averages several transport mechanisms 
(e.g. several different routes trough the stratum corneum or implicit binding phe-
nomena) of the diffusant. This important fact must be kept in mind when develop-
ing and applying mathematical models as well as trying to generalize basic relation-
ships, such as Equation 1-7 and Equation 1-10. Since literally all mathematical mod-
els heavily oversimplify the underlying physics, parameters derived from mathemat-
ical concepts might obfuscate the governing mechanics. 
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1.3.1 Mathematical analysis of skin permeation 
As mentioned before, permeation experiments are usually performed to measure 
the amount permeated through the barrier over time in relation to the diffusion 
area. For an in-vitro setup this relates to the accumulated mass in an acceptor com-
partment. Typical concentration/mass/flux versus time profiles for the infinite, 
semi-infinite (volume larger than 10 μl/cm2, but with a depletion of the donor 
which is already perceptive) and finite dose cases are depicted in Figure 1-5. These 
theoretical calculations were performed using the DSkin® software1. An aqueous 
donor/acceptor with a drug diffusion coefficient of 6.33E-5 cm2/sec, stratum corneum 
lipid channel diffusion coefficient of 1.87E-8 cm2/sec and partition coefficient of 
6.56 was used for simulations. The initial donor concentration was set to 1 mg/ml 
and the donor volume for the semi-infinite dose and finite dose scenario was set the 
2 μl and 20 μl respectively for an area of diffusion of 1.767 cm2. A tortious stratum 
corneum lipid path length of 180 μm was assumed which corresponds to a swollen 
membrane for an in-vitro setup [16]. Perfect sink conditions of the acceptor com-
partment are assumed.  
The chosen values correspond to a model compound of approximate 300 Da with a 
logKO/W of 2 in an aqueous vehicle and model parameters were estimated by 
DSkin®. The concentration-over-time profile depicted in Figure 1-5 A shows the 
characteristic depletion of the donor for the finite dose case and less pronounced for 
the semi-infinite case. The barrier mass-over-time curve for an infinite dose setup 
does reach a plateau as soon as the steady-state is reached (Figure 1-5 B). As opposed 
to this, the mass of the finite dose case decreases after reaching a maximum (Figure 
1-5 B). In case of the infinite dose setup the accumulated mass inside the acceptor 
compartment reaches the typical straight steady-state line (Figure 1-5 C). This corre-
sponds to a plateau of the flux-over-time profile (Figure 1-5 D). In contrast the finite 
dose scenario will reach a theoretical mass plateau in the acceptor compartment if 
all substance has traveled through the membrane. Obviously the flux reaches a max-
                                                   
1DSkin® http://www.scientific-consilience.com (Developer: D. Selzer) 
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imum and subsequently decreases with time. For the simulation of the semi-infinite 
dose case shown in Figure 1-5 D the applied volume per area was set slightly higher 
than the finite dose threshold defined by the OECD [54, 55]. This shows clearly that 
the assumption of an infinite dose (no significant depletion) does not automatically 
hold by applying fixed volume-based rules.  
A B  
C D  
Figure 1-5  Theoretical change of concentration in the donor compartment over time (A), 
    change of mass inside the stratum corneum (B), accumulated mass inside the 
    acceptor compartment (C) and change of stratum corneum outgoing flux (D) for 
    infinite (solid line), semi-infinite (dashed line) and finite dosing (dotted line).  
    Simulations were performed using the DSkin® software. 
This is crucial when applying the mathematical concepts since choosing faulty as-
sumptions can lead to serious misinterpretation of experimental data. One has to 
keep in mind that even if small volumes of highly concentrated solutions are ap-
plied and the permeation is low, the system might behave like an infinite dose case 
due to the fact that significant donor depletion only occurs at very long experimental 
time periods in relation to the permeated solute amount in the acceptor compart-
ment. Investigation of infinite and finite dose experiments typically differ concern-
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ing their parameters of interest and application of mathematical concepts (e.g. ana-
lytical solutions of the diffusion equation are always tailored to certain boundary and 
initial conditions). In the next two sections analytical solutions of the diffusion 
equation and mathematical concepts for the most typical experimental settings are 
summarized. For an exhaustive compilation of solutions regarding the diffusion 
equation for various boundary and initial condition the author kindly refers to [63]. 
1.3.1.1 Investigations of infinite dose experiments 
Analysis of infinite dose in-vitro skin permeation is typically accomplished by meas-
uring the cumulative amount of substance inside the acceptor compartment over 
time. For short times the amount increases exponentially until reaching a steady 
line (the steady-state) with constant flux JSS (see Figure 1-6). From a mathematical 
point of view a few assumptions must be made to derive an analytical solution for 
the diffusion equation by defining initial and boundary conditions. In this case we 
assume a constant and steady concentration in the donor compartment, perfect sink 
conditions (zero concentration in the acceptor at all times) and that no compound of 
interest is located inside the barrier at time t = 0. 
 
Figure 1-6  Accumulated mass over time in the acceptor compartment of an infinite dose 
    experiment (solid line) and linear part of the steady state phase (dashed line). 
    The intersection of the linearized steady state phase and time-axis denotes the 
    lag-time. 
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By incorporating these rules, for a homogenous membrane the absorption curve 
can be described by an analytical solution of Ficks second law of diffusion [63, 68] 
with 
 
Equation 1-11 
Here A denotes the area of application, K is the partition coefficient between donor 
and barrier, C0 is the concentration of applied formulation in the donor which is 
assumed not to change significantly during experimental time periods, D is the 
macroscopic diffusion coefficient, l is the macroscopic thickness of the barrier and t 
is the time after application. It is obvious that with t leaning towards infinity (and 
hence reaching the steady-state) the solution simplifies to the linear part of the 
steady-state (Figure 1-6) with 
 
Equation 1-12 
From Equation 1-12 we can examine important parameters when it comes to analy-
sis of infinite dose experiments. The first parameter is the so-called apparent per-
meability coefficient kp which is often given in units of cm/h and is defined as 
 
Equation 1-13 
It is independent of area of application and initial concentration and hence a direct 
parameter for the strength of permeation for a compound through a certain barrier 
from a specific vehicle under infinite dose and perfect sink conditions. Mathemati-
cally it denotes a normalization of steady-state flux JSS with 
 
Equation 1-14 
Such parameters might heavily depend on experimental conditions. Hence, this has 
to be kept in mind when comparing parameters (inter-laboratory and intra-
laboratory). Although kp may be a useful and popular parameter when it comes to 
examination of permeation experiments it can be sometimes misleading when 
comparing the permeation of several compounds [66, 69]. The apparent permeabil-
ity coefficient kp describes an intrinsic property of a solute to permeate across a spe-
cific medium (for example the skin) which is independent of the dose but influ-
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enced by the applied vehicle. Therefore comparisons are only possible between 
compounds which are applied in identical vehicles. In 2006 Sloan et al. introduced 
a change of paradigm when it comes to explaining experimental data [70]. They 
suggested using the more expressive parameter Jmax which denotes the maximum 
possible flux of a solute through a barrier for comparing permeability. By using Jmax 
it is possible to overcome the limitations addressed before with: 
 
Equation 1-15 
Here, Sv is the saturated permeant concentration in the vehicle and Sm is the solu-
bility of the solute within the barrier. In other words, by removing the influence of 
the partition coefficient between skin and vehicle, Jmax should be independent of the 
vehicle applied. Thus, it describes an intrinsic permeability of a solute in a certain 
medium making it an ideal parameter to compare permeability of different solutes. 
Obviously, this is the case as long as the vehicle does not affect the transport kinet-
ics in the barrier [71]. In contrast to epidermal kp which is optimally correlated to the 
molecular weight and lipophilicity of a compound [72-74], Magnusson et al. could 
show that molecular weight is the main determinant when is comes to predicting 
solute maximum flux [75]. 
A further parameter to characterize infinite dose absorption is the so-called lag-time 
tlag given by 
 
Equation 1-16 
It is a measure that relates to the time it takes for a compound to travel trough the 
barrier and ro establish a steady-state. A word of caution is necessary concerning the 
meaning of tlag. tlag does not directly represent the time when the steady-state is 
achieved (see Figure 1-6), however it can be approximated by multiplying tlag with 
2.7 (Crank showed that steady- state is achieved when  approximately 
(Crank,1975)). 
 
Jmax = kp ⇥ Sv = D ⇥ Sm
l
tlag =
l2
6D
Dt
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1.3.1.2 Investigations of finite dose experiments 
In contrast to the infinite dose exposure scenario a typical finite dose absorption 
profile does not reach a steady-state, but builds a mass plateau inside the acceptor 
compartment at late time points (Figure 1-5 C). Finite dose experiments also show a 
characteristic depletion of donor concentration (Figure 1-5 A) and increase in flux 
until reaching the so-called peak flux Jpeak at time tpeak (Figure 1-7). As opposed to the 
infinite dose case, deduction and application of an analytical solution for the de-
scription of absorption curves requires a more sound mathematical foundation. 
Based on the theory of heat flow by Carslaw and Jaeger a description of the flux of 
the compound leaving the barrier at time t is given by the following equation [76, 
77]: 
 
Equation 1-17 
with 
 
Equation 1-18 
and the roots of the transcendental equation, αi, given by 
 Equation 1-19 
Here, M∞ denotes the applied mass and hv is the height of the formulation in the 
donor compartment. The remaining parameters keep their meaning as introduced 
above. 
 
Figure 1-7  Sketch of outgoing flux across the barrier-acceptor interface over time of a finite 
    dose experiment (solid line). The maximum of the the curve denotes the peak 
    flux Jmax at time to peak flux tmax . 
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Integrating Equation 1-17 yields the accumulated mass per area [78] with 
 
Equation 1-20 
In comparison to Equation 1-11 for the infinite dose case solving Equation 1-20 re-
quires a more skillful evaluation since Equation 1-20 must be solved for arbitrary 
values of i. A basic strategy to solve the transcendental equation is to use logistic 
regression to tabulated values of the first roots (see Figure 1-8). To find further roots 
a subsequent linear extrapolation from previous roots (rootn = 2 × rootn-1 - rootn-2) 
followed by a refinement step (root finding with e.g. Newton’s method) [78] is key.  
 
Figure 1-8  First five roots of the transcendental Equation 1-19 for continuous values of β 
    from 0 to 5. Values fitted by logistic regression to tableted values from Crank [63]. 
 
Important parameters for evaluation of finite dose permeation experiments are the 
peak flux Jpeak and time to peak flux tpeak. 
A general strategy to easily find Jpeak and tpeak is finding the root of the first derivative 
of J(t) and hence solving the following equation for tpeak: 
 
Equation 1-21 
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A reliable solution for the root finding problem is e.g. Brents method [79]. For small 
doses (β < ∼ 0.1) Jpeak and tpeak can be calculated by the following simple equations 
[78, 80]: 
 
Equation 1-22 
 
Equation 1-23 
For the finite dose case, finding a parameter related to the permeability coefficient is 
obviously not possible since the flux changes with time. However, in 1974 Scheu-
plein defined the so-called transfer coefficient kt with units of percentage of dose per 
time [78, 80] with: 
 
Equation 1-24 
He used the early flux of the linear part of the curve to estimate the fraction of ab-
sorbed dose after a certain time by multiplying kt by t. Besides the fact that this pa-
rameter depends on the applied dose, the amount will be heavily overestimated 
when the flux drops and leans towards zero. These two major drawbacks tremen-
dously limit the usefulness of this parameter. 
It has to be kept in mind that finite dose kinetics are also prone to variability of drug 
distribution in the donor, as shown in Chapter 3 and drug distribution to the non-
incubated lateral parts in an Franz diffusion-cell setup (see Chapter 4) yielding a 
high variability in fitted parameters. 
1.3.2 Mathematical analysis of skin penetration 
Besides permeation profiles (accumulated mass over time) which provide valuable 
information about the absorption process and the transport to the blood circulation 
and deeper tissue, skin-concentration depth profiles supply precious data about the 
distribution of solute inside the barrier over time. 
As for permeation experiments the kinetics clearly differ for different exposure sce-
narios. Figure 1-9 shows theoretical skin-concentration depth profiles for the infi-
nite dose case (Figure 1-9 A), semi-infinite dose case (Figure 1-9 B) and finite dose 
case (Figure 1-9 C). These curves were produced with the help of the DSkin® soft-
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ware and show the change of concentration over time and space in the stratum 
corneum. The used input parameters correspond to the simulation parameters used 
to produce the permeation curves in the previous section. 
The infinite dose curves show the typical exponential decay for short exposure times 
and transition into a straight line when steady-state is reached (Figure 1-9 A). The 
semi-infinite case shows comparable kinetics at short times, reaches a pseudo 
steady-state with a straight line that will drop due to the depletion of the donor over 
time (Figure 1-9 B). For the finite dose scenario a straight line in the concentration 
over space kinetics is typically not reached and a significant drop can be recognized 
over time (Figure 1-9 C). 
As for permeation experiments analytical solutions for the diffusion equation can be 
obtained to describe the change of concentration over time and space by using the 
appropriate initial and boundary conditions. For the infinite dose case, assuming a 
homogeneous membrane one can calculate the concentration inside the barrier at 
point x and time t [63] with 
 
Equation 1-25 
As for the permeation case, K denotes the barrier/vehicle partition coefficient, C0 
the initial concentration in the vehicle, D the apparent diffusivity and l the macro-
scopic thickness of the barrier membrane with 0 ≤ x ≤ l. The equation can only be 
applied if the donor does not deplete over time (typical infinite dose assumption), 
the receptor compartment is kept at a theoretical zero concentration (perfect sink 
conditions) and no solute is present inside the barrier at t = 0. Obviously, only the 
passive diffusion process is modeled. Hence, permeation enhancement, binding 
phenomena, convection effects are not part of the model. 
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A B  
C  
Figure 1-9  Theoretical change of concentration in the barrier over time for the infinite dose 
    (A), semi-infinite dose (B) and finite dose (C) case. Simulations were performed 
    using the DSkin® software. 
Equation 1-25 can be of great benefit to estimate values for partition coefficient (K) 
and diffusion coefficient (D) and extrapolate the skin-concentration depth profile 
for later time points [81] or even other exposure scenarios (see Chapter 4 and 
[82]). For late times the skin-concentration depth profile will reach steady-state and 
Equation 1-25 simplifies to 
 
Equation 1-26 
Obviously, information about diffusivity can only be obtained before the steady-state 
is reached. Hence, in order to obtain kinetic parameters fitting Equation 1-25 to ex-
perimental data should focus on short incubation times. 
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For the finite dose case an analytical solution for the diffusion equation can be ob-
tained with α and β (as defined earlier in Equation 1-18 and Equation 1-19) [78]: 
 
Equation 1-27 
As for the infinite dose case the same limitations hold (e.g. perfect sink conditions 
and no solute in the barrier at t = 0). 
1.3.3 Pharmacokinetic models in skin absorption 
Compartmental or pharmacokinetic models (PK) are used since the early begin-
nings of mathematical description to study the fate of a substance that was applied 
in the systemic circulation and are also part of the history of describing transdermal 
drug absorption. They treat the body as a series of well-stirred compartments. The 
basic idea is the elimination of space dependence of the partial differential diffusion 
equation (Equation 1-2) to obtain a series of ordinary differential equations (ODEs) 
that describe the change of amount of solute in different compartments over time. 
For the family of PK models a set of first-order rate constant can be assigned to de-
note the transfer of a compound from one compartment to another. Figure 1-10 
shows two examples of skin compartment models: a one-compartment skin model 
and a two-compartment skin model. 
The corresponding first-order ODE of the one-compartment model can be expressed 
by the following expression: 
 
Equation 1-28 
For the two-compartment model the following equations hold, respectively: 
 
Equation 1-29 
 
Equation 1-30 
The separation of the skin in a lipophilic part (the stratum corneum) and hydrophilic 
part (viable epidermis) is common practice to mimic the heterogeneity of the skin [83, 
84]. 
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A  
B  
Figure 1-10  Exemplary sketch of a one-compartment (A) and two-compartment (B) skin 
     model. Here, the number denotes the number of compartments used to  
     describe the skin barrier, rather than the number of overall compartments. 
     C denotes to the average concentration  in the compartment, assuming  
     simplified well-stirred conditions and V is the volume of the compartment 
     that is accessible for the solute distribution. 
 
The underlying ODEs can be solved either analytically (for the most part only for 
easy equations) or numerically. Numerical solvers for non-stiff equations are for 
example Euler’s method or the fourth-order Runge-Kutta method (widely known as 
RK4). For stiff equations the Backward Differentiation Formula (BDF) is a well 
known algorithm.  
In comparison to solutions of the diffusion equation, using compartmental models 
can have some advantages. (A) Obviously, the solution of a set of ODEs can often be 
derived with little hassle in comparison to complex multi-compartmental diffusion 
models which are more cumbersome mathematically. For simple models even ana-
lytical solutions can be derived with ease. (B) Complicated exposure scenarios with 
e.g. periodic application or evaporation can be implemented very easily in compari-
son to complex diffusion models. (C) Adding systemic PK models to a skin PK 
model can be achieved with little overhead. (D) Even numerical integration of the 
ODE is typically much faster than solving the diffusion equation numerically. 
One big drawback comes with the oversimplification of having well-stirred com-
partments that obviously does not reflect reality. Certain kinetics, such as the transi-
tion of first-order to zero-order characteristics can only be described unsatisfactorily. 
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PK models were typically used in the past to analyse in-vivo data [85, 86]. A lot of 
effort was spent to relate rate constants to physicochemical parameters of the dif-
fusant and fit experimental plasma-curves or in-vitro permeation profiles to PK 
models [87, 88] generally with less success than for the class of diffusion models 
[65]. Despite a growing trend towards numerical diffusion models, the class of PK 
models recently regained attention by the work of Davies et. al [89]. They showed 
that an efficient skin compartmental model can be constructed by a two-layer ap-
proach. For excellent overviews on PK models the interested reader is kindly re-
ferred to references [83, 90, 91]. Besides PK models, in 1992 Seta and coworkers 
presented another compartmental approach and successfully studied the transport 
of radiolabeled hydrocortisone through hairless guinea-pig skin using three skin 
layers (stratum corneum, viable epidermis and dermis) [84]. They divided each com-
partment in several hypothetical thin elements and calculated the flux between each 
element. This approach can be numbered among compartmental models but rather 
trends towards numerical finite differences approaches. 
1.3.4 Numerical solutions of the diffusion equation 
Numerical methods for solving the diffusion equation for various initial and bound-
ary conditions are important techniques and allow a more flexible construction of 
advanced skin models (e.g. incorporation of binding effects [92], iontophoretic 
transdermal delivery [93], repeated applications [94], controlled release vehicles [95] 
and in-vitro lateral transport (see Chapter 4). In comparison to classical PK skin 
compartment models (see previous section), it is typically much more convenient to 
relate the necessary input parameters (for the simple diffusion problem only diffu-
sivities and partition coefficients are needed) to physicochemical parameters of the 
diffusant [65]. These models can be used for descriptive and predictive tasks as well 
as for the theoretical investigation of the interplay among input parameters.  
The basic idea consists of the discretization of time and space domain (gridding) 
and a numerical approximation of the partial differential diffusion equation (e.g. for 
the most trivial form see Equation 1-2). The discretization allows the construction of 
coarse-grained macroscopic and fine-grained microscopic models (a basic example 
is depicted in Figure 1-11). 
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A B  
Figure 1-11  Simplified depiction of a macroscopic diffusion model with effective diffusivi-
     ties and partition coefficients (A) and a microscopic representation of the 
     brick-and-mortal structure [6] of the stratum corneum (B) with diffusivities 
     and partition parameters for the lipid and the corneocyte phase. Figures are 
     not drawn to scale. 
 
Macroscopic models do neglect the heterogeneity of different skin layers and use 
effective kinetic parameters of a diffusant for each layer to describe the transport 
process. Usually, these kind of models are only needed for solving the underlying 
diffusion equation for the one-dimensional case and hence treat the skin as a series 
of multi-layered slabs (Figure 1-11 A). Microscopic models allow a heterogeneous 
representation of the stratum corneum [96] (lipid phase and protein phase, see Fig-
ure 1-11 B and hence yield a more in-depth analysis of the underlying transport pro-
cesses. In this case, the absorption kinetics do not only rely on the definition of dif-
fusion parameters but also on the definition of spatial geometry. Due to the high 
spatial resolution these models typically require much higher computational costs 
in comparison to coarse-grained macroscopic models. By mathematical homogeni-
zation it is possible to reduce a microscopic model to a macroscopic one with 
preservation of model properties (e.g. anisotropic diffusivity in the stratum corneum) 
(see Chapter 4 and [97]). 
From a numerical perspective, several techniques exist to approximate the solution 
of the diffusion equation. For the one-dimensional case, probably the most promi-
nent method is the finite differences approach. Assuming a constant diffusivity 
Equation 1-2 can be approximated by 
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Equation 1-31 
The left-hand side of the equation is approximated by first-order forward differences 
and the right-hand by second-order central differences that both arise from Taylor 
series expansions. As for every numerical method, the time and space domain is 
discretized. In this case Ci
t denotes the concentration at point i×∆x for time t×∆t 
with a system of constant space step size ∆x and time step size ∆t. Obviously the 
above mentioned equation can be easily generalized to problems in 2D and 3D 
space. Reformulation of Equation 1-31 yields 
 Equation 1-32 
with 
 
Equation 1-33 
Because of the fact that every point of a certain layer only depends on points from 
the past there is no functional relationship between different points of one time lay-
er (it is a so-called uncoupled problem). This leads to the problem of numerical insta-
bilities that depend on the value of M (Equation 1-33) and hence on the choice of ∆t 
for a given spatial resolution ∆x. It can be shown that this explicit method is only 
stable for values of M ≤ 0.5 (for the one-dimensional case). A violation of this rec-
ommendation can produce noise which may result (empirically it always does for 
the diffusion equation) in non-smoothable rounding errors. For small diffusion co-
efficients (e.g. in the stratum corneum) this restriction can lead to extremely small 
time steps and therefore to high computational runtimes. 
An elegant way to overcome this problem is the use of implicit methods that rely 
not only on data from the last time point (Figure 1-12).  
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Figure 1-12  Implicit finite differences method. Orange points indicate unknown values, 
     yellow points represent known values. 
Undoubtful, the most widely used approach is the so-called Crank-Nicolson method 
[63] (Equation 1-34 and Figure 1-13) that is unconditionally stable and provides a bet-
ter overall error than the explicit approach. 
 
Equation 1-34 
 
 
Figure 1-13  Crank-Nicolson method with the additional artificial time layer (with blue  
     point). Orange points indicate unknown values, yellow points represent  
     known values. 
This equation yields a system of linear equations (Equation 1-37) that can be effi-
ciently solved by e.g. the Thomas algorithm (an optimized form of Gaussian elimi-
nation that can solve tridiagonal systems of equations).  
2.2 Solving Fick’s Second Law Numerically
One big advantage is the fact that every cm+1i only depends on three constant values from the
previous time layer m. Given initial values, it is straightforward to parallelize the computation
of every time layer. Also the implementation is really easy, because we do not have to solve a
system of linear equations as we have to do in the following approaches.
But this convenience comes at a price. Because of the fact that every point of a certain layer
only depends on points from the past there is no functional relationship between di↵erent points
of one time layer (it is about an uncoupled problem). Therefore we pay the price of numerical
unstability which forces us to only use small time steps.
This choice of the length of a time step is a↵ected by the module M from Equation 2.17. It
can be shown that the explicit method is only stable for values of M  0.5[17]. A violation
of this recommendation can produce noise which may result (empirically it always does) in non
smoothable rounding errors. The complexity of the (global) error is O( t, x2).
2.2.3 An Implicit Finite Di↵erences Method
This implicit method uses again Equation 2.14 for discretization of time and also the same method
to discretize the right hand side of Fick’s second law. However the method uses the values of the
actual time layer that results in the following equation:
cm+1i   cmi
 t
= D
cm+1i 1   2cm+1i + cm+1i+1
 x2
(2.22)
By transposing the previous equation one arrives at:
(2M + 1) cm+1i  M
 
cm+1i 1 + c
m+1
i+1
 
= cim (2.23)
An illustration of this method is given in Figure 2.4. It is obvious that we have to solve a system
of linear equations for every new time layer.
diffusion space
time
Figure 2.4: Implicit finite di↵erences method. Orange points indicate unknown values, yellow points represent
known values.
With the help of the following matrix
A =
2666666664
(2M + 1)  M 0 · · · 0
 M (2M + 1)  M . . . ...
0  M . . . . . . 0
...
. . . . . . . . .  M
0 · · · 0  M (2M + 1)
3777777775
(2.24)
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2 The Mathematics of Di↵usion
we have to solve the next equation:
Acm+1 = cm (2.25)
To solve such a system of linear equations one can use a Gaussian elimination or in this special case
(triagonal matrix) the Thomas algorithm which is a simplified form of Gaussian elimination[18].
Thus, the solution can be obtained in O(n) with n being the number of space steps. In this
case we have a coupled problem because we comprise values from the same layer which better
specifies the physics of the underlying concept. One big advantage is that there is virtually no
constraint concerning the module M. The implicit method is unconditionally stable, even for
values of M > 0.5. Hence, it is possible to choose larger time steps and space steps, which leads
to an decrement of the number of computational steps in spite of the fact that the solving of the
system of linear equations is computationally more complex compared to the explicit method.
The complexity of the error is just like in the former method of order O( t, x2).
2.2.4 Crank-Nicolson Second Order Implicit Method
The following method uses the implicit and explicit method from the previous sections and is
called Crank-Nicolson method. This second order implicit concept was developed 1947 by John
Crank nd Phyllis Nicolson[19]. The main idea is to use an additional artificial time layer at
m+ 12 by using the mean of he explicit a d the implicit method (for illustration see Figure 2.5).
Once again the left hand side term of Fick’s second law is approximated using first order forward
di↵erences. As already mentioned the right hand side is defined as the mean of the explicit and
implicit second order central di↵erence.
This res lts in the following equation:
cm+1i   cmi
 t
=
D
2
 
cm+i 1   2cm+1i + cm+1i+1
 x2
+
cmi 1   2cmi + cmi+1
 x2
!
6
By defining w with
w =
M
2
(2.27)
we obtain
 wcm+1i+1 + (1 + 2w)cm+1i   wcm+1i 1 = wcmi+1 + (1  2w)cmi + wcmi 1 (2.28)
diffusion space
time
m
m + 1
m + ½
Figure 2.5: Second order Crank-Nicolson method with the additional artificial time layer (with blue point). Orange
points indicate unknown values, yellow points represent known values.
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Equation 1-35 
 
Equation 1-36 
 Equation 1-37 
Using this implicit methods, it is possible to choose larger time steps, which de-
creases the number of computational steps in spite of the fact that the solving of the 
system of linear equations is computationally more complex compared to the explic-
it method. Various work on modeling transdermal transport that are based on finite 
differences exist ([92, 94, 95, 98], see Chapter 5).  
Finite differences are not the only mesh-based technique to find approximate solu-
tions to partial differential equations, such as the diffusion equation. The method of 
finite elements that is widely used in the field of mechanical engineering and finite 
volume approaches that can efficiently handle unstructured girds and is often ap-
plied in the field of computational fluid dynamics are known to successfully model 
transdermal transport ([81, 99, 100], see Chapter 5). For excellent overviews about 
numerical models the interested reader is kindly referred to [101, 102]. 
1.3.5 Quantitative structure activity relationships (QSAR) 
Quantitative structure activity relationships typically try to correlate molecular prop-
erties to some kind of biological activity. Here, an activity response variable is often 
related to a set of molecular descriptors or features of a chemical entity by a regres-
sion model. A typical workflow to construct a QSAR-model starts with the gathering 
of training and validation data of the objective. Subsequently, a set of descriptors for 
each entity (molecular properties or features) should be generated or collected. At 
this stage, a subset of the descriptor space must be chosen to train the model and 
compare the predicted objective value with the validation set. To avoid overtraining, 
2.2 Solving Fick’s Second Law Numerically
By moving the unknown values to the left hand side and the known values to the right hand side
one can co struct two matrices A and B:
A =
2666666664
(1 +M)  M2 0 · · · 0
 M2 (1 +M)  M2
. . .
...
0  M2
. . . . . . 0
...
. . . . . . . . .  M2
0 · · · 0  M2 (1 +M)
3777777775
(2.29)
B =
2666666664
(1 M) M2 0 · · · 0
M
2 (1 M) M2
. . .
...
0 M2
. . . . . . 0
...
. . . . . . . . . M
2
0 · · · 0 M2 (1 M)
3777777775
(2.30)
Thus, the system of linear equations to solve is defined as:
Acm+1 = Bcm (2.31)
It can be solved in O(n) (see Section 2.2.3). Using this method we combine the benefit of the
implict method (unconditional stability1) with a better error of order O( t2, x2). One drawback
with Crank-Nicolson, however, is that the solution has a tendency to oscillate for huge values of
M.
2.2.5 Boundary Conditions
The numerical approach necessitates the definition of boundary conditions (a fixed behavior at
the beginning and the end of the system). We have to distinguish between finite and infinite
dose experiments and b tween th explicit and Crank-Nicolson m thod. For all cases we assume
perfect sink conditions (a non-saturated receptor/acceptor).
Infinite Dose
For infinite dose conditions we set the first element to a fix concentration and the last element
to a fix concentration (zero for perfect sink) which is called Dirichlet boundary conditions. The
explicit approach needs an altering of the matrix A an a setting of c1 = cfix and cn = 0 which
yields:
A =
2666666664
1 0 0 · · · 0
M (1  2M) M . . . ...
0 M
. . . . . . 0
...
. . . . . . . . . M
0 · · · 0 0 1
3777777775
(2.32)
1In spite of von Neumann stability analysis and textbook conclusion Bieniasz et al.[20] showed that the Crank-
Nisolson method can be numerically unstable, if M exceeds a critical value associated with the presence of
mixed boundary conditions.
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2.2 Solving Fick’s Second Law Numerically
By moving the unknown values to the left hand side and the known values to the right hand side
one can construct two matrices A and B:
A =
2
64
(1 +M)  M2 0 · · · 0
 M2 (1 +M)  M2
. . .
...
0  M2
. . . . . . 0
...
. . . . . . . . .  M2
0 · · · 0  M2 (1 +M)
3
75
(2.29)
B =
2
64
(1 M) M2 0 · · · 0
M
2 (1 M) M2
. . .
...
0 M2
. . . . . . 0
...
. . . . . . . . . M
2
0 · · · 0 M2 (1 M)
3
75
(2.30)
Thus, the system of linear equations to solve is defined as:
Acm+1 = Bcm (2.31)
It can be solved in O(n) (see Section 2.2.3). Using this method we combine the benefit of the
implict method (unconditional stability1) with a better error of order O( t2, x2). One drawback
with Crank-Nicols n, however, is that the solution h s a tendency to oscillat for huge values of
M.
2.2.5 Boundary Condi ions
The numerical approach necessitates the definition of boundary conditions (a fixed behavior at
the beginning and the end of the system). We have to distinguish between finite and infinite
dose experiments and between the explicit and Crank-Nicolson method. For all cases we assume
perfect sink conditions (a non-saturated receptor/acceptor).
Infinite Dose
For infinite dose conditions we set the first element to a fix concentration and the last element
to a fix concentration (zero for perfect sink) which is called Dirichlet boundary conditions. The
explicit approach needs an altering of the matrix A and a setting of c1 = cfix and cn = 0 which
yields:
A =
2
64
1 0 0 · · · 0
M (1  2M) M . . . ...
0 M
. . . . . . 0
...
. . . . . . . . . M
0 · · · 0 0 1
3
75
(2.32)
1In spite of von Neumann stability analysis and textbook conclusion Bieniasz et al.[20] showed that the Crank-
Nisolson method can be numerically unstable, if M exceeds a critical value associated with the presence of
mixed boundary conditions.
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2666
4
(1 +M)  M2 0 · · · 0
 M2 (1 + )  M2
. . .
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0  M2
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...
. . . . . . . . .  M2
0 · · · 0  M2 (1 + )
3777
5
(2.29)
B =
2666666664
(1 M) M2 0 · · · 0
M
2 (1 M) M2
. . .
...
0 M2
. . . . . . 0
...
. . . . . . . . . M
2
0 · · · 0 M2 (1 M)
3777777775
(2.30)
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It can be solved in O(n) (see Section 2.2.3). Using this method we combine the benefit of the
implict method (unconditional stability1) with a better error of order O( t2, x2). One drawback
with Crank-Nicol on, however, is that the solu ha a tendency o scillate for huge values of
M.
2.2.5 Boundary Cond tions
The numerical approach necessitates the definition of bounda y conditions (a fixed behavior at
the beginning and the end of the system). We have to distinguish between finite and infinite
dose experiments and between t e explicit and Crank-Nicolson met od. For all cas s we assum
perf ct sink co ditions (a non-s turated receptor/acc ptor).
Infinite Dose
For infinite dose conditions we set the first element to a fix concentration and the last element
to a fix concentrati (zero for p rfect sink) which is called Dirichle bou dary conditions. The
explicit approach needs an altering of he matrix A and a sett ng of c1 = cfix and cn = 0 which
yields:
A =
266
4
1 0 0 · · · 0
M (1  2M) M . . . ...
0 M
. . . . . . 0
...
. . . . . . . . . M
0 · · · 0 0 1
377
5
(2.32)
1In spite of von Neumann stability analysis and textbook conclusion Bieniasz et al.[20] showed that the Crank-
Nisolson method c n b numerically unstable, if M exceed a critical value associa ed with the presenc of
mixed boundary conditions.
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only the most significant descriptors should be incorporated into the model. Stand-
ard methods from the field of machine learning, such as cross-validation and boot-
strapping can be useful to build a meaningful and robust prediction model. 
Obviously, this class of models is highly restricted since these concepts typically 
provide only one type of static output (e.g. a number or class).  Moreover, infor-
mation about time-dependency of the objective cannot be provided. Another draw-
back is the lack of predictive confidence of most models when using input parame-
ters beyond the feature space of the training set. Despite these limitations, QSAR 
models have been used successfully to predict various properties of a compound 
and are suggested by the European Union in the field of risk assessment [21].  
In the case of skin studies, a prominent measure of interest is the normalized 
steady-state flux (permeability kp). Widely used data sets that provide permeability 
values were published by Flynn in 1990 [103] and Wilschut et al. in 1995 [104]. One 
of the most famous QSAR-models to predict stratum corneum kp of a compound 
solved in an aqueous donor solution was published by Potts and Guy in 1992 [74]: 
𝑙𝑜𝑔  𝑘  !   = 𝑎  + 𝑏 ∙ 𝑙𝑜𝑔𝐾!/! −   𝑐 ∙𝑀𝑊 Equation 1-38 
This equation is in direct correlation to the log-transform of Equation 1-13 assuming 
similar relationships of partition and diffusion coefficient as stated in Equation 1-7 
and Equation 1-10. Here, the free parameter a denotes the characteristic of the bar-
rier. The heterogeneity and biological complexity of the startum corneum were vastly 
simplified and subsequently treated as a black-box-like structure. The model was 
trained by multi-linear fitting of a, b and c to available data from the Flynn database 
(93 compounds) and yielded reasonable accuracy (r2 = 0.67). Since a variation of 
30% in experimental data is reasonable, Potts and Guy assumed that their model 
completely describes the data used for training. A revised version of the model in 
comparison to similar approaches can be found in [104]. Needles to say, this class of 
QSAR-models is not restricted to molecular weight and lipophilic character as input 
parameters. Incorporation of hydrogen bond activity [105, 106], retardation coeffi-
cient (RC) [107] and charge [108] yielded promising results. 
Introduction 
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In contrast to the class of linear, mechanistic QSAR-models, empirical models typi-
cally do not rely on any physical-based assumptions and treat the whole process as a 
black box. Prominent examples are artificial neural networks (ANN) [109, 110] and 
k-nearest neighbor approaches (kNN) [111]. These empirical models typically provide 
no information about the underlying processes but might overcome uncertainties 
(e.g. possible protein binding inside the skin, metabolization, different routes of 
substance travel, ionization) due to their fuzzy nature and provide excellent results 
from a practical point of view [112]. 
A recent overview regarding mechanistic and empirical models can be found else-
where [112]. 
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2 Aims of the thesis 
The growing interest to address skin absorption of substances in the fields of risk 
assessment and drug delivery leads to serious challenges in investigating hundreds 
of substances in different formulations, mixtures and exposure scenarios. To over-
come the ethical and financial burden in-vivo human or animal studies impose on 
scientists, in-vitro methods have been developed in the past (see Chapter 1). These 
methods showed great potential and were successfully applied to explore different 
exposure settings of a great number of xenobiotics. However, the investigation of 
skin penetration and permeation using these techniques is often a cumbersome and 
time-consuming process, heavily limited by restricted access to excised human skin 
(considered the gold standard). Animal skin and reconstructed or artificial skin 
technologies still face difficulties in comparability and just shift the "availability 
problem" to another level. Since the beginning of 1960 mathematical models con-
cerning the underlying diffusion problem evolved quickly and gained more and 
more importance in the field of studying transdermal substance transport. Apart 
from the possibility to describe the fate of a substance in various degrees of com-
plexity (see Chapter 1) there is a clear vision of in-silico approaches to predict the 
outcome of an exposure or application scenario in-vivo – either totally from scratch 
using only substance and system descriptors (e.g. molecular weight and lipophilic 
character of the target substance) or with guidance from in-vitro experiments. At 
this, it is important to note that most models and concepts highly depend on precise 
and carefully examined input and validation data gathered for various application 
scenarios to perform well.   
The aims of this thesis were i) to address and explore distinct problems associated 
with finite and infinite dose experiments in-vitro with the help of mathematical 
models to improve data quality and offer insights into the underlying concepts of 
substance transport through the skin, ii) to construct a in-silico model to predict the 
in-vivo scenario from model input data derived from in-vitro experiments. 
First, we studied the influence of substance coverage on drug permeation experi-
ments using only small amounts of formulation (Chapter 3). Subsequently, the im-
portance of the lateral skin compartment in finite dose in-vitro studies was investi-
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gated using three different classes of computational models (Chapter 4).  This work 
has been done in cooperation with the Goethe Center for Scientific Computing 
(Professor Gabriel Wittum, Frankfurt University). Chapter 5 focuses on the con-
struction of a one-dimensional heterogeneous diffusion model that simulates and 
predicts in-vitro and in-vivo finite dose scenarios based on input parameters gath-
ered from infinite dose in-vitro experiments - a strategy that showed promising re-
sults in the field of in-silico - in-vivo correlation using experimental guidance. 
Chapter 6 (Outlook) quickly outlines work that was conducted to improve computa-
tional models on the microscopic scale (predicting keratin binding of substances to 
incorporate this concepts into mathematical models – see Section 6.1), to address 
the problem of signal damping in optical analytical methods measuring skin pene-
tration (see Section 6.3) and to theoretically investigate the impact of skin topogra-
phy on skin absorption using a GPU-accelerated 2D-diffusion model (see Section 
6.2). The work last mentioned was carried out by Jan Riehm as part of his master's 
thesis under supervision of D. Selzer. 
The thesis will be divided into the following four chapters: 
Chapter 3: "Influence of the application area on finite dose permeation in relation to 
drug type applied" 
Chapter 4: "Finite dose skin mass balance including the lateral part: Comparison 
between experiment, pharmacokinetic modeling and diffusion models" 
Chapter 5:  "A strategy for in-silico prediction of skin absorption in man" 
Chapter 6: "Outlook" 
Influence of the application area on finite dose permeation in relation to drug type applied 
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3 Influence of the application area on finite dose 
permeation in relation to drug type applied 
 
 
 
 
 
Parts of this chapter have been published in: 
Hahn, T., Selzer, D., Neumann, D., Kostka, K. H., Lehr, C.-M.,  Schaefer, U. F. 
(2012). Influence of the Application Area on Finite Dose Permeation in Relation to 
Drug Type Applied. Exp Dermatol, 21(3), 233–235.  
 
 
 
 
The author of the thesis made the following contributions to the publication: 
Developed the mathematical model to determine formulation coverage. Performed 
and interpreted all calculations. Wrote parts of the manuscript. 
 
Tsambika Hahn performed and interpreted all major experiments and wrote the 
manuscript. 
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3.1 Abstract 
For finite dose skin absorption experiments, a homogeneous donor distribution 
over the skin surface is usually assumed. However, the influence of the surface dis-
tribution on skin absorption is still unknown. The aim of this study was to evaluate 
the influence of the application area on the permeation of drugs during finite dose 
skin absorption experiments in static Franz diffusion cells. Permeation experiments 
with stained aqueous drug formulations were conducted and the application area 
was determined by a suitable, objective, automated computational approach. In con-
trast to the maximum incubation area possible in the diffusion cell setup, the appli-
cation area was the area actually in contact with the donor at the start of incubation. 
The permeation of caffeine is strongly dependent on the application area: The varia-
bility between single experiments decreased including the application area. In addi-
tion, biopsies from stained skin area contained significantly more caffeine than bi-
opsies of non-stained skin. For the lipophilic flufenamic acid this was not the case. 
The variability highly increased after inclusion of the application area. In contrast to 
caffeine, due to lipophilicity, flufenamic acid distributes fast in the stratum corneum 
covering the maximal possible diffusion area. Thus, a correction of the area is mis-
leading. In summary, depending on the drug’s physicochemical characteristics, the 
real application area may influence skin absorption. 
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3.2 Introduction 
In skin absorption studies infinite dosing is usually employed to evaluate kinetic 
parameters like permeation coefficient [104, 113]. However, this does not represent 
the in-vivo situation, where usually a finite dose is applied to the skin, and additional 
effects may influence drug absorption, e.g. the evaporation of excipients [114]. In the 
OECD guideline 428 [54] and the guidance document 28 [55] finite dose experi-
ments are defined as experiments with a maximum applied donor volume of 
10 µl/cm² of liquid formulations. For semisolid and solid substances, values range 
from 1 to 10 mg/cm² [54, 55, 115].   
The ideal application should result in a homogeneous layer of the drug formulation 
over the whole incubation area. Otherwise, the variation between the experiments 
will increase [116]. However, a homogeneous drug distribution over the whole incu-
bation area is problematic due to wrinkles of the skin.  
For creams and ointments even distribution may be confirmed visually, but for un-
coloured aqueous solutions and gels the distribution cannot easily be determined. 
To this day the distribution of a drug over the incubation area has only scarcely been 
analysed: In two publications, the distribution of a fluorescent model drug in sun-
screens over the skin was investigated in-vivo [117, 118] to correlate the results with 
the sun protection factor. Another publication investigated the distribution of the 
drug formulation containing a fluorescent dye with and without microparticles over 
the incubation area by in-vivo laser scanning microscopy [119]. These publications, 
however, did not correlate the skin surface distribution to the absorption of the 
model drug into the skin.  
To address this topic concerning the effect of inhomogeneous donor formulation 
distribution on in-vitro permeation results, in-vitro finite dose permeation experi-
ments were performed applying a donor by two different methods, i) distribution 
with a punch, and ii) distribution with a disc. To distinguish between skin with and 
without contact to donor formulation, aqueous drug solutions were stained with a 
dye. The drugs employed in this study were caffeine and flufenamic acid (FFA). Af-
ter incubation the application area was determined by a newly developed computer-
based method to ensure objectivity and to handle high-throughput data processing.  
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The influence of the application area on the permeation was investigated with re-
spect to its impact on the variability of the data. Furthermore, lateral drug distribu-
tion was analysed by quantification of skin biopsies with and without contact to the 
donor formulation. To quantify the skin absorption of both substances the relative 
peak flux, as well as the peak flux time were determined. 
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3.3 Materials and methods 
3.3.1 Materials and instruments 
All materials used were of highest analytical grade and were used as purchased. 
Ringer’s solution was provided by Fresenius Kabi, Bad Homburg, Germany. Puri-
fied water was prepared by a Millipore Synthesis device (Millipore GmbH, Schwal-
bach, Germany). The following instruments were used: static Franz diffusion cells 
type 4G-01-00-20 (PermeGear, Riegelsville, PA, USA), incubation area 1.767 cm2 
and receptor volume 12.1 ml, dialysis membranes with MW-cut-off of 12-14 kDa 
(Medicell International Ltd, London, Great Britain, VWR Darmstadt, Germany), 
25 mm syringe filters 0.2 µm cellulose acetate membrane (VWR International, West 
Chester, PA, USA).  
3.3.2 Skin  
Human abdominal skin was obtained from female Caucasian donors undergoing 
plastic reduction surgery at the Department of Plastic and Hand surgery, 
Caritaskrankenhaus, Lebach, Germany. The skin was prepared according to [38] and 
stored in the freezer at -26°C for a maximum of six months. During this time the 
skin’s absorption properties are not changed [120-122]. For this study, skin of three 
donors was used. The study was approved by the Ethical Committee of the Aerz-
tekammer des Saarlandes no. 204/08. Heat-separated epidermis (HSE) was pre-
pared by heat separation technique according to [123]. 
3.3.3 Permeation experiments 
Permeation experiments were performed in a static Franz diffusion cell as described 
elsewhere [113]. Before incubation, the epidermis was equilibrated with the receptor 
solution for one hour. The receptor solution consisted of PBS pH 7.4 for caffeine 
and Soerensen phosphate buffer pH 7.4 for FFA. To prevent microbial contamina-
tion the receptor was stabilized with 0.05% (w/v) sodium azide. Caffeine was used 
in a concentration of 1mg/ml in PBS without NaCl and stained with 0.1% (w/v) 
methylene blue (sodium chloride was omitted due to salt formation with methylene 
blue). Previous studies have shown that the same permeation coefficients are ob-
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tained with and without NaCl. FFA was used in a concentration of 1 mg/ml in Soer-
ensen phosphate buffer stained with 0.1% (w/v) eosin Y. All permeation experi-
ments were performed with the donor chamber sealed by parafilm and aluminium 
foil to avoid water evaporation. Samples were taken from 0 h to 41 h. For each set of 
experiments 6 to 8 single experiments were carried out. The removed receptor solu-
tion (400 µl) was replaced immediately by fresh buffer.  
3.3.4 Application of the donor 
Different finite dose application schemes were applied:  
• Punch:  application of 17.6 µl of the donor formulation, then distribution of 
the formulation by 360° rotation of a Teflon punch (in-house, 14 mm diame-
ter), removal of the punch and covering with a Teflon disc with a diameter of 
14 mm. The drug amount removed with the punch was determined by ex-
traction.  
• Disc:  application of 15.6 µl of the donor formulation, then distribution and 
covering with a Teflon disc with a diameter of 14 mm according to [124].  
In all finite dose experiments, a dose less than 10 µl/cm was incubated with the skin 
to meet finite dose conditions.  
3.3.5 Mass recovery 
After incubation, all compartments were thoroughly examined for drug content: the 
remaining donor on the surface of the skin, drug on the parts of the Franz diffusion 
cell, and the skin. Caffeine was extracted from the skin with methanol 50% (v/v), 
sonication for 30 min and further shaking for one hour followed by filtration 
through a cellulose acetate filter. FFA was extracted with 0.05 N NaOH for two 
hours at room temperature and filtration through cotton. In all experiments, a total 
mass recovery of 92.4 to 99.7% for caffeine and 94.0 to 114.5% for FFA were 
found. The extraction power of the drug from HSE was determined with standard 
solutions being 97.8 ± 3.8% for FFA [38] and 87.4 ± 5.1% for caffeine [125]. 
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3.3.6 Drug quantification 
Caffeine and FFA were quantified according to [125]. For calibration, both substanc-
es were dissolved in the respective extraction medium in concentrations of 0.03 – 
20 µg/ml. Stability tests were performed for both substances in all solvents used for 
at least 41 h at 32°C to ensure no degradation would take place during incubation. 
The dyes had no influence on the analytics and the permeation of the drug. 
3.3.7 Analysis of the application area 
For accurate determination of the application area, the donor formulation was 
stained with a dye. After incubation, the dye was still visible on the skin surface and 
the contact area of the donor formulation with the skin could be analysed. Following 
incubation, the skin was removed from the Franz diffusion cell and the donor dis-
tribution over the skin surface was visualized by means of a scanner with a resolu-
tion of 1200 dpi as tagged image file format (TIFF) data. The scans were analysed by 
a two-step approach to check for formulation coverage and homogeneity of the dis-
tribution.  
First, the coverage was determined by using a hue-saturation-value (HSV) colour 
model [126] and by comparison to a non-stained skin sample. Second, the stained 
area was inspected for homogeneity by comparison to a perfectly stained skin sam-
ple from infinite dose experiments using a red-green-blue (RGB) colour model.  
To obtain the fraction of formulation coverage Φ (Equation 3-1) each image file was 
mapped to HSV colour space using appropriate thresholds in the hue channel to 
separate stained and non-stained pixels (Figure 3-1 B, D). 
𝜙 = stained  pixels  of  the  incubation  areanumber  of  total  pixels  of  the  incubation  area Equation 3-1 
To analyse the homogeneity of dye distribution the stained area of the sample skin 
after incubation (Figure 3-1A, C) was compared to a reference image from infinite 
dose application with perfect staining (Figure 3-1 E, F). 
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To measure the difference to perfect staining the images were mapped to RGB colour 
space and the absolute robust z-score (z-score) of intensities of a dye-dependent colour 
channel of a reference staining (infinite dose case) and the stained parts of finite dose 
sample image, previously identified by the HSV method, was calculated according to: 
𝑧 = |𝑥  −   𝑟𝑒𝑓|𝜎!  Equation 3-2 
Here, x is the median of intensities in the separation channel of the sample image, ref is 
the median of intensities in the separation channel of the infinite dose reference image 
and σref is the median absolute deviation of the intensities in the separation channel of 
the infinite dose reference image. 
 
 
Figure 3-1  Visualization of the application area from scans. A: caffeine stained with   
    methylene blue, finite dose, B: caffeine stained with methylene blue, finite dose, 
    coverage; C: FFA stained with eosin Y, finite dose, D: FFA stained with eosin Y, 
    finite dose, coverage; E: caffeine stained with methylene blue, infinite dose  
    (reference); F: FFA  stained with eosin Y, infinite dose (reference); G: incubated 
    with unstained drug solution (blank), identical for both drugs.   
For methylene blue stained skin the red channel showed a Gaussian like distribution in 
intensities and allowed a clear separation (peak shift) between stained and unstained 
areas. For eosin Y stained skin the green channel showed the best separation potential.
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All methods were implemented using MATLAB 7.8.0 (The MathWorks, Natick, Mas-
sachusetts, USA) with the Image Processing Toolbox.  
Coverage, expressed as percentage of the whole incubation area and the homogenei-
ty of distribution (z-score) were determined for each experiment and the mean of all 
experiments was calculated. 
3.3.8 Determination of relative peak flux and peak flux time 
To characterize different finite dose experiments the relative peak flux relmaxJ and the 
peak flux time tmax were calculated. This was done by applying a three-step approach 
by first fitting the experimental data to obtain diffusion and partition parameters of 
the permeant. Secondly, the flux profile for every finite dose experiment was calcu-
lated. Finally, the relative peak flux relmaxJ  and the peak flux time tmax were evaluated. 
Furthermore, the flux characteristics for every experiment using an uncorrected and 
corrected incubation area (using the calculated application area) were compared. 
First, the cumulative amount of drug leaving the membrane at time t was fitted for 
every time point of an experiment (Equation 3-3 [78]). Here, M  is the applied mass 
per area, D is the apparent diffusion coefficient, K the partitioning coefficient be-
tween donor and skin, h is the macroscopic thickness of the skin and hv is the theo-
retical height of the applied volume to the skin in the Franz diffusion cell. 
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with 
vh
lK=β  
Equation 3-4 
and the roots of the transcendental equation, αn, given by 
αn tanαn = β  Equation 3-5 
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To avoid the use of a fixed macroscopic thickness of the skin, p1=D/h
2 and p2=K*h 
were used as dependent variables for the fitting procedure [18, 127].  
Secondly, the fitted values p1 and p2 as well as the corresponding values for Mt and 
hv were used in the analytical solution to describe the flux J over time curve 
(Equation 3-6 [77, 128]). Finally, the relative peak flux relmaxJ  and the corresponding 
peak flux time tmax were obtained by numerically differentiating Equation 3-6 with 
respect to t, setting the derivative to zero and finding of the root by using Newton’s 
method. 
( ) ( )∑
∞
=
∞ ⎟⎟
⎠
⎞
⎜⎜
⎝
⎛
−
++
=
1
2
2
22
2
2 expcos
2
n
n
nn
n
l
Dt
l
DMtJ α
αββα
α
β  
Equation 3-6 
To compare experiments with different amounts of applied substance the relative 
peak flux relmaxJ  was calculated by normalizing the absolute peak flux Jmax to the ap-
plied dose M : 
𝐽!"#!"# = 𝐽!"#𝑀!  Equation 3-7 
All equations and mathematical operations were implemented using Python 2.7.12 
and the SciPy package [129]. 
3.3.9 Analysis of lateral drug distribution 
Drug distribution in stained and unstained skin parts was analysed after incubation 
in the permeation setup. 15.6 μl of the stained drug formulation were applied to the 
skin as a drop without further distribution. This setup led to inhomogeneous for-
mulation distribution over the incubation area. Thus, not all skin available for diffu-
sion was in contact with the donor formulation. After predetermined time intervals 
of incubation (after 41 h, and additionally for FFA after 2 h and 20 h), 5 mm biop-
sies were taken from both completely stained and from completely unstained skin 
                                                   
2 http://www.python.org/ 
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parts of the skin inside the donor area of the Franz diffusion cell and analysed for 
their drug content. This allowed for comparison of the biopsy with contact to the 
donor formulation to the one without contact. 
3.3.10 Statistics 
Statistical tests were performed with Sigma Stat 3 (SYSTAT Software Inc., Point 
Richmond, CA, USA) to determine significant differences in results. A significant 
difference was detected at p < 0.05. 
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3.4 Results 
3.4.1 Permeation profiles, uncorrected surface distribution  
The permeation profiles of caffeine are only slightly in accordance with typical finite 
dose profiles including an approach of the curve to a maximum (Figure 3-2, black 
circles). A flattening of the curve can only be assumed. For the disc application the 
profile is similar to infinite dose behaviour (Figure 3-2 B, black circles). In both ap-
plication schemes, a similar cumulative drug amount permeated after 41 h incuba-
tion (punch: 38.4 ± 9.4 %/cm , disc: 37.7 ± 10.5 %/cm ) and a high variability be-
tween the single experiments was found (Figure 3-2). The permeation profiles of 
FFA resembled typical finite dose permeation graphs (Figure 3-3, black circles) ap-
proaching a maximum after longer incubation times. Both application methods led 
to this characteristic permeation profile. With the punch, however, the maximum 
was statistically lower than for the disc (Figure 3-3 B), i.e. 40.5 ± 2.6 %/cm  versus 
48.2 ± 3.4 %/cm  after 41 h incubation. The variability between the individual ex-
periments was low.  
A    B  
Figure 3-2  Permeation profiles of caffeine through heat-separated epidermis. Black circles: 
    Relative cumulative caffeine amount per applied dose normalized to total incu-
    bation area (uncorrected). Red triangles: Relative cumulative caffeine amount 
    per applied dose normalized to application area (inclusion of application area). 
    Donor: caffeine 1 mg/ml. A: punch application, n=7. B: disc application, n=6.  
    Mean, SD (provided only in one  direction for the sake of clarity). 
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A   B  
Figure 3-3  Permeation profiles of FFA through heat-separated epidermis. Black circles:  
    Relative cumulative FFA amount per applied dose normalized to total incubation 
    area (uncorrected). Red triangles: Relative cumulative caffeine amount per ap-
    plied dose normalized to application area (inclusion of application area). Donor: 
    FFA 1 mg/ml. A: punch application, n=8. B: disc application, n=8. Mean, SD  
    (provided only in one direction for the sake of clarity). 
 
3.4.2 Donor surface distribution 
Coverage was similar for both dyes with high variability between the different exper-
iments (Table 3-1). Results of this identification method for methylene blue are 
shown in Figure 3-1 B (compared to Figure 3-1 A), and for eosin Y in Figure 3-1 D 
(compared to Figure 3-1 C). Z-scores were dependent on the dye, however, within 
each group very similar (Table 3-1). 
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Table 3-1  Mean relative peak flux, peak flux time, and coverage of FFA and caffeine  
    (CAF) using different application methods in comparison to the mean relative 
    peak flux using the  application area. Mean ± SD. 
 FFA Disc FFA Punch CAF Disk CAF Punch 
Employed dye Eosin Y Eosin Y Methylene blue Methylene blue 
rel
maxJ   x 10
-2 
[%/cm2 h] 
4.0 ± 0.6 
 
3.2 ± 0.5 
 
1.8 ± 0.7 
 
2.3 ± 0.9 
 
rel
maxJ  x 10
-2 
(eff. incl. area) 
[%/cm2 h] 
Not applicable 
 
Not applicable 
 
2.5 ± 0.1 
 
3.1 ± 0.7 
 
tmax [h] 5.6 ± 1.1 3.8  ± 0.9 16.2 ± 6.0 12.2 ± 3.6 
Coverage [%] 67.9 ± 18.6 68.5 ± 16.2 74.2 ± 18.5 73.7 ± 18.1 
z-score 0.7 ± 0.5 0.9 ± 0.7 4.9 ± 1.7 5.9 ± 0.4 
 
3.4.3 Permeation data combined with calculated application 
area/coverage 
To find out whether the application area had an effect on permeation, the previously 
obtained permeation profiles for caffeine and FFA were normalized to the applica-
tion area of each single experiment.  
Inclusion of the application area led to a decrease in variability of the permeation 
profiles of caffeine (Figure 3-2 red triangles). The relative standard deviation de-
creased strongly, too, and was slightly reduced over the incubation time (e.g. after 
41 h for the punch 24% before and 11% after correction).  
The permeation experiments with FFA exhibited a much lower variability between 
the different experiments compared to caffeine, even though the coverage was simi-
lar to the caffeine experiments. After including the application area, the variability 
between the experiments highly increased (Figure 3-2 red triangles), as well as the 
relative standard deviation (e.g. after 41 h for the punch 7% before and 25% after 
correction). 
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3.4.4 Relative peak flux and peak flux time 
The relative peak flux determined for the caffeine finite dose experiments was sig-
nificantly lower than the values obtained for FFA permeation for both application 
methods (Table 3-1). Also, the relative peak flux of FFA was significantly higher for 
the disc than for the punch. For caffeine this was not the case. Using the calculated 
application area for caffeine the relative peak flux increased considerably, whereas 
for FFA this inclusion was not applicable (Table 3-1). The peak flux time was signifi-
cantly higher for caffeine than for FFA for both application methods. Furthermore, 
the peak flux time for FFA was higher for the disc application compared to the 
punch.  
3.4.5 Lateral drug distribution 
After 2 h incubation with FFA, only in the skin parts in contact with the donor for-
mulation FFA could be detected. With increasing incubation time, the FFA amount 
in the stained skin parts decreased while in the non-stained parts it increased. After 
20 h no significant difference between stained and non-stained skin could be de-
tected any more (2.33 ± 2.52% of applied dose vs. 0.31 ± 0.05% of applied dose, 
mean ± SD), and after 41 h the amount of FFA in biopsies with or without staining 
was similar (0.28 ± 0.04% of applied dose vs. 0.26 ± 0.01% of applied dose, mean ± 
SD).  For caffeine, no lateral distribution could be observed after 41 h incubation. 
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3.5 Discussion 
The goal of this study was to evaluate the influence of drug distribution of the appli-
cation area on the results of finite dose permeation experiments using aqueous do-
nor solutions. Therefore, two different application methods were tested and an au-
tomated detection system for surface distribution based on dyes was developed. In 
addition, a three-step approach to calculate relative peak flux and peak flux time to 
characterize permeation was introduced. 
3.5.1 Dye as a marker for skin contact with the donor formulation 
The aqueous donor phase employed in this study shows a high contact angle on the 
skin surface and therefore does not spread easily. The highly water soluble dyes 
employed in this study can be assumed to remain in the aqueous donor solution 
and are not distributed laterally over the lipophilic stratum corneum, making them 
an ideal compound for marking the contact area of the hydrophilic formulation with 
the skin (application area). 
3.5.2 Suitability of the automated computer-assisted approach for 
determination of coverage 
Based on the analysis of hue values and z-scores by an automated computer-assisted 
method the determination of coverage and homogeneity is an objective method to 
characterize the formulation distribution on skin’s surface. However, since the HSV 
colour space is a cylindrical-coordinate representation, two thresholds to define the 
blank skin (hue range) have to be determined. Within this range all pixels from the 
sample skin image will count as blank skin and all pixels outside this range will 
count as stained skin. Hue values between 0.02 and 0.35 were chosen empirically to 
identify non-stained skin pixels from a non-stained skin sample (Figure 3-1 G). The-
se thresholds did guarantee a conservative prediction of staining since no false posi-
tive pixels were detected in a negative test set with only blank skin samples. Chang-
ing these parameters can significantly impact the definition of the coverage. Thus, 
for every batch of experiments a blank reference skin sample image (Figure 3-1 G) 
should be used to gather appropriate thresholds. The original sample images of skin 
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(Figure 3-1 A, C) showed excellent consistency with the determined application areas 
(Figure 3-1 B, D).  
Calculation of the absolute robust z-score requires a median intensity level and the 
median absolute deviation of the RGB colour channel of a perfectly stained refer-
ence skin sample image (Figure 3-1 E, F). Since eosin Y showed z-scores near zero, 
this indicates that the dye distribution was close to a perfect staining (Table 3-1). For 
methylene blue, the values are reasonable.  
Besides increasing the speed of the evaluation process, the great benefits from us-
ing this automated approach is objectivity and stability of coverage, and colour dis-
tribution analysis for finite dose experiments that is not possible using a manual 
inspection method. In addition, the transfer of this method to evaluate formulation 
distribution in-vivo is possible, if digital images made by photography were used 
instead of the scanned. 
3.5.3 Calculation of relative peak flux 
Determination of the highest flux during finite dose skin absorption experiments is 
quite difficult. Some approaches determine the steepest and linear part of the curve 
and from there calculate the flux [116, 130].  
Flux values calculated from cumulative amount per time measurements without 
fitting the data can lead to fuzzy values, especially if only limited time points close to 
the flux plateau are available. By using the diffusion and partition parameters from 
the fitting procedure a fine-grained flux profile can be calculated by using the analyt-
ical solution. A subsequent numerical derivation of the formula guarantees a pre-
cise determination of relative peak flux and peak flux time without the limitation 
given by the sample intervals of the experimental setup.  
The relative peak flux for caffeine calculated in this study was significantly lower 
than for FFA for both application methods (Table 3-1) and the peak flux time was 
much higher. This is in accordance with previously published data [124, 125].  
Using coverage correction to obtain the application area and subsequent calculation 
of the relative peak flux yields a clear increase in peak flux values. These coverage 
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corrected relative peak flux values are more reliable. Certainly, peak flux times are 
not affected. These corrections should be applied carefully, since the potency of a 
substance for lateral distribution strongly affects the area actually available for sub-
stance absorption. This correction cannot be applied, if other phenomena like 
strong lateral distribution (see next paragraph) do affect the diffusion area. This is 
the case for FFA and therefore the relative peak flux values are not provided. 
3.5.4 Permeation profiles and lateral drug distribution 
The permeation profiles for caffeine do not resemble the typical finite dose charac-
teristics (Figure 3-2). It is possible that after 41 h the effect of donor depletion is just 
not yet visible in the permeation profiles due to slower permeation of caffeine 
(Table 3-1).  
The lower permeated FFA amount after application with the punch (Figure 3-3) may 
be explained by transfer of donor formulation to the upper part of the Franz diffu-
sion cell during distribution over the incubation area by spreading, reducing the 
amount of formulation in contact with the incubation area.   
The effect of the application area on the permeation profiles depends on the drug 
employed. For FFA, the variability between the experiments increased after includ-
ing the application area, leading to the assumption that other additional effects may 
influence the drug absorption. These effects may be explained by lateral distribution 
of the lipophilic FFA (log Ko/w ~4.8) [124, 125]. Skin biopsies taken after different 
incubation intervals from stained and unstained skin resulted in information about 
the time profile of lateral distribution of FFA, which was distributed homogenously 
over the whole incubation area after 20 h. As caffeine is a relatively hydrophilic 
compound (log Ko/w -0.08) [124, 125] it cannot be transported into the lipid bilayers 
as easily as FFA.  
Lateral distribution was investigated from aqueous solution. This medium was cho-
sen to gain general data for a substance and make the data comparable to the ex-
tended Flynn database [131, 132]. Moreover, penetration enhancing effects, e.g. of 
oils or ethanol, were excluded.  
Influence of the application area on finite dose permeation in relation to drug type applied 
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A direct visualization of lateral drug distribution over time would be preferred. For 
fluorescent dyes, the fluorescent recovery after photo bleaching (FRAP) technique 
can be employed [133] to analyse lateral diffusion. However, quantitative results are 
difficult to obtain for non-fluorescent drugs due to the low amount of drug actually 
diffusing laterally and thus of analytics. This problem is even increased by finite 
dose application. Thus, lateral distribution in our study was investigated by means 
of skin biopsies. 
3.5.5 Remarks and the clinical relevance 
In-vivo experiments are quite expensive and its number will be reduced in the fu-
ture. Therefore, in-vitro skin absorption studies are important to gain first infor-
mation about the absorption kinetics of a substance. Correlations between in-vitro 
and in-vivo experiments have been shown previously [38, 134, 135]. Thus, for exam-
ple for bioequivalence studies in-vitro experiments are beneficial to determine e.g. 
the difference between two vehicles [136].  
Finite dose experiments are even closer to the real-life scenario of a patient applying 
a small amount of a topical formulation. Due to that similarity, finite dose experi-
ments are of major interest to predict the drug absorption. During in-vivo applica-
tion, differences in the homogeneity of donor formulation distribution are also pos-
sible, thus an analysis of the influence of inhomogeneous donor distribution is im-
portant, too.  
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3.6 Conclusion 
As shown in this paper, including the application area does not automatically im-
prove the results from skin permeation studies using aqueous solutions, leading to 
more consistent results. Depending on the physicochemical characteristics of the 
drug, especially lipophilicity, different behavior has to be considered. For the more 
hydrophilic substances (e.g. caffeine) the degree of contact to the skin is evident for 
permeation and this parameter should be included in the analysis of finite dose ex-
periments. For lipophilic substances, e.g. FFA, however, the application area has 
less effect on the permeation of the drug.  
It is assumed that lipophilic substances might be distributed over the whole incuba-
tion area by lateral diffusion in the lipophilic stratum corneum. For more hydrophilic 
compounds, lateral distribution over the lipophilic stratum corneum is unlikely.  
One question that remains is whether a limit of lipophilicity exists up to where dis-
tribution has an influence on permeation. To answer this question, another study 
with substances covering a wide range of lipophilicity would be required. 
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4 Finite dose skin mass balance including the lateral 
part: Comparison between experiment, 
pharmacokinetic modeling and diffusion models 
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4.1 Abstract 
In-vitro finite dose skin absorption of flufenamic acid and caffeine was investigated 
experimentally and mathematically. Mass balance over time in the different com-
partments of skin in the Franz-diffusion cell experiments (donor, stratum corneum 
(SC), deeper skin layers (DSL), lateral skin parts and acceptor) was analyzed. Espe-
cially the mass inside the lateral, compressed skin part was considered. Three math-
ematical models, a pharmacokinetic model (PK), a detailed two-dimensional diffu-
sion model (DIFF) and a homogenized diffusion model (HOM) were applied to the 
experimental data. The PK model and HOM model were able to determine sub-
stance mass in the lateral skin compartment. The DIFF and the HOM models em-
ployed input parameters derived from infinite dose studies to predict the underlying 
diffusion process and the PK model was fitted to the experimental data. For both 
drugs high amounts of substance could be found in the lateral skin compartment 
after 6 hours of incubation, which emphasizes not to elide the lateral parts in the 
modeling during finite dose skin absorption studies. All models could satisfyingly 
predict or describe the experimental data. 
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4.2 Introduction 
As delivery of drug to the skin is gaining more relevance nowadays, the pharmaceu-
tical industry is interested in evaluating the absorption of active entities to the skin. 
Moreover, the cosmetic industry is also interested in a risk assessment, since the 
systemic availability of topically applied cosmetic substances, is usually desired to be 
avoided. 
To achieve this, usually infinite dose skin absorption experiments are performed. In 
these experiments, the dose on the application site and the amount of substance in 
the donor are large and effectively do not vary with time. Unfortunately, one obvious 
drawback of these experiments is that they have often little in common with realistic 
in-vivo exposure scenarios, when only a small amount of a topical formulation is 
evenly distributed on the skin surface. Correspondingly, the OECD guideline 428 
[54] and the guidance document 28 [55], define finite dose experiments by an ap-
plied dose of 10 µl/cm  or less to the skin. Due to the limited amount of substance, 
the transient character may lead to a substantial deviation from the steady-state situ-
ation that is characteristic for an infinite dose setting. In this context, in particular 
the role of the lateral compartment in experimental studies, has recently gained 
some attention [137-139]. 
As skin absorption experiments are generally time consuming, the development of 
suitable mathematical tools and descriptions is equally important (i) to investigate 
the absorption behaviour and (ii) to offer predictions of substance absorption, in 
order to reduce the number of experiments significantly. For the finite dose situa-
tion, different models have been developed. Most of them solely focus on the per-
meation profiles of a drug through a skin membrane [30, 140]. However, these do 
not consider the drug amount in each skin layer. The effect of lateral diffusion has 
to the best of our knowledge not yet been investigated before. 
The aim of the present work is to investigate in-vitro skin absorption for the transi-
ent case and under finite dose conditions both experimentally and from a modeling 
perspective. We applied three different mathematical models (pharmacokinetic 
model, detailed diffusion model and homogenized diffusion model) and in particu-
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lar shed some light on the influence of a lateral compartment on mass balance pro-
files  
Thus, as a first step, mass balance profiles for the different skin layers were estab-
lished experimentally. After incubation with one of the two model drugs flufenamic 
acid (FFA) or caffeine (CAF), the skin compartments were separated carefully by a 
highly standardized method for tape-stripping the stratum corneum (SC) [38, 39] and 
subsequent separation of the DSL compartment from the lateral compartment (see 
supplementary information). From quantification of the drug amount in each com-
partment, information about the absorption behaviour of the substance to the skin 
can be gained, e.g., the formation of a drug depot in the upper skin layers [35, 141]. 
Depots in skin layers may play an important role for controlled release systems ap-
plied to the skin such as application of nano-sized systems [142, 143].  
On the modeling side, a pharmacokinetic model (PK) was developed describing the 
mass profiles of the drug in each skin compartment over time. The novelty of this 
model was the separation of the skin into not only the SC and the deeper skin layers 
(DSL), but also into an additional lateral skin part. This compartment is usually ne-
glected during mathematical descriptions of experimental data. To simulate mass 
profiles in the different compartments, a microscopic detailed diffusion model 
(DIFF) previously developed for infinite dose [81] was adapted to the finite dose sce-
nario. The input parameters for this model were previously derived from infinite 
dose experiments [125], and the same parameters were used for the finite dose case. 
Finally, a homogenized diffusion model (HOM) was used to predict the mass pro-
files on a larger scale than the detailed diffusion model, including the lateral com-
partment into the model. 
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4.3 Materials and Methods 
4.3.1 Materials and instruments 
The following chemicals were used: potassium dihydrogen phosphate, citric acid x 
H2O (Merck, Darmstadt, Germany), caffeine, flufenamic acid, acetonitrile, metha-
nol (Sigma-Aldrich, Steinheim, Germany), orthophosphoric acid, sodium hydrogen 
phosphate dihydrate (Riedel-de Haën, Sigma-Aldrich, Seelze, Germany). Purified 
water was prepared by a Millipore Synthesis device (Millipore GmbH, Schwalbach, 
Germany).  
Static Franz diffusion cells type 6G-01-00-15-12 with a receptor volume of 12.1 ml 
and an incubation area of 1.767 cm2 were provided by Perme Gear, Riegelsville, PA, 
USA; tesa® Film kristall-klar, (t-tape, 33 m x 19 mm, #57330-00000-02, cut to piec-
es of 16 x 19 mm) was provided by tesa AG, Hamburg, Germany; cryomicrotome 
(MEV) was provided by SLEE, Mainz, Germany; centrifuge (Rotina 420R) was pro-
vided by Hettich Zentrifugen, Tuttlingen, Germany. 
4.3.2 Skin 
Excised human full-thickness skin was obtained from three female Caucasian do-
nors undergoing abdominal plastic surgery. The study was approved by the Ethical 
Committee of the Aerztekammer des Saarlandes no. 204/08.  
The skin was treated according to [38] and stored in the freezer at -26°C for a maxi-
mum of six months. Care was taken to strictly avoid repeated freezing and thawing 
of the skin. It has been shown that this treatment does not impair the barrier func-
tion of the skin [120-122, 144].  
4.3.3 Skin absorption experiments 
A 25 mm punch of the frozen skin was taken on the day of the experiment and al-
lowed to thaw. After cleaning the skin with distilled water and drying it with cotton 
balls, the skin was mounted in a Franz diffusion cell (FD-C) with the epidermis side 
up. The skin was equilibrated with the receptor solution (Soerensen phosphate 
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buffer pH 7.4) for one hour. Previous studies have shown that after this time the 
skin hydration is in equilibrium state. 
Afterwards, 25 µl of the donor solution was applied to the skin. The donor formula-
tion was spread evenly over the incubation area by means of a teflon punch with a 
diameter of 14 mm [145]. After removal of the punch, a teflon disc with a diameter 
of 14 mm was placed onto the donor to prevent evaporation during incubation. The 
punch was later rinsed off and the actual amount of donor formulation remaining 
on the skin was determined. In all experiments, a finite dose was achieved accord-
ing to [54, 55]. After application of the donor, the donor compartment was sealed 
with parafilm and aluminum foil. The whole setup was incubated at 32 ± 1 °C. 
The donor consisted of the respective drug dissolved in Soerensen phosphate buffer 
pH 7.4 in concentrations of 1 mg/ml for flufenamic acid (FFA), and 1 mg/ml and 
12.5 mg/ml for caffeine (CAF). For all experiments sink conditions have been main-
tained. 
4.3.4 Isolation of the different skin compartments and determination of 
the stretching factor for data correction 
After incubation, the skin was cleaned of remaining donor formulation by cotton 
balls. Then, tape-stripping was performed in-vitro with tesa® Film kristall-klar under 
highly standardized conditions according to [37, 39].  
After complete removal of the SC by tape-stripping, the rest of the skin was frozen 
using expanding carbon dioxide. Then, a punch of 13 mm diameter was taken from 
the stripped area of the frozen skin and cut by cryo-sectioning.  
The experimental methodology (skin stretching before tape-stripping and the usage 
of a smaller punch to separate the DSL) does promote the formation of a “pseudo-
lateral” skin part in addition to an actual lateral skin part (Figure 4-1).  
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A      B     
Figure 4-1  Schematic visualization of the geometric problems associated with stretching 
the skin before tape-stripping. A: skin during incubation. B: skin stretched after 
incubation. 
Since this effect does falsify mass recovery results and the degree of stretching of 
the skin is typically unknown, the stretching factor f was introduced to scale mass 
recovery data from the experiment with 
𝒇 =   𝑨𝑺𝒕𝒓𝒆𝒕𝒄𝒉𝒆𝒅   −   𝑨𝑰𝒏𝒄𝒖𝒃𝒂𝒕𝒆𝒅𝑨𝑰𝒏𝒄𝒖𝒃𝒂𝒕𝒆𝒅  Equation 4-1 
We assumed a horizontal uniform drug distribution within each model compart-
ment (Donor, SC, DSL, Lateral, and Acceptor) and used a first order mass balance 
model (Figure 4-2) to estimate the stretching factor f. 
 
Figure 4-2  Mass balance model to estimate the stretching factor f. 
SC
Donor
DSL
Compressed lateral parts
15 mm SC
Application area
DSL
Compressed lateral parts
13 mm
15 mm
Pseudo lateral parts
Donor SC + DSL
Lateral
k2
k1
k4k3f · k1
f · k2
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f is the ratio of the difference between stretched area AStretched and incubated area 
AIncubated normalized to AIncubated. We assumed an artificial flux from the donor com-
partment directly to the lateral compartment via the »pseudo-lateral« compartment 
that corresponds to skin stretching induced by the used tape-stripping procedure 
(Fig. S1a B). In this mass balance model the rate constants of the flux through the 
stretched skin part outside of the stripped area to the lateral skin part should com-
mensurate with the rate constants to the skin parts of the incubated area. The pro-
portionality factor should correspond to the scaling factor f. The set of ordinary dif-
ferential equations (ODEs) of the model was solved numerically and the rate equa-
tions as well as the stretching factor f were fitted to the mass over time curves by 
minimizing the root mean square deviation (RMSD) of the fitted results and exper-
imental data points. The procedure was implemented using Python 2.7.1 and the 
SciPy package [129].  
The amount of drug in the SC, DSL and the lateral skin part was scaled according to 
the ratio of surface area of the stretched skin and the area of incubation. 
The extension of the increase of incubation area was calculated by: 
𝒔 =   𝒅𝒊     ∙   ( 𝒇  +   𝟏   −   𝟏)𝟐  Equation 4-2 
Here, di is the inner diameter of the Franz diffusion cell. 
4.3.5 Validation of the stretching factor 
To validate the stretching factor, full-thickness skin was incubated in a Franz diffu-
sion cell with the donor formulation as before. After incubation, the skin was not 
stretched in preparation for tape stripping. Instead, a 16 mm biopsy was taken to 
remove all incubated skin parts. The remaining skin rest was regarded as com-
pressed, lateral parts without any contact to the donor formulation. All skin com-
partments (Donor, Incubated skin (SC+DSL), Lateral skin parts, Acceptor) were 
quantified for their drug content. For each drug the longest incubation time of the 
experimental range was chosen, for FFA and for CAF (12.5 mg/ml) at 6 h and for 
CAF (1 mg/ml) at 12 h. 
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4.3.6 Mass balance  
After incubation, all compartments of the setup were thoroughly examined for drug 
content, namely the donor solution remaining on the skin surface (donor), the tape-
strips (SC), the cryo-cuts (DSL), and the lateral skin parts. FFA was extracted using 
0.05 N sodium hydroxide solution and CAF with phosphate buffer pH 2.6 for 2 h. 
The samples from the acceptor were measured without further dilution steps. FFA 
and CAF were quantified by HPLC according to [125] at the wavelength of 262 nm 
for CAF. For all experiments, the obtained total recovery for FFA (LLOQ of 50 
ng/ml) ranged from 83.8% to 96.8% and for CAF (LLOQ of 30 ng/ml) from 87.9% 
to 107.3%. 
4.3.7 Pharmacokinetic modeling 
Pharmacokinetic (PK) modeling was applied to analyze mass profiles in the differ-
ent compartments for FFA and CAF finite dose experiments. The model treats the 
different skin layers as well stirred compartments. First-order kinetics were as-
sumed to describe the substance mass flux for every compartment which yielded a 
set of ordinary differential equations (ODEs). As an extension of the classical mod-
els, a lateral compartment was added explicitly, into which the drug can enter 
(Figure 4-3). The transport constants k5 and k6 in this model represent an averaged 
transport via the SC and DSL to the lateral compartment. 
 
Figure 4-3  Pharmacokinetic model developed to analyze drug distribution between various 
 relevant compartments in the skin. Here, k1 to k7 are first-order rate constants. 
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The set of ODEs was numerically integrated and fitted (nonlinear least squares re-
gression) to experimental data using Python 2.7.2 with the SciPy package [129]. The 
root mean square deviation (RMSD) was used as an indicator for accuracy. A grid 
search was applied to find appropriate starting values in order to avoid sticking in a 
local minimum. 
4.3.8 Detailed diffusion model 
An alternative transport model is a diffusion process in an idealized, two-
dimensional model membrane. This has previously been described for an infinite 
dose setting [81, 125], and is now extended to a finite dose scenario. The core part of 
the model is a brick-and-mortar like structure, which represents the SC. On the top 
and bottom side of this structure two additional compartments have been added, 
(c.f. Figure 4-4).  
 
Figure 4-4  Microscopic diffusion model (modified from [81]): dimensions (left) and do- 
 mains and interfaces (right). The bottom boundary ΓSINK provides a perfect 
 sink. Diffusion and partition coefficients are listed in Table 4-1. 
 
These model the donor chamber (DON) of the diffusion cell and the deeper skin 
layers (DSL) respectively. The heights for DON and DSL compartments are hDON = 
0.1 mm and hDSL = 3 mm, respectively. The substance mass in the acceptor com-
partment is defined as the mass that is leaving the system at hDSL = 3mm. Initially, 
no substance is present in SC and DSL, and a defined concentration, which matches 
the experimental setup, is provided in the donor.  
Initially no substance is present in SC and DSL, and a deﬁned concentra-
tion, which matches the experimental setup, is provided in the donor.
The model equation is given by [22]
∂t kuð Þ þ ∂x −kD∂xu½ % þ ∂y −kD∂yu
h i
¼ 0
where the solution u=u(x,y,t) is deﬁned by a set of diffusion and parti-
tion coefﬁcients, which are assumed to be piecewise constant for any
phase A∈{DON, COR, LIP, DSL}. Deﬁning the concentration c :=ku, the
functions k are uniquely deﬁned up to a constant factor by the interface
conditionKA/BcB=cA. In this case the function u is assumed to be contin-
uous on the interface between two phases A, B∈{DON, SC, DSL}, A≠B.
By deﬁnition, ﬂuxes across the interface are preserved. The boundary
ΓSINK provides a perfect sink, natural no-ﬂux conditions are imposed
on all remaining exterior boundaries.
Similar models have been discussed in the literature, e.g. [23,24].
However, the ﬁnite dose model employed in this work is to the best
of our knowledge the ﬁrst model considering the microscopic struc-
ture of the stratum corneum. A lateral compartment is not included
in the model, since modeling a diffusion cell with a diameter of
15 mm in a full resolution model with a corneocyte width of 30 μm
leads to unreasonably expensive computations.
The model relies on a variety of diffusion and partition coefﬁcients,
which are provided in Table 1. Except for the diffusion coefﬁcient in
the donor, DDON, all parameters were taken from the previously pub-
lished inﬁnite dose experiments [14,15].
A relationship to predict the diffusion coefﬁcient DDON in an aqueous
solution from the solute molecular weight was proposed by Anderson
et al. [25] with
DDON ¼ D0DON•MW−n ð1Þ
where DDON is the diffusion coefﬁcient in a certain medium, n and
DDON0 are constants associated with the medium at a deﬁned temper-
ature, and MW the molecular weight in Da. Using 37 substances and
their corresponding molecular weight (gathered from the PubChem
database [26]) and diffusion coefﬁcient in water at 27 °C [27] the
previous equation was ﬁtted to the log-transformed data using a lin-
ear model. This resulted in DDonCAF=2.92×10−2 cm2/h with a 95% CI of
[2.77, 3.08]×10−2 cm2/h and DDonFFA =2.47×10−2 cm2/h with a 95%
CI of [2.31, 2.65]×10−2 cm2/h respectively.
2.6. Homogenized (macroscopic) diffusion model
As an alternative,we consider a homogenized (macroscopic) diffusion
model (MACRO). Thismodel considers an axisymmetric setup in cylindri-
cal coordinates. A sketch of the underlying model geometry, which in-
cludes a lateral compartment, is depicted in Fig. 3.
On this geometry we seek a continuous solution u=u(r,z,t) of the
model equation
∂t rkuð Þ þ ∂r −r !Drr∂ru
! "þ ∂z −r !Dzz∂zu! " ¼ 0 ð2Þ
in the new spatial variables r, z for the lateral (r) and transversal (z)
direction respectively. This approach is similar to [28,29], but in addi-
tion, the radius r is used as a scaling factor which reﬂects the increase
in volume in the outer parts of the diffusion cell. The diffusion coefﬁ-
cients Drr and Dzz are the diagonal entries of an anisotropic diffusion
tensor, which allow the inclusion of the structure of the corneocytes
implicitly.
Diffusion in the donor (DON) and in the deeper skin layers (DSL)
is undirected, i.e., !DDON;rr ¼ !DDON;zz ¼ kDONDDON and !DDSL;rr ¼ !DDSL;zz ¼
kDSLDDSL. Diffusion in the SC is modeled by coefﬁcients
!DSC;ii∶¼ DLIP aii ξð Þ ð3aÞ
with the non-dimensional factor
αii ξð Þ ¼ α0ii þ
α∞ii−α0ii
# $
1−α0ii
# $
ξ
α∞ii−1
% &þ 1−α0ii% &ξ ð3bÞ
representing the anisotropy as a function of the effective corneocyte
diffusivity
ξ ¼ DCOR
DLIP
KCOR=LIP ð4Þ
and of two geometry dependent constants aii0 and αii∞. Representative
values for lateral (arr0 =1.76×10−1, arr∞=3.51×103) and transver-
sal (arr0 =7.35×10−4, arr∞=6.51×103) anisotropies were selected
according to the theoretical foundations in [30].
hDON= 0.1 mm Donor 
ΩDON
 
Deeper skin layers 
DSL
Lipid layers 
LIP
ΓCOR/LIP
ΓDSL/LIP
Corneocytes
COR
ΓDON/LIP
ΓSINK
Interface
Interface
 Interface
 hDSL= 3 mm 
 hCOR= 1 µm 
 δLIP = 0.1 µm 
 wCOR= 30 µm 
Ω
Ω
Ω
Fig. 2. Microscopic diffusion model (modiﬁed from [14]): dimensions (left) and do-
mains and interfaces (right). The bottom boundary ΓSINK provides a perfect sink. Diffu-
sion and partition coefﬁcients are listed in Table 1.
Table 1
Input parameters for simulation of skin absorption with 2D diffusion model [14,15].
Parameter FFA CAF
DDON [cm2/h] 2.47×10−2 2.92×10−2
DLIP [cm2/h] 1.10×10−4 2.10×10−4
DCOR [cm2/h] 5.10×10−7 1.40×10−7
DDSL [cm2/h] 4.90×10−3 2.30×10−3
KLIP/DON 20.32 2.15
KCOR/LIP 0.21 2.22
KDSL/LIP 0.1 0.08
Fig. 3. Homogenized diffusion model: the model geometry is a cross-section through
half a diffusion cell (not drawn to scale).
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The model equation is given by [62] 
∂! 𝑘𝑢 + ∂! −𝑘𝐷 ∂!𝑢 + ∂! −𝑘𝐷 ∂!𝑢 = 0 Equation 4-3 
where the solution u is defined by a set of diffusion and partition coefficients, which 
are assumed to be piecewise constant for any phase 𝐴   ∈ 𝐷𝑂𝑁,𝐶𝑂𝑅, 𝐿𝐼𝑃,𝐷𝑆𝐿 . 
With the concentration , the functions k are uniquely defined up to a con-
stant by the interface condition 𝐾!/!𝑐! = 𝑐!, if u is continuous on the interface be-
tween two phases 𝐴,𝐵   ∈ 𝐷𝑂𝑁, 𝑆𝐶,𝐷𝑆𝐿 ,𝐴 ≠ 𝐵. By definition, fluxes are preserved. 
Several other models have been discussed in the literature, e.g. [78, 128]. However, 
the finite dose model employed in this work is to the best of our knowledge the first 
model considering the microscopic structure of the stratum corneum. A lateral com-
partment is not included in the model, as modeling a diffusion cell with a diameter 
of 15 mm in a full resolution model with a corneocyte width of 30 µm is not viable 
within a reasonable timescale. The model relies on a variety of diffusion and parti-
tion coefficients, which are provided in Table 4-1. Except for the diffusion coefficient 
in the donor, DDON , all parameters were taken from infinite dose experiments per-
formed previously [65, 81]. A relationship to predict the diffusion coefficient DDON 
in an aqueous solution from the solute molecular weight was proposed by Anderson 
et al. [64]  with 
𝐷!"# = 𝐷!"#!    ∙𝑀𝑊!! Equation 4-4 
where DDON is the diffusion coefficient in a certain medium, n and 𝐷!"#!  are con-
stants associated with the medium at a defined temperature, and MW the molecular 
weight in Da. Using 37 substances and their corresponding molecular weight (gath-
ered from the PubChem database [146]) and diffusion coefficient in water at 27°C 
[147] the previous equation was fitted to the log-transformed data using a linear 
model, resulting in 𝐷!"#!"# = 2.92𝐸 − 02  𝑐𝑚!/ℎ  with a 95% CI of [2.77E-02,  
3.08E-02] and 𝐷!"#!!" = 2.47𝐸 − 02  𝑐𝑚!/ℎ  with a 95% CI of [2.31E-02, 2.65E-02]. 
 
 86 
Table 4-1  Input parameters for simulation of skin absorption with 2D diffusion model  
    [81, 125]. 
Parameter   FFA CAF 
DDON [cm2/h] 2.47E-02 2.92E-02 
DLIP [cm2/h] 1.10E-04 2.10E-04 
DCOR [cm2/h] 5.10E-07 1.40E-07 
DDSL [cm2/h] 4.90E-03 2.30E-03 
KLIP/DON  20.32 2.15 
KCOR/LIP  0.21 2.22 
KDSL/LIP   0.1 0.08 
 
4.3.9 Homogenized diffusion model 
The above mentioned diffusion model does not consider lateral. As an alternative, 
we consider the following homogenized diffusion model (HOM): In this case the mi-
croscopic heterogeneous structure of the SC is not resolved explicitly, but is treated 
as a macroscopic homogeneous compartment. A sketch of the underlying model 
geometry is depicted in Figure 4-5. On this geometry, we solve the model equation 
in cylindrical coordinates: 
∂! rkc + ∂! −rD!! ∂!c + ∂! −rD!! ∂!c = 0 Equation 4-5 
with a continuous solution 𝑢 = 𝑢(𝑟, 𝑧, 𝑡). Now the diffusion coefficients 𝐷!! ,𝐷!!  are 
the diagonal entries of an anisotropic diffusion tensor. This tensor represents the 
structure of the corneocytes implicitly in terms of different diffusion coefficients in 
lateral (r) and transversal (z) direction. This approach is similar to [148, 149], but in 
addition, r is used as scaling factor. Thus, it reflects the increase in volume in the 
outer parts of the diffusion cell. 
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Diffusion in the donor (DON) and in the deeper skin layers (DSL), is undirected, 
i.e., 𝐷!"#,!! = 𝐷!"#,!! = 𝐷!"# and 𝐷!"#,!! = 𝐷!"#,!! = 𝐷!"#. Diffusion in the SC is 
modeled by coefficients 
 D!",!! ≔ D!"#  α!!(ξ) 
 
Equation 4-6 
where the non-dimensional factor 
𝛼!! 𝜉 = 𝛼!!! + (𝛼!!!   −   𝛼!!!)(1  −   𝛼!!!)𝜉𝛼!!!   −   1   +   (1  −   𝛼!!!)𝜉 Equation 4-7 
represents the anisotropy as a function of the effective corneocyte diffusivity 
ξ = D!"#D!"# K!"#!"#  Equation 4-8 
and of two geometry dependent constants  and 𝛼!!!. The theoretical foundations 
can be found in [97].  
 
Figure 4-5  Homogenized diffusion model: The model geometry is a cross section through 
 half a diffusion cell (not drawn to scale). 
 
For this model, two different approaches were applied: In the HOM1 model, all pa-
rameters except for the diffusion coefficients in the SC, 𝐷!",!! and 𝐷!",!! ,  are taken 
from [81]. This basic data is provided in Table A-1 A. The coefficients are determined 
Donor
SC
DSL
100 µm 
17.6 µm 
3 mm
7.5 mm 5 mm 
12.5 mm 
r-direction
z-direction
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from Equation 4-6 by a least squares regression analysis for the diffusivity    𝜉 ∶= exp θ! . In order to improve on this further, a model with three regression 
parameters, 𝜃!,𝜃! and 𝜃!, referred to as HOM3, was applied. In addition to the pre-
viously mentioned parameter , DSL diffusivity and partition coefficients were pa-
rameterized by: 
𝐷!"#∗ := 𝐷!"#  exp  (𝜃!) Equation 4-9 𝐾!"/!"#∗ := 𝐾!"/!"#  exp  (𝜃!) Equation 4-10 
𝐾!"/!"#∗ :=   𝐾!"/!"# 𝐾!"/!"# 𝐾!"/!"#∗  Equation 4-11 
In this model all parameters except for DDON were determined by regression.  
4.3.10 Model overview and parameter estimates 
A comparison of the above mentioned models is provided in Table A-1 A. For the 
PK and both HOM models some parameters were optimized using a non-linear 
regression analysis to obtain a better fit to the experimental data. In these parameter 
estimations, which were performed by a Gauss-Newton solver, the standard devia-
tion (sum of squared residuals / number of degrees of freedom) was used as the 
objective. 
4.3.11 Statistics 
Graph Pad Prism 6.0 for Macintosh (GraphPad Software, La Jolla, California, USA) 
was used for calculating student t-test. Significant differences were found at  
p < 0.05.   
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4.4 Results 
4.4.1 Experimental data 
FFA finite dose experiments resulted in a relatively fast decrease of drug in the do-
nor. Already after 15 min the drug amount in the donor was reduced to around 60% 
of the applied dose (Figure 4-6 A). After this quick donor reduction, the donor con-
tinued to deplete more slowly, reaching around 20% remaining in the donor com-
partment after 6 h incubation. In the SC around 30% of the applied dose was found 
after 15 min and a plateau was reached and maintained until 2 h after application 
(Figure 4-6 B). Afterwards, the FFA amount decreased to 10-20% with high variabil-
ity at the 4 h and 6 h data points. The drug amount in the DSL increased constantly, 
reaching a plateau at approximately 50% after 4 h of incubation (Figure 4-6 C). No 
FFA could be quantified in the acceptor compartment until 6 h of incubation due to 
analytical reasons (Figure 4-6 D). The drug amount determined in the lateral skin 
part appeared to increase after longer incubation (Figure 4-6 E). However, data is 
affected by high variability, especially for later time points, a tendency comparable to 
the other compartments. 
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A B  
C D  
E  
Figure 4-6 FFA mass profiles over time: experimental data, PK fitting, detailed diffusion 
simulation and homogenized diffusion models. A: Mass profile of the Donor 
compartment. B: Mass profile of the SC compartment. C: Mass profile of the 
DSL compartment. D: Mass profile of the Acceptor compartment (diffusion 
model with mass leaving the system). E: Mass profile of the lateral compartment 
(diffusion model data not available). 
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A B  
C D  
E  
Figure 4-7  CAF (1 mg/ml) mass profiles over time: experimental data, PK fitting, detailed 
diffusion simulation and homogenized diffusion models. A: Mass profile of the 
Donor compartment. B: Mass profile of the SC compartment. C: Mass profile of 
the DSL compartment. D: Mass profile of the Acceptor compartment (diffusion 
model with mass leaving the system). E: Mass profile of the lateral compartment 
(diffusion model data not available). 
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A B  
C D  
E  
Figure 4-8  CAF (12.5 mg/ml) mass profiles over time: experimental data, PK fitting, de-
tailed diffusion simulation and homogenized diffusion models. A: Mass profile of 
the Donor compartment. B: Mass profile of the SC compartment. C: Mass profile 
of the DSL compartment. D: Mass profile of the Acceptor compartment (diffu-
sion model with mass leaving the system). E: Mass profile of the lateral com-
partment (diffusion model data not available). 
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In the 1 mg/ml CAF experiments, the drug in the donor did not decrease as fast as 
for FFA. After 5 min, still more than 85% of the initial dose could be found, decreas-
ing slowly and reaching around 60% remaining on the skin after 6 h (Figure 4-7 A). 
At the last measuring time point (12 h), still more than 40% of the drug was found 
in the donor. 
In the SC, a plateau at around 25% was reached after 2 h and maintained until 6 h, 
then slowly increasing to around 35% at the end of incubation after 12 h (Figure 4-7 
B). 
The amount of drug in the DSL remained very low until 6 h due to values close to 
the lower limit of quantification and then increased to around 10% at 12 h (Figure 
4-7 C). Only after the longest incubation at 12 h, CAF was found in the acceptor 
(Figure 4-7 D).  
However, the variation was quite high due to concentration values close to the 
LLOQ. The CAF amount in the lateral compartment slowly increased, reaching 
around 10% of the applied dose after 12 h incubation (Figure 4-7 E). 
For the 12.5 mg/ml experiments, the course of relative drug amount in the donor 
was similar to the 1 mg/ml data (Figure 4-8 A). In the SC, a plateau was reached 
very fast between 10% and 15% and maintained until 6 h after application (Figure 
4-8 B). The amount of CAF in the DSL increased slowly, reaching around 10% after 
6 h (Figure 4-8 C). After 6 h incubation, around 5% of the applied CAF was found 
in the acceptor phase (Figure 4-8 D). No CAF was found at earlier time points. In 
the lateral compartment the CAF amount increased to around 15% after 6 h (Figure 
4-8 E). 
For the 12.5 mg/ml and 1 mg/ml CAF data differences in relative amount in the SC 
(Figure 4-7 B and Figure 4-8 B) and DSL (Figure 4-7 C and Figure 4-8 C) were ob-
served. 6 hours after application SC levels at 1mg/ml were approximately 1.5 times 
the relative amount of the 12.5 mg/ml experiments and DSL levels at 12.5 mg/ml 
approximately 6 times the relative amount of the 1 mg/ml experiments. The donor 
depleted roughly 10 percent faster in the 1 mg/ml CAF experiments. 
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4.4.2 Results for different models 
The outcome of all three models for FFA and CAF is depicted in Figure 4-6 to Fig-
ure 4-8. A summary of standard deviations for all models is additionally provided in 
Table 4-2 B. The deviations of the objective are found to be reasonably small in all 
cases. 
The DIFF and HOM models slightly overpredict the amount in the SC for the  
12.5 mg/ml CAF experiments and slightly overpredict the amount in the DSL for 
the 1mg/ml CAF experiments. For the PK model the rate constants found by regres-
sion and the corresponding standard errors are reported in Table A-2. For FFA it 
was obviously not possible to fit the efflux rate constant k7, which was thus set to 
zero. The optimized diffusivities for the HOM1 model are shown in Table A-1 A. 
The optimized parameters for the HOM3 model, indicated by a *, are listed in Table 
A-1 B. The corresponding regression coefficients are reported in Tables A-3 A and 
A-3 B respectively. 
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Table 4-2  Overview of models features and comparison of goodness of fit. 
 
 
 
  
  PK HOM(3) HOM(1) DIFF 
A General information    
 Primary Purpose Fit   Prediction 
 Type of input 
parameters 
Rate con-
stants 
Diffusion and 
partition coeff. 
Diffusion and 
partition coeff. 
Diffusion and  
partition coeff. 
 Number of input 
parameters 
6 for FFA/ 
7 for CAF 6 +geometry 6 +geometry 7 + geometry 
 Number of re-gression parame-
ters 
6 for FFA/ 
7 for CAF 3 1 none 
 Time dependence yes yes  yes  yes  
 Spatial resolution No, only  compartment intermediate intermediate 
Up to cellular 
structures 
 Lateral compart-
ment modeled  
separate for 
SC and DSL 
separate for 
SC and DSL not modeled  
 Computational 
cost Low intermediate intermediate High 
B Regression results  
Standard deviation and number of independent variables (in parentheses) 
 FFA 4.82 (24) 5.23 (27) 6.61 (29) 8.47 (24)* 
 CAF 
(1mg/ml) 3.26 (13) 4.32 (17) 5.03 (19) 5.76 (16)* 
 CAF  
(12.5 mg/ml) 3.56 (13) 3.99 (17) 5.94 (19) 5.27 (16)* 
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4.5 Discussion 
Based on the experimental design and the anatomical conditions, we investigated 
mass balance profiles for in-vitro finite dose skin diffusion experiments. Full thick-
ness skin was separated and analysed in different compartments (Donor, SC, DSL, 
lateral compartment, Acceptor) for two substances in aqueous solution: FFA (1 
mg/ml) and CAF (1 mg/ml and 12.5 mg/ml).  
This experimental setup was then represented in different mathematical models. 
4.5.1 Data correction and validation of the stretching factor 
By scaling of the experimental data the drug amount in the lateral skin parts de-
creased and in the SC+DSL compartments it increased. Experiments with un-
stretched skin resulted in similar drug amounts in the SC+DSL and in the lateral 
skin compartments as the scaled experimental data set (Figure 4-9).  
A B  
Figure 4-9  Relative drug amount recovered from the different compartments. Donor: For-
mulation recovered from the skin surface and surface of donor compartment. 
SC and DSL: skin punch of incubated area. Lateral: Skin outside of the incubat-
ed area. Acceptor: drug in acceptor compartment. Original: data from tape-
stripping experiments. Scaled: data from tape-stripping experiments scaled with 
stretching factor. Reference: data from experiments without stretching. A: FFA 
1 mg/ml: n=5. B: CAF 1 mg/ml: n=4 
No significant differences (t-test, p > 0.05) could be found between the scaled exper-
imental data and the data obtained from the experiments with unstretched skin 
(Reference) both for FFA and CAF. The difference between Reference and Original 
in the lateral part was significant for both drugs. This showed that estimation of a 
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stretching term is a suitable method to correct the experimental data for the condi-
tions during incubation and tape-stripping for this setup 
4.5.2 Experimental data 
Experimental mass profiles for FFA show clearly a finite dose behavior with a strong 
depletion of the donor and a depletion of mass in the SC after reaching a plateau in 
the course of the experiment (Figure 4-6 A,B). In contrast, CAF experiments show 
more infinite dose-like properties with a significantly slower depletion of the donor 
and a constant mass plateau in the SC over sample time (Figure 4-7 A,B and Figure 
4-8 A,B). This is in agreement with experiments from the infinite dose scenario, 
showing a slower penetration of CAF in comparison to FFA [81]. Mass profiles of 
CAF in the SC are clearly different for the different concentrations: For CAF at 
1 mg/ml around 25 to 35% of the drug can be found in the SC, whereas for the 
higher concentration at 12.5 mg/ml the values reach only up to 15%. One explana-
tion for the different profiles is a saturation effect in the SC, allowing only a certain 
CAF amount to be taken up by the SC, e.g. reversible protein binding to keratin. 
Binding in SC was shown recently for theophylline, which has a very similar struc-
ture to CAF [58, 98, 150]. 
This effect has consequences for the amount of substance in the DSL over time, 
showing a much higher amount for 12.5 mg/ml (11%) in comparison to 1 mg/ml 
(2%) after 6 h of incubation. Surprisingly, for both concentrations nearly the same 
relative amount was found in the lateral compartment.  
4.5.3 Drug transport to the lateral parts 
Speaking of the lateral skin parts, a high amount of drug can be found (e.g. more 
than 10% for CAF at 12.5 mg/ml after 6 h of incubation, Figure 4-8 E). Thus, there 
is evidence not to elide the lateral parts in the modeling during finite dose skin ab-
sorption studies. Most studies investigating finite dose experiments do not discuss 
the lateral drug amount found in their studies but lateral diffusion of e.g. benzyl 
alcohol into the clamped parts of the diffusion cell has been assumed previously 
[151]. In agreement with results from Gee et al. [137], which determined the lateral 
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transport of CAF, hydrocortisone, and ibuprofen, the lipophilic FFA exhibited a 
lower tendency to move laterally than the hydrophilic CAF. From microscopic pic-
tures (Figure 4-10) taken both from untreated skin and from skin squeezed in a FD-
C for 20 h, no significant difference was found for the SC thickness (p=0.218). The 
dermis, however, appeared much denser than before. The geometry and physiology 
of the skin is clearly changed and it is assumed that this altered configuration may 
reduce the possibility of using measured diffusivity and partition behavior from ful-
ly hydrated skin experiments.  
A  
B  
Figure 4-10  Cross sections of skin biopsies from untreated skin (A), and from the lateral, 
 compressed part of a skin sample squeezed in a Franz diffusion cell during in
 cubation with buffer for 20 h (B). Stained with haematoxylin. Magnification is 
 200 x.  
 
Finite dose skin mass balance including the lateral part: Comparison between experiment, 
pharmacokinetic modeling and diffusion models 
 99 
4.5.4 Model comparison and evaluation 
With the PK, DIFF and HOM models this study employed three different computa-
tional models serving very different purposes to describe and predict the experi-
mental setup. 
In contrast to Seta and coworkers [84], the experimental resolution of the epidermis 
is divided in lipophilic (SC) and hydrophilic parts (viable epidermis), which is more 
reasonable from a physiological point of view in our opinion. The same holds true 
for the works by Kasting and coworkers [78, 151] which focused on volatile com-
pounds and thus did only supply mass balance information about skin as a whole 
tissue [140, 152] and, in a further study, about epidermis and dermis [153]. For the 
modeling part, the aforementioned works belong to the class of one-dimensional 
diffusion models, e.g., [76], [86, 154, 155], [128]. The primary focus in these works 
was on absorption, i.e., mass accumulation in the acceptor, however. None of the 
above cited models do consider lateral diffusion to parts of the skin outside the in-
cubated application area. 
To explain the mass transport between different compartments and to evaluate this 
influence of the lateral compartment further, an easy to use extended pharmacoki-
netic model (PK) was constructed. In this approach the whole experimental setup is 
described in terms of compartments. Interestingly enough, the class of PK models 
recently gained some attention again: The work by Davies and coworkers [89], e.g., 
showed to be efficient with two skin compartments already. Overview articles relat-
ing to one or two compartment PK models can be found in the literature [83, 90, 
91]. PK models using first-order rate constants were typically used to monitor the in- 
vivo situation [85, 86] and a lot of effort was spent trying to relate rate constants to 
physicochemical properties of the diffusant and to fit a model to plasma-level curves 
or in-vitro permeation profiles [87, 88]. In contrast to the previous mentioned work, 
a lateral compartment was added to fully describe the experimental setting. 
Although, when compared to the DIFF model, this approach does only provide a 
very limited spatial resolution, the model features a low computational complexity. 
In order to provide additional insight of all effects occurring during incubation, 
model parameters were determined by parameter fitting with respect to the experi-
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mental data. To reduce the number of constants an averaged transport (rate con-
stants k5 and k6) between SC and lateral compartment as well as between DSL and 
lateral compartment, was assumed. Unsurprisingly this yields excellent agreement 
to the experimental data. For the CAF experiments the ratio of rate constants k3 and 
k4 (SC and DSL) and k5 and k6 (SC/DSL and lateral compartment) are in agreement 
with the experimental findings, showing a faster transport from the SC to the DSL 
for the 12.5 mg/ml experiments and a faster transport from the SC/DSL to the lat-
eral compartment for the 1 mg/ml experiments. 
After successful description of the experimental setup a detailed diffusion model 
(DIFF) driven by input parameters gathered from infinite dose experiments was 
applied. It has been shown, that this is reasonable even for finite dose kinetics [30, 
84], whereas estimation from finite dose experiments may show great intra-
individual variability [155]. In contrast to one-dimensional models cited above, the 
work at hand relies on a microscopic two-dimensional geometry. This model is thus 
meant to be predictive, as all parameters are in principle directly related to physico-
chemical properties of the substance.  
An out of the box use of the DIFF model provided good predictions of the mass pro-
files in each compartment for both drugs over the incubation times of 6 h or 12 h: 
While the agreements with the experiment are excellent for FFA, some minor dif-
ferences are found for CAF. At low donor CAF concentration, e.g., the model pro-
duces an overestimate of DSL concentration, whereas at high donor CAF concentra-
tion, an overestimate of SC concentration is obtained. Due to the differing experi-
mental results, this finding could be expected. Explanations for the overestimation 
could be lateral diffusion in the DSL and a saturation effect in the SC. Furthermore, 
some minor differences in the acceptor compartment can easily be explained by 
analytical reasons, e.g. concentration below the LLOQ. 
The general drawback of the model is however the absence of a lateral compart-
ment. As explained above, this is due to the very high resolution. Also note, that 
although a parameter optimization is possible in principle, it was not applied here, 
because of the high computational complexity. 
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As some authors suggest, high resolution PK models, e.g., [30], provide an im-
proved spatial resolution in z-direction. In this case, each compartment represents a 
single layer of tissue in SC and DSL respectively. As this corresponds to a set of dis-
cretized partial differential equations, we pursue a different approach with the class 
of HOM models.  
The homogenized HOM models serve as a compromise between the previously 
mentioned models: In contrast to the DIFF model the cells in the SC membrane are 
not resolved in full detail, but sophisticatedly represented in an averaged (homoge-
nized) way. This allows representing a diffusion cell with realistic dimensions on a 1 
cm scale (cf. Figure 4-4). Like in the PK model it is thus possible to study the influ-
ence of lateral diffusion with the HOM models as well. In addition, these models 
inherit the desirable features of prediction and interpretation of parameters from 
the DIFF model. Note however, that the yet unknown variation in physiology and 
the involved alteration of the diffusion and partition parameters at the boundary to 
the lateral compartment were not included in the computational model.  
Due to the reduced computational complexity of the HOM models, these models are 
also suitable for optimization of parameters on a reasonable computational time-
scale. When it comes to accuracy, not surprisingly, the HOM models range between 
the PK model, which was optimized by parameter fitting, and the DIFF model, 
which has a predictive character. The HOM1 model being optimized based on a sin-
gle parameter produces slightly weaker results than the HOM3 model, which is ob-
tained by optimizing three parameters. As indicated in Table A-1, the absolute val-
ues of the corresponding diffusion and partition coefficients are quite comparable 
between both models however. 
The apparent diffusion coefficients in transversal direction, 𝐷!",!!, is three orders of 
magnitude smaller than the coefficients for lipid diffusion 𝐷!"#. For CAF, the result-
ing values for 𝐷!",!! are in the range reported in [81]. Similarly, the lateral coeffi-
cients 𝐷!",!! are one order of magnitude smaller than 𝐷!"# . For the interpretation of 𝐷!"# it is important that this value may be afflicted with some error, as a constant 
thickness of 3 mm was assumed. 
 102 
As shown in Equation 4-6, the SC diffusion coefficients 𝐷!",!!  and 𝐷!",!!   are cou-
pled. This has another important consequence for the interpretation of the contribu-
tion of lateral diffusion. In particular when considering CAF at 1 mg/ml, overshoot-
ing occurs for the amount in DSL (Figure 4-7 C), whereas undershooting occurs for 
the amount in LAT (Figure 4-7 E). Less pronounced, the same phenomenon also 
occurs for CAF at 12.5 mg/ml (Figure 4-8 C and Figure 4-8 E).  
Thus, it is not possible to accelerate diffusion into the lateral part of the SC and to 
slow down diffusion into the DSL at the same time. Controversially, for the PK 
model, an appropriate choice of rate constants k5 and k6 may have a compensating 
effect. This completely allows for reflecting the experimentally observed lateral dif-
fusion. In contrast to the PK model, both HOM models distinguish between the 
lateral part of the SC and of the DSL compartment. More precisely, both HOM 
models indeed support the hypothesis that lateral diffusion in the SC is subordinate 
and mainly occurs in the DSL (Figure 4-11 A-C). Due to the larger cross-sectional 
area of the DSL compared to the SC this seems reasonable. 
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A  
B  
C  
Figure 4-11  Homogenized modeling of FFA (1 mg/ml) (A), CAF (1 mg/ml) (B) and CAF (12.5 
mg/ml) (C) mass profiles over time. Relative mass distribution inside the lateral 
compartments of SC and DSL   
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4.6 Conclusion 
With the help of the presented mathematical models the experimental setup of fi-
nite dose skin absorption experiments in a Franz diffusion cell can be thoroughly 
investigated. All models explain and, to a certain extent, also predict the experi-
mental data. In-vitro mass transport to the lateral parts for the transient case should 
be considered to get optimal recovery experimentally and proper mass balance for 
mathematical models. 
The PK model is suitable for describing the whole setup and gives information 
about the diffusion process also into the lateral skin parts. It includes some struc-
tural information, but is primarily based on fitted parameters (rate constants) that 
are difficult to interpret. This approach may expand the knowledge about the whole 
absorption process in a Franz diffusion cell.  
Reflecting a different philosophy, the detailed diffusion model predicts the diffusion 
of FFA and CAF into the different skin compartments in a finite dose setup reason-
ably. It is a transfer of an infinite dose model to the finite dose scenario and does 
not rely on fitted parameters. Due to the computational complexity it currently does 
not include a lateral compartment however. 
In between the homogenized diffusion model has the advantage of describing the 
experimental setup more accurately while keeping the advantages of a diffusion 
model except for domain separation in the SC (corneocytes and lipid channel). 
Thus, simulation of the drug transport into the different compartments including 
the lateral part is possible. 
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5 A strategy for in-silico prediction of skin absorption 
in man 
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5.1 Abstract 
Some for time, in-silico models to address substance transport into and through the 
skin are gaining more and more importance in different fields of science and indus-
try. Especially, the mathematical prediction of in-vivo skin absorption is of great in-
terest to overcome ethical and economical issues. 
The presented work outlines a strategy to address this problem and in particular, 
investigates in-vitro and in-vivo skin penetration experiments of the model com-
pound flufenamic acid solved in an ointment by means of a mathematical model. 
Experimental stratum corneum concentration-depth profiles (SC-CDP) for various 
time intervals using two different in-vitro systems (Franz diffusion cell, Saarbrueck-
en penetration model) were examined and simulated with the help of a highly opti-
mized three compartment numerical diffusion model and compared to findings of 
SC-CDPs of the in-vivo scenario. 
Fitted model input parameters (diffusion coefficient and partition coefficient with 
respect to the stratum corneum) for the in-vitro infinite dose case could be used to 
predict in-use conditions in-vitro. Despite apparent differences in calculated parti-
tion coefficients between in-vivo and in-vitro studies, prediction of in-vivo scenarios 
from input parameters calculated from the in-vitro case yielded reasonable results. 
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5.2 Introduction 
The importance of substance transport into and trough the skin has grown consist-
ently in different fields of science and industry over the past decade. Not only phar-
maceutical applications for the local or systemic administration of drugs or applica-
tions in the cosmetic industries rely on carefully investigations of the underlying 
transport kinetics, especially regulation authorities such as REACH (Regulation, 
Evaluation, Authorization and Restriction of Chemicals) [21] request information 
about characteristics of potential harmful xenobiotic exposure to the human skin 
[156, 157].  
In-vivo experiments in the field of skin absorption are considered the gold standard 
but are difficult to perform and evaluate due to the complexity of processes involved 
and obviously face ethical concerns [19, 20]. Hence, experiments with regard to in-
vitro test systems are used frequently to overcome these issues [22, 23, 158]. In the 
past, it has been shown repeatedly that these test systems are capable of mimicking 
the in-vivo situation reasonably [38, 44, 134]. Many investigations on dermal re-
search were performed under infinite dose conditions, which were done by applying 
a sufficiently large amount of the test formulation to the surface of the skin, so that 
neither the drug nor any of the vehicular components were appreciably reduced dur-
ing the course of the experiment. The advantage of this procedure is that a very re-
producible way of application can be performed, quasi steady-state conditions might 
be reached in the stratum corneum (SC) [159] and effects caused by rubbing are 
avoided. On the other hand, this procedure is very distant from in-use applications, 
where typically small amounts of drug preparation are applied on a relatively large 
area of the skin by massaging. 
Until now, abundant information about drug distribution within the skin are availa-
ble concerning infinite dosing. In contrast, the amount of data for finite dosing is 
rather limited [160], and much sparser, if experiments with semisolid drug prepara-
tions and other objectives than permeation data are of interest.  
Based on available data [161] it was decided to carry out a study gathering input pa-
rameters (SC diffusivity and partition coefficient) with respect to a mathematical 
model based on experimental results of two different in-vitro test systems, the Saar-
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bruecken penetration model (SB-M) and the Franz diffusion cell (FD-C), using the 
tape stripping technique [39]. With the help of an in-silico model these input param-
eters were used to predict the situation in-vivo. Experimental data was examined 
under infinite dose and finite dose conditions for the aforementioned test systems 
and in-vivo studies. Finite dosing was carried out on the basis of different guidance 
documents, which state that finite dosing is given when the amount of ointment 
applied to the skin is between 1-10 mg/cm  [54-56]. Consequently, infinite dose 
conditions were implemented by application of more than 10 mg/cm  of formula-
tion. These procedures were performed with a semisolid drug preparation. 
For some time past, mathematical models predicting skin absorption are considered 
alternatives to experimental investigations by different regulatory agencies [162-
164]. For complex mechanistic models it could be shown that in-vitro infinite and 
finite dose concentration-depth profiles could be predicted reasonably but require a 
complex set of input parameters [81, 82, 125]. In contrast, in this work a sparse pa-
rameter one-dimensional diffusion model was used to not only investigate and pre-
dict the in-vitro situation but to predict the in-vivo situation with help of in-vitro 
based model input parameters as well. For this purpose, the underlying diffusion 
equation was solved numerically. First of all, the model was fitted to in-vitro concen-
tration-depth profiles to obtain information about diffusivity and partition coeffi-
cient with respect to the SC. Subsequently, in-vitro infinite dose fitting results were 
used to predict the in-vitro finite dose scenario as conducted successfully before for 
aqueous formulations [82, 165]. Finally, in-vivo concentration-depth profiles for the 
finite and infinite dose case were predicted from data obtained from in-vitro studies. 
A schematic overview about the used strategy is provided in Figure 5-1. 
Predictions for the in-vitro finite dose setup as well as predictions of in-vivo scenari-
os showed promising results. A positive outcome of the presented study should not 
only give a better hint on the theory of the drug’s diffusion into the SC but most 
likely be a starting point to reduce experimental work in-vitro and in-vivo. It will 
therefore reduce costs and time within the development of semisolid drug formula-
tions and other dermally applied formulations. 
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A  
B  
Figure 5-1  Two-step strategy to analyze and predict in-vivo and in-vitro concentration-
depth profiles. First, model input parameters (partition coefficient and diffusion 
coefficient) were fitted to experimental data (A). In a second step, the in-vitro fi-
nite dose scenario is predicted by using model input parameters taken from in-
vitro infinite dose fittings (first step). Furthermore, the in-vivo setup is predicted 
from fitted in-vitro model input parameters (first step). 
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5.3 Materials and methods 
The following materials and equipment were used: Flufenamic acid (Kali-Chemie 
Pharma, Hannover, D); wool alcohols ointment and Multifilm kristall-klar (Beiers-
dorf, Hamburg, D); Ringer solution, McIlvaine citric acid-phosphate buffer pH 2.2, 
NaOH (Merck, Darmstadt, D); Plastibase® (Heyden GmbH, Muenchen, D); metha-
nol (Baker, Deventer, NL); Franz diffusion cells type 4G-01-00-20-15, area = 3.142 
cm2 , acceptor volume = 15 ml (PermeGear, Riegelsville, PA, USA) teflon filter 
Minisart - pore size 0.2 µm (Sartorius, Goettingen, D); isocratic HPLC consisting of 
a 655 A 40 autosampler, L 4250 detector, L 6220 pump, 6000 K data interface and 
5 µm LiChrospher® 100 / RP-18 column / 12.5 cm x 4 mm (Merck-Hitachi, Darm-
stadt, D); Dialysis membrane, cut off 10,000 (Dianorm GmbH, Munich, Germany); 
Cellulose membrane, cut off 10,000 (Medicell International LTD, London, GB).  
The non-steroidal drug flufenamic acid (FFA), solved in a concentration of 0.9% in 
wool alcohols ointment (German Pharmacopoeia 1999), was used as drug prepara-
tion under infinite and finite dose conditions. Prior to the application, the drug 
preparation was stored at 32°C for one week to allow complete dissolution of the 
drug in the ointment base. This was checked by light microscopic investigations. 
5.3.1 Skin samples for in-vitro experiments 
Skin samples were taken from Caucasian female donors undergoing abdominal 
surgery with the approval of the ethic committee of the Caritas-Hospital Lebach, 
Germany. Immediately after excision the subcutaneous fatty tissue was removed 
using a scalpel. The skin was cut into 10 x 10 cm pieces, wrapped in aluminium foil 
and stored in polyethylene bags at -26°C until use. The maximum storage time was 
three months. 
5.3.2 Saarbruecken penetration model (SB-M) experiments 
Details of the experiments are given in [161]. Briefly, for infinite dosing an ointment 
layer of at least 2 mm was applied whereas for finite dosing 4-6 mg ointment per 
cm2 was evenly spread on the skin surface. All experiments were carried out at a 
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skin surface temperature of 32 ± 1°C for different time intervals (0.5, 1, 3 and 6 
hours) at occlusive conditions. 
5.3.3 Franz diffusion cell (FD-C) experiments 
Details of the experiments are given in [161]. In short, application of the ointment 
was conducted similar to the procedure described previously (SB-M). As receptor 
fluid Soerensen phosphate buffer pH 7.4 was used and mixed with a magnetic stir-
ring bar at 500 rpm. The skin specimen was prehydrated for 30 minutes prior to the 
application of the formulation. All experiments were carried out as described in the 
previous section (SB-M). 
5.3.4 Horizontal segmentation of the stratum corneum (SC) 
To compare the results of both models, the skin was always treated in exactly the 
same manner at the end of all experiments [38]. First, the remaining ointment was 
removed by wiping the skin with cotton. Second, the skin was successively stripped 
with 20 pieces of adhesive tape. In a standardized procedure (pressure: 2 kg for 10 
sec), tapes were removed rapidly and combined in 6 pools of 1, 1, 3, 4, 5 and 6 strips 
for analytical purposes. Due to this procedure, each of the removed cell layers had 
nearly the same thickness, which had been shown in previous studies in different 
laboratories [33, 166, 167]. The first tape strip was always discarded because of po-
tential contamination. 
5.3.5 In-vivo experiments 
6 human volunteers (3 male, 3 female), aged 23 - 29 years, from whom informed 
consent was obtained, participated in the study [38]. They were in good health and 
had no history of any dermatological disease. 
A template of Fixomull® with 4 holes was fixed on the volar left and right forearm of 
each volunteer. Each hole released an area of 15 mm in diameter and represented 
one experimental area. The drug preparation was applied according to the in-vitro 
experiments. The administration areas were not covered during the incubation time 
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(0.25, 0.5, 1 and 3 h), but the volunteers were asked to reduce their movements to 
avoid any loss of drug preparation. 
The tape-stripping procedure was performed by exerting the pressure just with the 
forefinger. To increase reproducibility, the procedure was carried out by the same 
person according to the AAPS/FDA Workshop report [34] and the Guidance for In-
dustry [168]. 
5.3.6 In-vitro release experiments 
The release of FFA from the ointment was examined for different concentrations 
(0.225%, 0.45%, 0.675% and 0.9%) using an infinite dose setup (approximately 0.3 
g of applied formulation). For that reason, by means of a FD-C setup, released mass 
over time across a dialysis membrane (0-6 h, 5 time points) and cellulose mem-
brane (0-53 h, 11-18 time points) was determined, respectively. 
5.3.7 Assay method and HPLC-procedure 
For a detailed description of the extraction procedure and the HPLC analysis [detec-
tion limit 20 ng/ml] see Wagner et al. [38]. The linearity of the HPLC method was 
checked over a quantification range from 50 to 10,000 ng/ml, providing a good lin-
earity between the area of the UV-absorption peak and the respective concentration 
with r = 0.999 and an accuracy of 97.8 ± 3.8%. 
5.3.8 Determination of diffusivity of FFA in the ointment 
As stated before, the release of FFA for different concentrations (0.225%, 0.45%, 
0.675% and 0.9%) was examined using a dialysis membrane and a cellulose mem-
brane. To estimate diffusivity D of FFA inside the vehicle the amount released per 
area Q over time t for initial concentration C0 (assuming a uniform distribution of 
FFA within the ointment at t=0) was fitted for every single experiment using a non-
linear least squares approach (Equation 5-1) [169]. 
𝑄 = 2𝐶!(𝐷𝑡𝜋 )!! Equation 5-1 
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Since equation 1 only holds true for a loss of initial concentration of approximately 
up to 30% over time, the general solution (Equation 5-2) with thickness of applied 
ointment layer h (h=2mm) was applied to analyze the impact of a potential loss of 
initial concentration and ensure valid results with respect to the diffusion coefficient 
[169]. 
𝑄 = ℎ𝐶! 1− 8𝜋! 1(2𝑚 + 1)! 𝑒(!!(!!!!)!!!!!!! )∞!!!  Equation 5-2 
Here, the underlying infinite sum was calculated until maximum possible machine 
accuracy was reached (comparison to the machine epsilon) [125] . 
5.3.9 Diffusion model 
The diffusion of FFA from the ointment through the SC was simulated using a one-
dimensional diffusion model. Three compartments (vehicle, SC, deeper skin layers) 
were implemented to address different diffusion kinetics of the heterogeneous sys-
tem for the in-vitro and in-vivo scenario. For every compartment a set of diffusion 
coefficients and partition coefficients with respect to adjacent compartments was 
assigned. The underlying diffusion equation (Equation 5-3) was solved numerically 
using an implicit Crank-Nicolson finite differences solver [63]. 
𝛿𝑐(𝑥, 𝑡)𝛿𝑡 = 𝛿𝛿𝑥 𝐷 𝛿𝛿𝑥 𝑐(𝑥, 𝑡)  Equation 5-3 
Phase transitions were modeled in two steps. First the change of diffusivity at com-
partment boundaries was addressed by decomposing the Crank-Nicolson scheme 
into in- and outgoing fluxes and by a subsequent substitution of every diffusion co-
efficient in the Crank-Nicolson scheme for a given cell (position in the discretized 
spatial domain) with the harmonic mean of the diffusion coefficients of its adjacent 
cells according to work of Seta et al. (Equation 5 in [84]). Partitioning was incorpo-
rated into the Crank-Nicolson scheme by reducing back diffusion (multiplication of 
assigned diffusivity in a cell with partition coefficient K) for the direction of a “nega-
tive jump” (K < 1). 
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A sufficient spatial resolution at phase transitions is crucial to achieve stable and 
reasonable results in simulation but can largely slow down the speed of computa-
tion. To overcome this problem while gaining maximum speed of computations a 
non-uniform grid approach according to [170] was applied. Here, a base space step 
size of 1 µm was used within every compartment. Towards phase transitions the 
step size was exponentially decreased to at least 1/10 µm. A test grid simulating a 
heterogeneous system with a change in diffusivity is depicted in Figure 5-2. Di-
richlet boundary conditions and reflecting boundary conditions were implemented 
to model infinite dosing and finite dosing, respectively. 
At the start of the calculation, the concentration in the donor was set to the concen-
tration of the drug in the ointment base as employed in the experiment. The con-
centration in all other elements was zero. 
As basis for calculations of infinite dosing the following assumptions were made: 
The thickness of the SC was assumed to be 15 µm for in-vitro simulations and 17 µm 
for in-vivo simulations that matches the findings from the tape-stripping procedure. 
The thickness of the deeper skin layers was assumed to be 2000 µm. 
 
Figure 5-2  Test simulation for different times (1 h, 2h, 3h, 4h) given a heterogeneous sys-
tem with a change of diffusivity at 80 µm using a non-uniform grid. Grey vertical 
lines denote to the one-dimensional grid and resolution increases exponentially 
towards the compartment boundary at 80 µm. 
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The thickness of the donor was calculated from the amount of ointment base ap-
plied and the specific density of the ointment base (= 0.836 g/cm ). While the do-
nor could be depleted of the drug, the tissue following the deeper skin layers was 
assumed to be a perfect sink (the concentration at the end of the deeper skin layers 
was always zero). 
5.3.10 Model input parameters, fitting and prediction 
Determination of diffusivity in the ointment was performed as mentioned previous-
ly. Diffusivity in the deeper skin layers was computed as the harmonic mean of val-
ues taken from the literature [125, 165] (DDSL = 8166.67 µm2/h). Partition coefficient 
KSC/DSL was taken from [165] (KSC/DSL = 4.36). 
KSC/Vehicle (henceforth referred to as KSC) and DSC were fitted using a non-linear least 
squares approach according to the following protocol: 
1. The concentration-depth profiles for every time point were fitted separately (ap-
proach 1). 
2. The total set of concentration-depth profiles for all times was fitted in one step 
(approach 2). 
This procedure was applied to infinite and finite dose data from FD-C and SB-M 
systems separately. For the in-vivo scenario, only approach 2 was applied.  
After comparison of the findings, in a first step the kinetic parameters from the in-
vitro infinite dose case were used to predict the in-vitro finite dose scenario – a pro-
cedure that could be successfully applied before with the help of complex 2D diffu-
sion models for the simulation of drug release from an aqueous formulation [82, 
165]. 
In a second step the potential to predict the in-vivo scenario from parameters fitted 
from the in-vitro case was examined. 
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5.3.11 Software and programming 
The diffusion model was implemented in C++ and compiled using the Apple LLVM 
version 5.0. Fitting was performed with the R programming language version 2.15.1 
[171]. For statistical evaluation GraphPad Prism version 6.0 for Macintosh 
(GraphPad Software, La Jolla, California, USA) was used. 
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5.4 Results 
5.4.1 Estimation of ointment diffusivity of FFA 
Distribution of fitting results (Figure 5-3) of the diffusion coefficient of FFA in the 
ointment released over two different membrane systems (dialysis membrane and 
cellulose membrane) showed significant differences between the two groups (dialy-
sis vs. cellulose membrane) with p=0.02 (Wilcoxon-Mann-Whitney test). 
 
Figure 5-3  Distribution of FFA diffusivity in the ointment determined by fittings to data from 
release experiments over a dialysis membrane (red bars) and a cellulose mem-
brane (blue bars).  
All single fits could be considered highly significant (p < 0.01). In comparison to 
results from the cellulose membrane, release over the dialysis membrane is acceler-
ated by a factor of approximately 1.6. 
Since variation of vehicle diffusivity in the given range did not alter concentration-
depth profiles of the SC significantly for various test simulations (e.g. maximum 
differences in concentration of < 0.01% for late times in the more error prone finite 
dose scenario), for the subsequent simulations the harmonic mean of all estimated 
diffusion coefficients with DVehicle = 6583.19 µm2/h was used as a model input pa-
rameter. 
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5.4.2 Fitting of in-vitro infinite dose profiles 
Experimental results for both FD-C and SB-M showed a characteristic jump in con-
centration at the Vehicle/SC boundary given a vehicle initial concentration of 7.55 
mg/ml (Figure 5-4). Here, concentrations in the upper segment of the SC are slight-
ly higher for the SB-M setup in comparison to the FD-C. Both sets of experiments 
approach towards steady state, whereas SB-M experiments tend to reach steady-state 
slower. Average relative standard deviation of experimental data is slightly higher 
for the FD-C setup (45%) in comparison to the SB-M (38%). 
A B  
Figure 5-4 Overall fitted stratum corneum concentration-depth profiles of the infinite dose 
FD-C setup (A) and infinite dose SB-M setup (B) for various time points. Open 
circles denote experimental findings and solid lines denote the fitted model out-
put. Data variation is given as standard deviation. 
 
Fitting of SC diffusivity and partition coefficient showed reasonable results with low 
residual standard errors  (Table 5-1). Figure 5-4 shows results from fitting every data 
point of all times in total (All times, Table 5-1). For both setups individual fittings 
show higher theoretical permeabilities kp (𝑘! = !×!! ) for early times in comparison 
to late times with a higher average permeability for the FD-C setup (factor of 2.33 
Table 5-1).  
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Table 5-1  Infinite dose fitting results (DSC, KSC) of FFA concentration-depth profiles for FD-
C experiments (A) and SB-M experiments (B) for different time points separate-
ly and total fit of all times points (All times). Theoretical permeability kp was cal-
culated from DSC, KSC and SC thickness. The residual standard error (RSE) is 
given for each fit separately. 
 
5.4.3 Fitting of in-vitro finite dose profiles 
As for the infinite dose scenario, experimental results for FD-C and SB-M showed a 
characteristic jump in concentration at the Vehicle/SC boundary (Figure 5-5). SB-M 
experiments tend to reach towards a pseudo steady-state for late times. Average rela-
tive standard deviation of experimental data is slightly higher for the SB-M setup 
(41%) in comparison to the FD-C (36%). 
Fitting of SC diffusivity and partition coefficient for finite dose experiments using a 
FD-C and SB-M setup showed very reasonable results with low residual standard 
errors (Figure 5-5, Table 5-2). Simulation results (fitted model) showed a decline of 
11 % (FD-C) and 17 % (SB-M) after 6 h of simulations for the vehicle concentrations 
indicating the transient nature of the underlying process. High permeability values 
could be detected for single fittings of short incubation times for both FD-C and SB-
M (Table 5-2). 
 
 Times [min] DSC ± SE [µm2/h] KSC ± SE kp [µm/h] ± SE RSE 
A 30 5.24 ± 1.55 1.93 ± 0.29 6.75E-01 ± 2.24E-01 0.63 
 60 5.71 ± 2.66 1.56 ± 0.30 5.99E-01 ± 3.01E-01 1.07 
 180 6.36 ± 1.46 1.10 ± 0.08 4.67E-01 ± 1.13E-01 0.51 
 360 1.84 ± 0.47 1.37 ± 0.12 1.68E-01 ± 4.57E-02 0.62 
 All times 6.53 ± 1.98 1.17 ± 0.11 5.09E-01 ± 1.62E-01 1.19 
B 30 3.67 ± 2.59 1.93 ± 0.92 4.74E-01 ± 4.03E-01 1.25 
 60 2.23 ± 1.48 1.83 ± 0.74 2.71E-01 ± 2.10E-01 1.26 
 180 0.95 ± 0.44 2.24 ± 0.60 1.42E-01 ± 7.63E-02 1.21 
 360 0.80 ± 0.22 1.97 ± 0.25 1.05E-01 ± 3.21E-02 0.77 
 All times 2.06 ± 0.57 1.59 ± 0.20 2.18E-01 ± 6.64E-02 1.33 
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A B  
Figure 5-5  Overall fitted stratum corneum concentration-depth profiles of the finite dose 
FD-C setup (A) and finite dose SB-M setup for various time points. Open 
circles denote experimental findings and solid lines denote the fitted model 
output. Data variation is given as standard deviation. 
Fitting of SC diffusivity and partition coefficient showed reasonable results with low 
residual standard errors (Table 5-2). Figure 5-5 shows results from fitting every data 
point of all times in total (All times, Table 5-2). 
Table 5-2  Finite dose fitting results (DSC, KSC) of FFA concentration-depth profiles for FD-
    C  experiments (A) and SB-M experiments (B) for different time points separate-
    ly and total fit of all times points (All times). Theoretical permeability kp was  
    calculated from DSC, KSC and SC thickness. The residual standard error (RSE) 
    is given for each fit separately. 
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 Times [min] DSC ± SE [µm2/h] KSC ± SE kp [µm/h] ± SE RSE 
A 30 9.65 ± 1.96 1.29 ± 0.11 8.28E-01 ± 1.84E-01 0.36 
 60 4.23 ± 1.04 1.05 ± 0.11 2.95E-01 ± 7.95E-02 0.35 
 180 1.24 ± 0.37 2.25 ± 0.35 1.86E-01 ± 6.18E-02 0.82 
 360 1.36 ± 0.14 1.54 ± 0.06 1.39E-01 ± 1.56E-02 0.25 
 All times 2.45 ± 0.57 1.58 ± 0.17 2.58E-01 ± 6.61E-02 1.07 
B 30 29.55 ± 8.29 0.71 ± 0.07 1.41E+00 ± 4.17E-01 0.36 
 60 8.55 ± 6.29 1.21 ± 0.34 6.91E-01 ± 5.44E-01 1.41 
 180 6.28 ± 2.78 0.88 ± 0.13 3.69E-01 ± 1.73E-01 0.75 
 360 1.53 ± 0.53 1.41 ± 0.18 1.44E-01 ± 5.28E-02 0.77 
 All times 5.85 ± 1.93 1.08 ± 0.12 4.22E-01 ± 1.47E-01 1.12 
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For both in-vitro setups fittings for every time point separately show higher theoreti-
cal permeabilities for early times in comparison to late times with an higher average 
permeability for the SB-M setup (factor of 1.64 Table 5-2). Overall, finite dose per-
meabilities showed similar values in comparison to infinite dose experiments. (All 
times, Table 5-1, Table 5-2). 
5.4.4 Prediction of in-vitro finite dose profiles from infinite dose input 
parameters 
Given this evidence, prediction of the in-vitro finite dose scenario from input values 
gathered from the infinite dose case was carried out and showed reasonable results 
(Figure 5-6) with low relative absolute errors of the fit (0.63 for FD-C and 0.61 for 
SB-M). 
A B  
Figure 5-6  Predicted in-vitro finite dose experiments for the FD-C setup (A) and SB-M set-
up (B). Open circles denote experimental findings and solid lines denote the 
simulation results (prediction). Dashed lines indicate the 95% confidence inter-
val. Data variation is given as standard deviation. 
5.4.5 Drug concentration – SC depth – profiles: In-vivo 
In-vivo experimental data showed a characteristic jump of concentration below the 
initial concentration of the vehicle for all time points (Figure 5-7). Concentration-
depth profiles for the infinite and finite dose tend to establish a (pseudo) steady-
state after 180 min. Fittings of SC diffusivity and partition coefficient using the dif-
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fusion model could describe the fate of the substance excellently (Figure 5-7, dashed 
lines). However, fitted diffusivities showed extremely high values in comparison to 
in-vitro studies leading to high theoretical permeability values (Table 5-3 A). Parti-
tion coefficients showed a reduction of factor 4-5 in comparison to in-vitro studies 
(Table 5-1 All times, Table 5-2 All times, Table 5-3 A). 
Table 5-3  Overall fitting results (DSC, KSC) of FFA concentration-depth profiles for in-vivo 
    infinite dose and finite dose scenarios (A). Lower part of the table (B) shows  
    fitting results for KSC with fixed values DSC* for stratum corneum diffusivity (taken 
    from in-vitro fittings). 
 Experiment DSC ± SE [µm2/h] KSC ± SE kp  ± SE [µm/h] RSE 
A Infinite dose 54.53 ± 17.16 0.35 ± 0.03 1.12E+00 ± 3.66E-01 0.37 
 Finite dose 36.60 ± 10.04 0.26 ± 0.02 5.60E-01 ± 1.59E-01 0.24 
B Infinite dose 5.85 ± 1.93 *(SB-M finite dose) 0.55 ± 0.06 1.89E-01 ± 6.58E-02 0.62 
 Finite dose 5.85 ± 1.93 *(SB-M finite dose) 0.38 ± 0.04 1.31E-01 ± 4.53E-02 0.37 
 
Due to the steady-state-like curve shape of both finite and infinite dose in-vivo stud-
ies (Figure 5-7, dashed lines) fitting of diffusivity can obviously lead to problems 
since the variation of DSC does not alter the curve shape when approaching steady-
state. To overcome this problem DSC was set to a fixed value (taken from in-vitro fi-
nite dose SB-M fittings of all time points to account for an average best description 
of all time points) and only the partition coefficient was varied by the fitting routine. 
Results of this approach are depicted in Figure 5-7 (solid lines). In comparison to 
the first approach the fitting error did only slightly increase (Table 5-3 B). Fitted par-
tition coefficients showed only minor differences and hence, permeability values 
decreased by a factor of approximately 4-6 (Table 5-3 A vs. Table 5-3 B).  
In-vivo permeability values (Table 5-3 B) showed a decrease of factor 1.2-2.7 in com-
parison to the in-vitro infinite dose case (Table 5-1) and a decrease of factor 2.0-3.2 in 
comparison to the in-vitro finite dose fittings (Table 5-2). The modeled finite dose 
scenario reveals a FFA vehicle depletion of only 5%. 
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A B  
Figure 5-7  Fitted stratum corneum concentration-depth profiles of the in-vivo infinite dose 
case (A) and finite dose case (B) for various times with fixed DSC (solid line, val-
ues taken from in-vitro fittings) and free DSC (dashed line). Open circles denote 
experimental findings and solid lines denote the fitted model output. Data varia-
tion is given as standard deviation. 
5.4.6 Prediction of in-vivo profiles from in-vitro input parameters 
In second step, model input parameters taken from the in-vitro infinite dose and 
finite dose case (All times, Table 5-1, Table 5-2) were used to predict the in-vivo sce-
nario yielding reasonable average relative errors of the fit (Table 5-4). 
Table 5-4  Prediction errors (average relative error) of FFA concentration-depth profiles for 
in-vivo infinite dose and finite dose scenarios. 
KSC and DSC 
taken from 
In-vivo infinite dose 
prediction error 
In-vivo finite dose 
prediction error 
FD-C Infinite 9.18E-01 1.21E+00 
FD-C Finite 9.19E-01 1.08E+00 
SB-M Infinite 9.15E-01 1.06E+00 
SB-M Finite 8.58E-01 1.03E+00 
 
For both application scenarios (finite and infinite dose) input values from the SB-M 
finite dose fittings led to the smallest fitting error (prediction results depicted in 
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Figure 5-8). Simulations (Figure 5-8) lead to reasonable results, especially for short 
times and concentrations below stratum disjunctum [172]. 
A B  
Figure 5-8 Predicted in-vivo experiments for the infinite dose case (A) and finite dose case 
(B). Open circles denote experimental findings and solid lines denote the simu-
lation results (prediction). Dashed lines indicate the 95% confidence interval. 
Data variation is given as standard deviation. 
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5.5 Discussion 
5.5.1 Fitting results and differences in in-vitro and in-vivo setups 
Model fitting results for infinite and finite dose in-vitro studies are in very reasona-
ble agreement with the experimental findings (Figure 5-4, Figure 5-5). Variation in 
diffusivity and partition coefficient (All times) can be explained by intra-individual 
variability in determined parameters from different experiments [173]. Average rela-
tive standard deviations of in-vitro and in-vivo concentrations over depth and time do 
show insignificant differences in variability (32–42% for in-vivo and 36-45% for in-
vitro). These observations are in reasonable agreement with findings from literature 
[173]. As stated before, finite dose experiments show a more semi-infinite nature 
during the time of application due to the rather low donor depletion (11-17%).  
The observed decrease of diffusion coefficient over time for finite and infinite sce-
narios is in reasonable agreement with in-vivo findings of Herkenne et al. [174]. 
These findings may be the result of the prolonged incubation time which can make 
fitting the curves more difficult. In addition, the resistance of the epidermis may 
have an impact on the curve shape after longer incubation times [160]. In contrast 
to the addressed diffusivity, variability of the fitted partition coefficient over time did 
not show a clear trend for both in-vitro systems (Table 5-1, Table 5-2). 
In-vivo fittings of diffusivity and partition coefficient showed lower partition coeffi-
cients with values below 1 and high diffusivity and subsequently high theoretical 
permeabilities. In comparison to experimental data an excellent correlation could be 
found (Figure 5-7, dashed lines).  
Due to the steady-state nature of the concentration-depth profiles after short times 
fitting results for DSC are prone to error. Therefore, SC diffusivity was set to con-
stant values gathered from in-vitro studies. Fitting results were in good agreement 
with experimental data (Figure 5-7, solid lines) for all time points. Partition coeffi-
cients were still lower in comparison to in-vitro experiments. Due to low partition-
ing, an even lower donor depletion was calculated, explaining the similar shapes of 
finite and infinite dose in-vivo experiments. 
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Speaking of theoretical permeabilities, lower calculated permeabilies for in-vivo ex-
periments (Table 5-3 B) in comparison to SB-M fitting results (Table 5-1 B, Table 5-2 
B, All times) could be observed. 
However, student’s t-test of SB-M in-vitro setup versus in-vivo setup did not indicate 
significant differences for the infinite dose (p=0.76) and finite dose scenario 
(p=0.06). 
The found differences in partition coefficient between in-vitro and in-vivo studies 
could be attributed to a potential contamination of skin slabs with subcutaneous 
fatty tissue during the process of preparation of ex-vivo skin samples (solubility of 
FFA in triglycerides:  7%; solubility of FFA in wool wax ointment: 0.9%) [175]. 
5.5.2 Prediction of the in-vitro finite dose scenario from model input 
parameters from the infinite dose case 
In 2013 it could be shown that parameters obtained from the in-vitro infinite dose 
case are suitable parameters to predict the in-vitro finite dose scenario for an aque-
ous vehicle [82, 165]. The investigations cited employ more complex two-
dimensional diffusion models that need a larger set of input parameters (e.g. SC 
lipid diffusivities, corneocyte diffusivities, SC lipid/corneocyte partition coefficients) 
in comparison to the model presented. We could confirm the findings of the afore-
mentioned works by applying a one-dimensional sparse-parameter model for a 
semi-solid donor formulation. Excellent agreement with experimental data for the 
prediction of in-vitro finite dosing of the two model systems (FD-C and SB-M) was 
found (Figure 5-6). 
5.5.3 Prediction of the in-vivo scenario from model input parameters from 
the in-vitro case 
We presented an in-silico model to analyse and predict in-vivo concentration-depth 
profiles of a drug for release from a semi-solid formulation. Work on predictions of 
in-vivo permeation is still scare. Pirot et al. could predict the in-vivo permeability of 
4-cyanophenol for 60 min of application from values fitted from tape-stripping data 
obtained after 15 min [176]. Variability of permeability of in-vivo fittings of FFA re-
A strategy for in-silico prediction of skin absorption in man 
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ported here is in reasonable agreement with results of Pirot and coworkers. Perme-
abilities for the in-vitro setups over time do show slightly larger variations (2-fold to 
6-fold between highest and lowest permeability of individual setups). Therefore, 
fitting of all data points from all measured times in total seems to be the most rea-
sonable option to capture the whole kinetic process over time. 
Using a simple analytical solution of the diffusion equation, Herkenne et al. could 
show the potential of in-vitro tape-stripping data to predict the situation in man [177]. 
Parameters from the in-vitro and in-vivo case were in reasonable agreement, but also 
some significant differences were observed. In contrast to the study presented here, 
only the infinite dose scenario was examined, vehicle diffusivity and resistance of 
the deeper skin layers were not taken into account and porcine skin was used for in-
vitro studies.   
In this study, predicted human in-vivo concentration-depth profiles from data ob-
tained from in-vitro cases using human skin showed promising results (Figure 5-8). 
Short times (15-30 min) could be described excellently but concentrations in super-
ficial SC depths are considerably overpredicted for later times (60-180 min). Obvi-
ously, differences in partition coefficients between in-vitro and in-vivo experimental 
findings yield to the aforementioned discrepancies. Hence, possible alterations of 
solubility due to preparation of ex-vivo skin samples (e.g. contamination with subcu-
taneous fatty tissue) should be taken into account when gathering kinetic de-
scriptors from in-vitro settings to describe the transdermal transport of substances 
in man. 
5.5.4 Mathematical diffusion model 
In contrast to analytical solutions of the diffusion equation, numerical approaches 
can be considered more versatile due to generalization (infinite vs. transient scenar-
io), extendibility (e.g. protein binding, evaporation, blood flow) and complexity (e.g. 
microscopic models of the SC, multi compartment approaches). The interested 
reader is kindly referred to overview articles about analytical solutions and numeri-
cal approaches in the field of modeling skin transport [58, 101, 160]. However, one 
major drawback of numerical solutions is often the speed of computation. Due to 
the high level of optimization (implicit finite differences, non-uniform gridding) the 
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presented model is capable to be incorporated in complex operations, like fitting 
routines, but still run in high spatial resolution on consumer hardware for reasona-
ble computational times. 
Considering the complex nature of the human skin and the underlying transport 
kinetics, one has to bear in mind the following facts: 
• In this study the morphological structure of the SC was simplified as a 
pseudo-homogenous membrane. This obviously, does not reflect the micro-
scopic structure of the SC. This limitation can be overcome by building 
more complex microscopic models of the SC [96] but this would increase 
the number of unknown parameters [81] as well as greatly increase compu-
tational complexity, making the model less generally applicable. 
• Additional mechanisms, such as binding were not considered but might in-
fluence parameters determined from in-vitro parameters as well as the un-
derlying kinetic assumptions [58, 62, 178]. 
• In-vivo blood flow was not modeled and might influence in-vitro in-vivo cor-
relation. 
5.5.5 Comparison of FD-C and SB-M to gather input parameters to predict 
in-vivo skin penetration 
Comparison of the two in-vitro systems for the determination of model input pa-
rameters to predict the in-vivo scenario shows a tendency to prefer the SB-M setup 
that typically describes the in-vivo case in a more natural way due to lower hydration 
states in comparison to the FD-C setup. However, the differences in average relative 
errors (Table 5-4) are small. Fitting errors (residual standard errors) for the in-vitro 
setups indicate slightly better results for the SB-M (Table 5-1, Table 5-2). This indi-
cates that SB-M concentration-depth profiles could be described better with the ap-
plied mathematical model and this subsequently might influence the slightly better 
prediction results. 
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5.6 Conclusion 
The application of an one-dimensional numerical in-silico model to simulate skin 
penetration turns out to be useful to describe in-vitro experiments for different sys-
tems (FD-C and SB-M), as well as in-vivo experiments for the infinite and finite dose 
scenario. Input parameters gathered from the in-vitro infinite dose case can be used 
to describe the in-vitro finite dose scenario for both model systems. Despite appar-
ent differences in calculated partition coefficients between in-vivo and in-vitro stud-
ies, prediction of in-vivo scenarios from input parameters calculated from the in-
vitro case seems to be a reasonable option. There is evidence to prefer the more in-
vivo like SB-M as an ethical inoffensive model to predict the fate of a substance in 
man but certainly, a careful evaluation for a wide range of different xenobiotics is 
necessary and should be addressed in future works. 
The application of in-silico models and the concepts presented in this study, will 
hopefully lead to an improved prediction of the in-vivo situation and a better under-
standing of the underlying physicochemical processes. 
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6 Outlook 
The following oulook provides contributions of the author to published and un-
published work in the field of modeling and measurement of skin absorption. The 
methods and results are presented in a condensed fashion to comply with the scope 
limitations associated with this thesis.   
6.1 Inclusion of binding kinetics into mathematical models to 
simulate transdermal absorption 
Parts of this section have been published in: 
Hansen, S., Selzer, D., Schaefer, U. F., Kasting, G. B. (2010). An Extended Database 
of Keratin Binding. J Pharmaceut Sci, 100(5), 1712–1726 
 
The author of the thesis made the following contributions to the publication: 
Performed the mathematical analysis of the data (fittings of the non-isotherm data, 
SMARTS analysis), investigated the data manually, produced the figures and wrote 
parts of the manuscript. 
Steffi Hansen performed the experiments, fitted the isotherm data and wrote the 
manuscript. 
 
6.1.1 Note 
This section shortly summarizes the contributions of the author on analyzing the 
extended database of keratin binding. The full published article on this topic can be 
found elsewhere [178]. 
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6.1.2 Introduction 
Diffusion modeling is a powerful tool for predicting skin absorption. However, cur-
rent advances in predicting absorption from finite doses usually fall short of expec-
tations [30]. Often skin levels are seriously under-predicted by current models, 
hampering their usefulness for regulatory purposes [151]. Transient exposure is rel-
evant to the majority of pharmaceutical and cosmetic dermal applications and often 
also to unintentional exposure to hazardous compounds. Predicting transient ab-
sorption of finite doses requires the understanding of processes that may only play a 
minor role in steady-state absorption. A major factor that will influence the kinetics 
of absorption is reversible binding of permeants to the tissue. Binding leads to dif-
ferences in the effective and true diffusion and partition coefficients, a retardation 
of the absorption process, and a sustained presence of the bound compound in the 
tissue. Therefore, accurate estimates of binding coefficients are essential to improve 
finite dose skin absorption models. The present work focuses on predicting binding 
coefficients to the major stratum corneum (SC) protein keratin. Keratin intermediate 
filaments account for over 90% of the weight of the proteins in the stratum 
corneum and form the body of the cellular phase of the stratum corneum. Therefore, 
binding coefficients to keratin should be a good predictor of binding to the stratum 
corneum proteins, if the keratin is accessible to the permeant. 
The current state of the art of evaluating the affinity to corneocyte proteins is to 
measure the partition coefficient into delipidized SC (DSC). It has earlier been rec-
ognized that the logarithmic protein/water partition coefficient logKpro/w is related to 
the logarithmic octanol/water partition coefficient logKo/w in terms of a linear energy 
relationship [64, 179]. However this relationship was developed for a rather small 
and largely homogeneous dataset of 16 hydrocortisone esters and methyl substitut-
ed p-cresols. Meanwhile a number of authors have published further partitioning 
data into DSC so that it seems worthwhile to update and extend the original dataset. 
In addition, the method of delipidisation has been criticized in the past as treatment 
with organic solvents may denature proteins and furthermore does not remove li-
pids covalently bound to the cornified envelope  [180]. In consequence DSC might 
not be representative of the affinity to the corneocytes in the context of intact SC. 
Therefore, the current analysis will focus not only on partitioning data into DSC but 
broaden the analysis to integrate further keratinous substrates from human as well 
Outlook 
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as animal origins, i.e., delipidized human callus (CAL), human nail (NAI), human 
hair (HAI), bovine hoof and horn (BHH), and sheep wool (WOO). Their suitability 
for predicting keratin binding will be evaluated. CAL, DSC, and BHH have been 
used for such a purpose before (e.g. by Hagedorn-Leweke et al. [181]). Human nail is 
closely related in composition and function to these keratinous substrates. Sheep 
wool keratin has been used extensively for analyzing the thermodynamics of water 
binding to keratin and the diffusion of water through keratin matrices [182, 183]. 
Human hair being the equivalent to animal wool this matrix was also included in 
the analysis. 
For this purpose we collected and, if necessary, re-analyzed binding data from the 
literature. Keratin affinity was expressed as a Nernst binding coefficient, i.e., in 
terms of a linear binding isotherm which is also equivalent to a partition coefficient. 
This approach is appropriate for bound concentrations that are far away from satu-
ration of binding sites. When possible, the binding coefficient was extrapolated to 
the temperature of the human skin surface, 32°C. As data for hydrophilic com-
pounds were sparse, binding to BHH and/or DSC was measured for five additional 
hydrophilic substances (glucose, mannitol, nicotinamide, nicotine, and sucrose).  
Furthermore, if lipophilicity is indeed the main factor determining binding as sug-
gested elsewhere [64, 179], then pH-induced changes should be compensated for by 
correcting logK for pH and using logD in the regression analysis. By this means the 
correlation would be broadened to also predict protein binding of ionizable com-
pounds. In the meantime binding to BHH or DSC has been published for other 
ionizable compounds (namely flufenamic acid) however, without looking at the in-
fluence of pH on the binding coefficient [125].  
Therefore, in the present work we present binding data to BHH for one more weak 
acid (diclofenac) and one weak base (nortriptyline) at different pH-values and de-
grees of ionization. Least squares regression analysis of the logarithm of the Nernst 
binding coefficient (logKNernst) was performed using descriptors for molecular size 
(molecular weight, MW), lipophilicity (logarithmic octanol water partition coeffi-
cient corrected fro pH, logD) and number of H-bond donor- and acceptor-groups in 
a molecule (Hbd, Hba). Furthermore a SMARTS-search was performed looking for 
aromatic rings, acid and basic groups as additional descriptors for keratin binding.  
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6.1.3 Data gathering and data treatment 
Data that was measured and gathered is summarized in  [178]. The procedure of data 
measurement is not shown in this thesis but can be found elsewhere [178]. A Nernst 
isotherm assumes that the relationship between bound (q) and free concentration 
(cfree) at equilibrium is linear with the factor of proportionality being the Nernst 
binding coefficient KNernst 
q = KNernst ⋅c free  Equation 6-1 
This is true as well for the low concentration limit of the Langmuir and the BET 
isotherm 
freeLangm.
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Equation 6-3 
Here kLangm. and qˆ  are the Langmuir binding coefficient and the maximum adsorp-
tion capacity of the monolayer while kBET is the BET binding coefficient. The BET 
isotherm is further limited by the saturation concentration of the compound csat. 
Therefore, as cfree → 0, the product of kLangm. and qˆ as well as the product of kBET., qˆ , 
and csat become equivalent to KNernst. If Langmuir or BET binding coefficients were 
provided in the original literature these were converted to kLangm. and kBET expressed 
as ml/mmol and qˆ  as mmol/g. If the data was presented graphically with no bind-
ing coefficients provided in the original literature we estimated the data from the 
plots to the best of our ability, re-plotted them expressing the amount adsorbed per 
gram protein (q) as mmol/g and the free concentration at equilibrium (cfree) as 
mmol/ml and fitted them to the appropriate model according to the former equa-
tions. 
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For those compounds where the influence of temperature on binding had been in-
vestigated logKNernst was extrapolated to 32 °C according to the Arrhenius relation-
ship 
T1KNernst /ln ∝  Equation 6-4 
6.1.4 Data analysis of the extended database 
The extended database contains 75 chemically diverse substances (MW 32 to 1373; 
logD -4.78 to 5.70; sum of H-bond acceptor and donor groups 0 to 41) [178]. Values 
for MW, logD, and numbers of H-bond donor and acceptor groups were retrieved 
from ACD/PhysChem 10.02 software. For logD, experimental values were preferred 
if available. Raykar and coworkers had reported a direct relationship between the 
logarithmic partition coefficient into DSC (which is the equivalent to the Nernst 
binding coefficient) and the logarithmic octanol-water partition coefficient logKO/w 
indicating that partitioning is governed by the lipophilicity of the compound [64, 
179]. We have now widely broadened the spectrum of keratinous substrates and 
substances that have been investigated. Figure 6-1 shows the relationship between 
logKNernst and logD with the individual keratinous substrates indicated as symbols. 
The original linear regression done by the Anderson group is shown together with a 
novel linear regression analysis performed for BHH, CAL, and DSC. Binding to 
HAI, and WOO is markedly different from the other keratinous substrates and will 
therefore be analyzed separately. Figure 6-1 confirms for a much larger database 
that for keratinous substrates such as BHH, CAL, and DSC the Nernst binding co-
efficient is directly related to the octanol-water partition coefficient as had been pro-
posed by the Anderson group. This relationship was further evaluated by defining 
subsets of the individual keratinous substrates and performing a linear regression 
analysis for these subsets as well as for the complete dataset assuming a linear en-
ergy relationship between binding to the respective keratins and octanol–water par-
titioning (Figure 6-2). The slopes were not significantly different for subset 1 
(BHH), subset 2 (combines CAL and DSC) these are morphologically closely relat-
ed), and the combination of subset 1 and 2 [one-way analysis of variance (ANOVA), 
not shown here] In comparison to the earlier results reported by the Anderson 
group the present correlation is slightly steeper due to the broadening of the data-
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base (although not significantly so, according to a one-way ANOVA). 
 
Figure 6-1  The logarithmic Nernst coefficient is shown as a function of lipophili-
    city for binding to BHH (filled triangle), CAL (filled square), DSC  
    (filled circle), HAI (open inverted triangle), NAI (open triangle), WOO 
    (open circle). The original regression analysis by the Anderson group 
    (solid line) is shown. 
While the slope of two subsets (BHH and CAL/DSC) are comparable the offset of 
subset BHH  is twice as high as the offset of subset CAL/DSC. Therefore the good-
ness of fit for the combination of subset BHH and CAL/DSC is noticeably de-
creased compared to the individual fits (not shown here). Due to the similar slope 
found for the subsets it is easily possible to correct the experimental values meas-
ured for one of the two for the difference in offset between the subsets. Specifically, 
we subtracted the difference of the offsets determined for the subsets from experi-
mental values measured for BHH. Subsequently a linear regression analysis was 
performed for the unified dataset (Figure 6-3). 
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Figure 6-2  The logarithmic Nernst coefficient is shown as a function of lipophili-
    city together with the results of a linear regression analysis for bin- 
    ding to BHH (filled circle, solid line) and CAL and DSC (open triange, 
    dashed line). 
 
 138 
 
Figure 6-3  The logarithmic Nernst coefficient is shown as a function of lipophili-
    city for the unified dataset, i.e. binding coefficients to BHH corrected 
    for difference in offset (filled circles), CAL, and DSC (open triangles). 
    A linear regression analysis of the complete dataset is performed (so
    lid line). 
6.1.5 Binding to bovine hoof and horn and human delipidized stratum 
corneum, ionizable compounds 
Figure 6-4 highlights subset BHH/DSC among the complete dataset which encom-
passes only acidic and basic compounds. The purpose of analyzing this subset sepa-
rately is to evaluate whether binding of ionizable compounds answers to the same 
principles as neutral compounds or whether additional aspects such as the charge 
play a role. The experimental conditions for the acids and bases considered here 
were such that the degree of ionization varied largely between these compounds 
spanning a range between 0.99 and 99.98%. Obviously, for acids and bases as well 
the main determinant for binding is lipophilicity. In consequence logKNernst can be 
predicted from logD for ionizable compounds. It is not surprising that due to the 
limited number of data in this subset the slope is slightly different from the com-
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plete dataset. Upon visual inspection of Figure 6-4 it becomes however clear that 
there are no fundamental differences between this subset and the remaining data. 
 
Figure 6-4  The logarithmic Nernst coefficient is shown as a function of lipophili-
    city together with the results of a linear regression analysis for bin- 
    ding to BHH (triangles), CAL (squares), DSC (circles). Only acids and 
    bases are considered. 
6.1.6 Binding to human hair and sheep wool keratin 
Binding to HAI and WOO seems to be governed by distinctly different principles 
compared to the other keratinous substrates (Figure 6-1). Regression analyses show 
that logD is no significant determinant for logKNernst [178]. The best prediction is 
achieved based on the molecular weight, closely followed by the number of H-bond 
acceptor and H-bond donor groups in the molecule. However, in all cases the corre-
lations are poor. A multiple linear regression analysis based on the four determi-
nants is not feasible as MW, Hba, Hbd are collinear and logD is neither a significant 
descriptor in itself nor in combination with any of the other descriptors. The results 
of the regression analysis confirm that lipophilicity is not a major factor determin-
ing binding to HAI and WOO. It may be that changes in pH led to structural 
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changes in the protein entailing changes in the binding affinity or number of avail-
able binding sites, phenomonena which cannot be accounted for by using logD. 
6.1.7 SMARTS analysis 
To investigate the correlation between the occurrence of certain chemical groups or 
structures and the protein binding affinity in different keratin matrices we gathered 
the corresponding SMILES from www.chemspider.com [184]. Accordingly, we 
searched for compounds with no ring system, compounds with alkaline groups and 
compounds with acidic groups using the obgrep tool from the Open Babel Package , 
version 2.0.1 and used the assistant SMARTS search suggestions from iBabel [185]. 
Figure 6-5 shows the chemical profile for binding to HAI and WOO respectively, 
generated in a SMARTS search.  
 
Figure 6-5  The logarithmic Nernst coefficient is shown as a function of lipophilicity for bin-
    ding to HAI (solid/bold symbols) and WOO (open/light symbols) and a SMARTS 
    analysis is performed. The following structural/chemical properties are indica-
    ted: No ring system (square), acidic group (circle), basic group (cross) and  
    remainder (triangle). Combinations of symbols are possible (e.g. cross and filled 
    circle for a compound binding to HAI having acidic and basic groups). 
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The question that can be answered with a SMARTS search is whether the remain-
ing scatter of the data can be explained by the presences or absence of chemical 
structural features. For HAI and WOO the presence of aromatic rings seems to no-
tably improve the binding affinity. Substances missing this feature are grouped at 
the bottom of the plot exhibiting logarithmic binding coefficients in the negative 
range or not greater than 1. Compounds that have acidic or basic groups tend to 
have higher logKNernst values. Especially those compounds having both acidic and 
basic groups tend to have the highest logKNernst values in the set of compounds that 
was investigated. 
6.1.8 Conclusion 
BHH, CAL, DSC and possibly also NAI are adequate surrogates for binding to SC 
keratins. This is not the case for HAI and WOO. Binding to SC keratins can be pre-
dicted from the lipophilicity of the solute according to a linear free energy relation-
ship to logKO/w. Ionizable compounds can be integrated into this relationship by 
using logD instead. This result suggests that binding to SC keratins is mainly a lipo-
philicity driven process. An earlier relationship developed for a much smaller da-
taset was confirmed and refined. Based on the extended dataset we could show that 
the relationship between logKNernst and logKO/w is steeper than originally assumed. 
This finding has consequences for the estimates of SC partition and diffusion coef-
ficients. 
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6.2 Adressing skin topograhy by means of a 2D diffusion 
model  
 
Images provided in this section have been taken from the master's thesis of Jan 
Riehm ("JSkin – A real-geometry based transdermal 2D skin diffusion model" 
(2013), Saarland University). Parts were taken from a manuscript in preparation for 
publication (written by J. Riehm and D.Selzer). 
 
The author of the thesis made the following contributions: 
Developed the concepts and provided advice and supervision to Jan Riehm during 
the work on his master's thesis at the Institute for Biopharmaceutics and Pharma-
ceutical Technology at Saarland University. 
 
Jan Riehm developed the mathematics, implemented the software, did the analysis 
and produced the images. 
 
6.2.1 Note 
This section briefly summarizes the preliminary results of the study. Details on the 
implementation of the algorithms and in-depth analysis of the data is not presented 
in this thesis. 
6.2.2 Introduction 
Substance skin absorption is gaining enhanced interest in the field of pharmaceu-
tics, cosmetics and risk assessment. To overcome ethical concerns regarding animal 
studies and human in-vivo investigations in-silico approaches are considered an al-
ternative approach. These mathematical based models typically assume a simplified 
flat skin surface – a situation that is not consistent with the wrinkled topography of 
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native human skin. Here, we present the preliminary results of in-silico simulations 
to investigate the influence of a wrinkled skin topography on substance absorption 
kinetics. 
6.2.3 2D-Diffusion model 
To simulate substance transport with respect to a non-trivial skin surface a two-
dimensional diffusion model was developed. The underlying diffusion equation 
(Equation 1-3) was solved numerically with the help of an explicit finite differences 
approach. The solver was implemented in C++ and CUDA-C to parallelize the com-
putations on the GPU-level. Periodicity in the horizontal direction of our test geom-
etry was implemented by applying periodic boundary conditions. Hindered diffu-
sion (inaccessible areas) was modeled using reflecting boundary conditions. Change 
of diffusivity and partition effects with respect to the different skin layers was mod-
eled similar to the 1D-approach presented in Chapter 5. The spatial domain was dis-
cretized using a uniform grid with a resolution of 1 µm. 
6.2.4 Test geometries and test set library 
Two test systems were created that are both 60 μm in width and 195 μm in height. 
Starting with the naive system (smooth SC), we have a donor compartment with a 
depth of 80 μm, a SC with 15 μm in thickness and a VE compartment with a height 
of 100 μm. All these compartments are rectangular in shape (Figure 6-6 A). The 
wrinkled geometry is more complex and shown in Figure 6-6 B. Integration of a 
pan that represents a wrinkle was accomplished by using a sine function in combi-
nation with a horizontal line at the borders that mimics a typical wrinkle formation. 
To preserve the thickness of the SC over the whole width of the system, we applied 
the normal of the function at each point and plotted a line with a distance of 15 μm 
along it. This symmetrical function was chosen to apply periodic boundary condi-
tions on the sides. For infinite dosing we chose Dirichlet boundary conditions at the 
top and perfect sink conditions on the bottom to measure the accumulated mass in 
the sink. The depth of the pan was chosen to be 30 μm and has a width of 20 μm 
(on the upper end).  
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A     B  
Figure 6-6   Snapshots of the naive (A) and wrinkled (B) model geometry. 10 pixels corres-
    pond to 1μm. Grid size was 10x10 pixels. The blue compartment denotes the 
    donor, the aquamarine one the SC with a thickness of 15 μm and the red com-
    partment denotes the VE. The depth of the wrinkle was chosen to be 30 μm. 
Due to the wrinkled structure and the simultaneously unchanged width and height 
of the whole system, we had to normalize the computed values according to the vol-
ume fractions of each domain within the system. Both systems have a depth of 1 μm 
and subsequently the surface area of the SC exposed to the donor was 60 μm2 for 
the naive case and 120 μm2 for the wrinkled one. This also affected the size of the 
VE compartment. 
 
After construction of geometries we created a test set of 9 combinations of different 
diffusion and partition coefficients (see Table 6-1). This was accomplished to inves-
tigate diffusion kinetics under different standardized conditions. A model substance 
of approximately 194 Da (comparable to e.g. caffeine (CAF)) was used to generate 
and gather basis values for diffusivities. An aqueous donor was modeled with a dif-
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fusion coefficient DDON of 1.00E-06 cm
2/s that was approximated according to 
[186]. DDON was never changed in the set since the effect of one magnitude in diffu-
sivity did not affect permeability and tlag. The diffusivity inside the SC and VE was 
assumed to be equal to CAF [125] for the basic tests (T1.1 - T1.3). Partitioning was 
varied (T1.1 - T1.3, T1.4 -T1.6 and T1.7 - T1.9) in a physically sound fashion (e.g. sub-
stances that solve better in the lipophilic SC than in water should mimic the same 
distribution characteristics at the boundary of the hydrophilic VE and lipophilic SC). 
DSC and DVE were varied within one magnitude (slower for T1.7 - T1.9 and faster for 
T1.4 - T1.6). The test set includes parameters that resemble small, medium sized 
and heavy molecules that are hydrophilic or lipophilic in character (good or poor 
solubility in the SC).  
Table 6-1  Test set to investigate influence of different partition and diffusion coefficients 
    on wrinkled and naive geometry. 
Test ID DDON [cm
2/s] DSC [cm
2/s] DVE [cm
2/s] KSC/DON KVE/SC 
T1.1 1.00E-06 9.00E-11 6.00E-07 1.00 1.00E-01 
T1.2 1.00E-06 9.00E-11 6.00E-07 10.00 1.00E-03 
T1.3 1.00E-06 9.00E-11 6.00E-07 1.00E-01 10.00 
T1.4 1.00E-06 9.00E-10 6.00E-06 1.00 1.00E-01 
T1.5 1.00E-06 9.00E-10 6.00E-06 10.00 1.00E-03 
T1.6 1.00E-06 9.00E-10 6.00E-06 1.00E-01 10.00 
T1.7 1.00E-06 9.00E-12 6.00E-08 1.00 1.00E-01 
T1.8 1.00E-06 9.00E-12 6.00E-08 10.00 1.00E-03 
T1.9 1.00E-06 9.00E-12 6.00E-08 1.00E-01 10.00 
 
6.2.5 Influence of wrinkles on infinite dose absorption kinetics  
The human skin is not smooth but it is wrinkled and full of surface irregularities. 
Therefore, we investigated the influence of a wrinkled structure on diffusion kinet-
ics in contrast to a smoothed structure (flat skin surface). For this and the following 
sections we denote the wrinkled case as "wrinkled" (W) and the smooth case as "na-
ive" (N). The results from our measurements are presented in terms of the permea-
tion kp and the lag-time tlag. We investigated an infinite dose application scenario 
with the aforementioned geometries and 9 different combinations of different 
combinations of diffusion and partition coefficients.  The results for permeability 
values are presented in Table 6-2. 
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Table 6-2  kp values calculated with the help of the 2D diffusion model for the wrinkled  
    and naive geometries and the ratio of both. 
Test ID kp wrinkle [cm/h]  kp naive [cm/h]  kp ratio (W/N)  
T1.1 2.43E-04 1.65E-04 1.48 
T1.2 1.16E-04 6.00E-05 1.93 
T1.3 3.10E-05 2.16E-05 1.44 
T1.4 2.42E-03 1.64E-03 1.47 
T1.5 1.16E-03 6.06E-04 1.91 
T1.6 3.09E-04 2.16E-04 1.43 
T1.7 2.33E-05 1.57E-05 1.48 
T1.8 5.46E-05 2.98E-06 1.83 
T1.9 3.07E-06 2.14E-06 1.43 
 
The kp values of the wrinkled geometry are always larger than their counterparts 
from the naive geometry (see column ratio of Table 6-2). The ratio did not change 
much with changing diffusion coefficients but changed with altering partition coef-
ficients. The bigger the difference in partition coefficients (KVE/SC , KSC/DON) 
the stronger the influence of geometry. 
Table 6-3  tlag values calculated with the help of the 2D diffusion model for the wrinkled  
    and naive geometries and the ratio of both.  
Test ID tlag  wrinkle [h]  tlag naive [h]  tlag ratio (W/N)  
T1.1 1.68 1.72 0.974 
T1.2 5,76 5.16 1.11 
T1.3 1.21 1.18 1.02 
T1.4 0.17 0.17 1.00 
T1.5 0.63 0.58 1.10 
T1.6 0.09 0.13 0.71 
T1.7 15.23 15.56 0.98 
T1.8 22.32 22.36 0.99 
T1.9 11.73 11.52 1.01 
 
Next we computed the lag-time with the help of the diffusion model. The lag-time 
describes the point in time when the system overcomes the exponential increase in 
mass inside the acceptor compartment and reaches towards steady-state.  
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An overview of the computed values is given in Table 6-3. For the faster diffusion 
coefficients in T1.4–T1.6 the lag-times are lowest and for the slowest diffusion coef-
ficient in T1.7-T1.9 the lag-times are highest. As expected, the ratios are close to one 
assuming no huge influence of geometry on lag-time. We only saw a large differ-
ence in test case T1.6 with a ratio of 0.71. If a substance does not have to establish a 
jump in concentration (KSC = 1) and moves extremely quick inside the SC (high 
diffusivity) the fill-up of the SC with a higher volume (wrinkled case) does influence 
the time needed to reach steady-state significantly. As seen in Table 6-3 this literally 
only holds true for this special case with this extremely low lag-times (between 5.4 
and 7.8 minutes to overcome the SC and VE).  
There is strong evidence that the reason for higher permeabilities observed in the 
case of wrinkled geometries originates from the higher surface area of the SC that is 
exposed to the VE. As depicted in Figure 6-7 (exemplary from T1.2) the differences 
of average concentrations within the SC for the wrinkled and naive case are ex-
tremely small while there are high differences within the VE.  
A B  
Figure 6-7   Average concentrations from T1.2 in the different compartments over time for 
    the wrinkled and naive geometry (A: SC, B: VE). 
Here, the average concentration is approximately two times higher for the wrinkled 
case in contrast to the naive case. This effect explains higher permeabilities for the 
wrinkled case since a higher concentration gradient inside the VE towards the sink 
can be established resulting in a stronger outgoing flux.  
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In summary, the created wrinkled geometry clearly leads to a higher permeability in 
comparison to flat skin surface and the effect is independent of change of partition 
coefficients and diffusion coefficients within the range of investigation. The influ-
ence on lag-time is typically negligible for risk assessment and pharmaceutical ap-
plication since differences were only detected for a test candidate with a lag-time 
within the minute range.  
6.2.6 Hindered diffusion 
With our next application scenario we intended to investigate the influence of air 
bubbles on top of the skin surface. For example, when a transdermal patch is ap-
plied to the skin, it might not lay rigid on the skin surface. Since the skin is wrin-
kled and irregular on the surface it might happen that air bubbles occur under the 
patch (between donor and SC). In our model, air bubbles are designed as inaccessi-
ble parts of the system. Due to that fact, diffusion must occur along the boundaries 
of those air bubbles. To have a standard and to study the behavior for the wrinkled 
and non-wrinkled case we chose the presented standard geometries. The parameters 
of T1.2 were chosen for the modeling approach. Hindered diffusion was simulated 
by placing an air bubble into the mould of the wrinkle as well as on the flat SC of 
the naive geometry. Assuming infinite dose conditions, periodic boundaries on the 
left and right side and perfect sink conditions on the bottom, we performed three 
different runs over 2500 minutes on the two geometries under the following condi-
tions:  
1. Wrinkled geometry: 
 1.1 No air bubble  
 1.2 Air bubble covering 23.3% of the surface of the SC (23IS)  
 1.3 Air bubble covering 43.3% of the surface of the SC (43IS)  
2. Naive geometry: 
 2.1 No air bubble 
 2.2 Air bubble covering 23.3% of the surface of the SC (23IS)  
 2.3 Air bubble covering 43.3% of the surface of the SC (43IS)  
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As stated before, the depth of the wrinkle was fixed at 30 µm. We placed air bubbles 
with a height of 8 µm and 15 µm (starting from the bottom) into the wrinkle. Hence 
the area that was occupied by the air bubbles corresponds to 23.3% and 43.3% of the 
surface of the wrinkled SC. Starting from the wrinkled case, we adapted the values 
of the inaccessible surface and applied it to the naive geometry (equal surface cover-
ing and equal bubble volume in comparison to the wrinkled case).  
We computed the kp values and lag-times. The computed values are displayed in 
Tables 6-4 and 6-5. As expected, the diffusant needs more time to reach the steady-
state for the non-hindered counterparts (between 65% and 100% more time for the 
wrinkled case and between 32% and 69 % more time for the naive case). Addition-
ally, the kp values are smaller as for the non-hindered geometries (between 16% and 
25% for the wrinkled case and between 9% and 10 % for the naive case). When 
comparing the ratios of the kp values and lag times between the hindered and non-
hindered geometries, on can observe an increase for tlag and a decrease for kp for the 
hindered geometries. With increasing size of the inaccessible surface area the per-
meation gets worse and the ratio between wrinkled and naive geometry decreases. 
The larger the inaccessible surface the larger the lag-time. As for the fully accessible 
case the wrinkled structure shows a higher permeability but needs more time to 
establish the steady-state. Besides the same surface coverage the effect on permea-
bility and lag-time is much higher in case of the wrinkled geometry in comparison 
to the naive case.  
Table 6-4  tlag values calculated with the help of the 2D diffusion model for the wrinkled  
    and naive geometries and the ratio of both (hindered diffusion) 
Geometry tlag  wrinkle [h]  tlag naive [h]  tlag ratio (W/N)  
23IS 9.48 6.79 1.39 
43IS 11.59 8.71 1.33 
 
Table 6-5  kp values calculated with the help of the 2D diffusion model for the wrinkled  
    and naive geometries and the ratio of both (hindered diffusion) 
Geometry kp  wrinkle [cm/h]  kp naive [cm/h]  kp ratio (W/N)  
23IS 9.70E-05 5.45E-05 1.78 
43IS 8.70E-05 5.37E-05 1.61 
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In summary we could show that besides the same surface coverage of inaccessible 
parts the influence on wrinkled geometry is much higher (higher factor of kp reduc-
tion) as for the naive case.  
6.2.7 Conclusion 
Simulation of infinite dosing using a two-dimensional numerical diffusion model 
clearly showed the theoretical influence of skin topography on skin absorption.  In 
comparison to a wrinkled geometry permeability was lower for an idealized flat skin 
surface. These findings were independent of any combination of tested partition 
and diffusion coefficients addressing the SC and viable epidermis. In comparison to 
the idealized case, the increased SC surface area seems to be responsible for this 
effect. Simulations with incomplete formulation coverage on the surface of the skin 
revealed a delayed and reduced skin absorption process in dependence of the degree 
of coverage for an idealized flat skin surface and a wrinkled geometry. However, this 
effect was expressed much stronger for incomplete filled wrinkles. The differences 
in lag-time seem to be negligible for risk assessment and pharmaceutical applica-
tion.  
In conclusion, the simulation of different application scenarios provides evidence 
that the distribution of formulation on the skin as well as the in-vivo skin topogra-
phy should be considered when investigating skin absorption processes. The im-
portance of these findings in regard to therapeutic formulation application should 
be investigated experimentally in future studies. Data on formulation distribution 
on the skin surface is still scarce. A potential technique to obtain this information 
could be MS-Imaging that has the potential to visualize and quantify the compound 
with respect to the spatial compound distribution [187].  
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6.3 Mathematical assistance to address the problem of 
confocal Raman microscopy signal attenuation in 
measuring transdermal drug transport 
Parts of this section have been published in: 
Franzen, L., Selzer, D., Fluhr, J., Schaefer, U. F., Windbergs, M. (2013). Towards 
drug quantification in human skin with confocal Raman microscopy. Eur J Pharma-
ceut Biopharmaceut, 84(2), 437–444 
 
The author of the thesis made the following contributions to the publication: 
Performed the mathematical analysis of the data (fitting of the data and profile cor-
rection) and wrote parts of the manuscript. 
Lutz Franzen performed the experiments and wrote the manuscript. 
 
6.3.1 Note 
This section shortly summarizes the contributions of the author on the correction of 
the Raman intensity depth profiles for signal attenuation within a skin surrogate to 
allow concentration-depth profiling of the skin using Raman microscopy. The full 
article on this topic can be found elsewhere [188].  
6.3.2 Introduction 
Investigation of substance penetration thought human skin is an important part for 
rational drug development addressing the delivery via the skin route. Information of 
substance distribution inside the distinct skin layers is of special interest since it 
provides a clearer picture about the absorption mechanism. The analysis of penetra-
tion processes in the different layers is a complex and laborious procedure which 
requires destructive segmentation as well as extraction [189]. Furthermore, the ana-
lytical determination lacks spatial resolution. Recently, biophysical techniques like 
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confocal laser	  scanning microscopy [190] or two photon microscopy [191] have been 
proven to be of value by providing spatially resolved information about kinetics and 
depth of dermal penetration and molecular interaction with the skin. In this context, 
Raman spectroscopy as a complementary analytical technique to IR spectroscopy 
bears a lot of potential for the analysis of skin. In contrast to IR, Raman spectrosco-
py is not constraint by the presence of water. By detecting the frequency shift of 
scattered laser light after irradiating a sample, chemically selective information of 
the sample composition is acquired. Furthermore, combining Raman spectroscopy 
with a confocal microscope provides spatially resolved analysis of the sample. Thus, 
confocal Raman microscopy is a promising analytical approach for label free and 
non destructive follow-up of substances within human skin.  
Confocal Raman spectroscopy has already been applied for analysis of skin hydra-
tion status [192], the effect of penetration enhancers [193] and the epidermal antiox-
idative potential [194, 195] of skin. However, for rational development and in vitro 
testing of novel dermal drug delivery systems quantitative analysis of drug penetra-
tion processes is mandatory. Unfortunately, so far drug quantification within skin 
based on Raman microscopy is exacerbated by Raman signal attenuation, as with 
increasing depth a decrease in Raman signal intensity distorts reliable drug quanti-
fication. One approach to overcome the influence of Raman signal attenuation in 
skin was already performed by relating the intensity of a drug Raman peak to the 
intensity of a skin derived Raman peak [52]. Unfortunately, as skin is a complex and 
inhomogeneous biological tissue, the intensity changes of a skin derived peak are 
due to Raman signal attenuation as well as unpredictable concentration changes of 
individual compounds within the tissue. For reliable quantification of substances 
inside human skin by Raman microscopy the exact extent of Raman signal attenua-
tion has to be determined. 
Here, we present a novel approach to quantify Raman signal attenuation in human 
skin. A simplified and reproducible surrogate system mimicking the optical proper-
ties of human skin was developed. Caffeine was homogeneously incorporated with-
in the skin surrogate and Raman depth profiles of caffeine were acquired. To ad-
dress the issue of Raman signal attenuation, these profiles were mathematically 
fitted and a	   correction algorithm was derived. Furthermore, excised human skin 
samples (heat-separated epidermis HSE) were incubated with caffeine and Raman 
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intensity depth profiles were acquired. Using the surrogate algorithm, these human 
skin intensity depth profiles were successfully corrected for Raman signal attenua-
tion. Information about the development and characterization of the skin surrogate 
as well as Raman measurements can be found in [188]. 
6.3.3 Correction of Raman signal attenuation 
One aim of the study is to develop a mathematical procedure which allows to correct 
Raman intensity depth profiles for signal attenuation within the surrogate. Based on 
this algorithm, drug concentration profiles with a direct correlation of Raman inten-
sity changes and drug concentration changes shall be realised. In a further step, this 
procedure is meant to be transferred to skin samples for correction of Raman depth 
profiles.  Based on the drug intensity depth profiles of three different skin surro-
gates, a mean curve is calculated. In a next step, the decrease  in this curve is fitted 
by an exponential function (Equation 6-5). Exponential fitting is chosen because it is 
well known that the intensity of  electromagnetic waves undergo an exponential de-
cay while penetrating an opaque medium. To avoid overfitting, a simple exponential 
relationship as presented in Equation 6-5 is applied.  
𝐷(𝑥) =   𝑎  𝑒!!!+(1-a) 
Equation 6-5 
Least-square  regression with constraint D(0) = 1 is applied to mathematically de-
scribe the decrease of the curve, with x being the depth along  the z-axis and x = 0 
being the skin surrogate surface (Equation 6-6).  
𝐷(𝑥) =   0.9997  𝑒! !!".!"#$+(1-0.9997) 
Equation 6-6 
The residual standard error is 0.04848, and the variables a and b are  significantly 
different from zero with p < 0.001. Equation 6-6 exhibits a representative mathe-
matical description of the drug Raman signal intensity attenuation within the skin 
surrogate. Figure 6-8 displays the mean drug intensity depth profile and the corre-
sponding fit (Equation 6-6).  
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Figure 6-8  Raman mean intensity-depth profile for three skin surrogates after caf-  
    feine incorporation fitted by an exponential function (dashed line);    
    mean +/- SD; n = 3 
 
Apart from three single data points within the steepest decrease of the profile, the fit 
accurately describes the recorded data points. To obtain caffeine intensity depth pro-
files based on a direct correlation of Raman signal intensity and caffeine concentra-
tion in the surrogate, the attenuation based intensity decrease has to be mathemati-
cally corrected. Using the attenuation function (Equation 6-6), a signal re-
attenuating algorithm is derived with f(x) representing the detected Raman intensi-
ty at depth x and R(x) representing the corrected signal.  
 𝑅 𝑥 = 𝑓 𝑥 + 1 − (0.9997 ∗ exp − x15.7581   + 1 − 0.9997 ) Equation 6-7 
As the skin surrogate simulates the optical properties of human stratum corneum, 
the re-attenuation algorithm is supposed to correct drug intensity profiles in human 
skin samples. 
For a proof of concept, the re-attenuation algorithm is used to recalculate caffeine 
intensity depth profiles in HSE samples. Figure Equation 6-9 shows mean drug 
intensity depth profiles of two different skin donors based on raw spectral data 
without any correction (solid line) and after processing the data with the re-
attenuation algorithm (dashed line).  
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Figure 6-9  Raman mean intensity-depth-profile for donor A and B (solid line) and   
    corrected profile (dashed line) mean +/- SD; n = 3 
 
After correction, the drug intensity depth profiles exhibit a nearly constant Raman 
intensity, which is directly related to the drug concentration within the whole skin 
sample. A slight deviance in the first part of the corrected profile is based on a less 
accurate fit in the steep part of the profile as discussed above. Incubating the skin 
samples in caffeine solution bypasses the stratum corneum barrier function and 
facilitates complete soaking with drug solution. Assuming that the caffeine concen-
tration is constant in each depth in the HSE, a calculated constant intensity of the 
caffeine related Raman peak over depth in HSE is plausible. These results indicate 
the suitability of the correction algorithm to correct intensity depth profiles for Ra-
man signal attenuation. So far, most studies relied on a relative method to deal with 
Raman signal attenuation. By applying this method, the intensity of a drug repre-
senting Raman peak is related to a skin derived Raman peak [52, 196]. Inconsisten-
cies in Raman peak intensity due to inhomogenities in skin composition are poten-
tially causing uncertainties in depth profiling. Against this background, our novel 
approach to quantify Raman signal attenuation in a chemical skin surrogate with 
similar optical properties as skin and to generate a mathematical algorithm for cor-
rection of attenuation within skin samples bares many advantages. This approach 
potentially allows direct quantification of drug in skin tissue solely based on Raman 
peak intensities. Furthermore, the influence of skin inhomogenities on concentra-
tion depth profiles is reduced. On the contrary to the existing qualitative and semi-
quantitative studies, this facilitates the acquisition of quantitative concentration 
depth profiles [52, 193]. However, future studies will investigate the applicability of 
the developed algorithm on a larger set of different drug depth profiles including a 
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comparison of Raman spectroscopy results and established standard techniques for 
the acquisition of drug depth profiles. 
6.3.4 Conclusion 
A mathematical function for the description of Raman signal attenuation in the skin 
surrogate was derived from an incubation study with a homogeneously distributed 
model drug and successfully applied to correct drug intensity depth profiles in hu-
man skin. This novel mathematical approach serves as a first step towards a reliable 
acquisition of drug concentration profiles by confocal Raman microscopy. 
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7 Summary 
Mathematical models for the simulation and prediction of transdermal absorption 
can be considered as an alternative to ethically problematic in-vivo experiments on 
humans and animals. Reasonable approaches for prediction are typically based on 
previously generated experimental data – either to verify the model against a valida-
tion set or to use statistical methods to estimate model input parameters. For both 
cases, high quality in-vitro or in-vivo data is needed. In the presented work, various 
studies on the improvement and correction of experimental data were elaborated. 
Furthermore, mathematical models were developed to provide a better in-vitro and 
in-vivo prediction of substance transport through the skin.  
First, the influence of the application area on finite dose permeation kinetics was 
investigated. Here, the in-vitro absorption of two model compounds (hydrophilic 
caffeine (CAF) and lipophilic flufenamic acid (FFA)) was analyzed for finite dosing. 
By application of different dyes the surface distribution of the different formulations 
could be visually determined. Using an automated, computer-controlled approach, it 
was possible to characterize and quantify the exact wetting of formulation. Using 
this information, the experimental permeation data could be corrected by the area of 
application. It was found that the permeation of the hydrophilic caffeine is highly 
dependent on the application area and a correction of the experimental data yielded 
a significant decrease in the variability of the experimental data.  However, a correc-
tion of the experimental data of the lipophilic flufenamic acid greatly increased the 
variability. Skin biopsies after application of the formulations showed that caffeine – 
in contrast to flufenamic acid – did not distribute laterally. Thus, it can be said that a 
correction of experimental finite dose permeation data should be conditioned on the 
chemical properties of the active compound (likely lipophilicity). 
During the investigation of the surface distribution of substance formulations, addi-
tionally, preliminary studies on the effect of skin topography on the absorption be-
havior were conducted. Here, a two-dimensional, numerical diffusion model was 
developed to investigate the in-vivo situation applying formulations on wrinkled 
skin. It could be shown that wrinkles might have an influence on the permeability.  
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In comparison to an idealized, smooth skin surface without skin furrows and wrin-
kles simulations have shown a significant increase in the calculated permeability for 
a wrinkled skin model when assuming perfect formulation coverage of the skin sur-
face. This effect was independent of lipophilicity and size of the permeant. Differ-
ences in lag-time were negligible from a therapeutic point of view. If only part of 
skin surface were covered by formulation, the decrease in permeability for the wrin-
kled skin model was much more pronounced in comparison to the idealized, 
smooth skin model. 
When investigating finite dosing, a complete mass balance is of great importance to 
obtain a complete picture of the underlying kinetic processes. In studies concerning 
in- vitro finite dose penetration of FFA and CAF using a Franz diffusion cell, a mass 
balance covering various (skin) compartments (donor SC, DSL, lateral skin part) was 
conducted. For both compounds high amounts of substance were found in the so-
called lateral part (part of the test skin outside of the application area). Subsequent-
ly, the experimental setup was examined using three mathematical models: A 
pharmacokinetic model, a microscopic diffusion model and a homogenized diffu-
sion model. The pharmacokinetic model was fitted to the data. The two diffusion 
models used experimentally determined model input parameters gathered from 
studies on infinite dosing. All models were able to satisfactorily describe and predict 
the experimental data. However, in comparison to the other models, the microscop-
ic diffusion model showed the worst performance - the only model without a mod-
eled lateral part. These findings provided evidence not to elide the lateral compart-
ment when modeling in-vitro finite dosing. 
Since the collection of necessary input parameters for microscopic diffusion models 
is a difficult and work-intense process, a simple-to-use strategy for the prediction of 
in-vivo penetration was developed. Here, in-vitro and in-vivo skin penetration exper-
iments of the model compound flufenamic acid solved in an ointment was investi-
gated by means of a mathematical model. Experimental stratum corneum concentra-
tion-depth profiles (SC-CDP) for various time intervals using two different in-vitro 
systems (Franz diffusion cell, Saarbruecken penetration model) were examined and 
simulated with the help of a highly optimized three compartment numerical diffu-
sion model and compared to findings of SC-CDPs of the in-vivo scenario. Fitted 
model input parameters (diffusion coefficient and partition coefficient with respect 
Summary 
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to the stratum corneum) for the in-vitro infinite dose case could be used to predict in-
use conditions in-vitro. Despite apparent differences in calculated partition coeffi-
cients between in-vivo and in-vitro studies, prediction of in-vivo scenarios from input 
parameters calculated from the in-vitro case yielded reasonable results. 
Traditional techniques for the determination of skin concentration-depth profiles 
are invasive and lack spatial resolution. Optical methods could overcome these dis-
advantages. Confocal Raman microscopy bares the potential due to its non-
destructive, label-free and chemically selective properties. However, the quantifica-
tion of a substance inside the skin is impeded by attenuation of the Raman signal. A 
first try was made to solve this problem. Here, the signal attenuation was corrected 
for a skin surrogate using a simple algorithm. Subsequently, its applicability was 
demonstrated by correcting human concentration-depth profiles. 
When modeling skin absorption, often the reversible binding to keratins within the 
skin is neglected. This may have consequences for the determination of partition 
and diffusion coefficients. A relationship between binding affinity of a drug and its 
octanol/water partition coefficient has been known for some time. However, the 
known model to predict binding affinity was only validated using a very limited da-
taset. Therefore, we extended the known record for binding data with respect to dif-
ferent keratin sources (delipidized SC, bovine hoof and horn, human hair, human 
nail and sheep wool). It was shown that only keratins originated from delipidized 
SC, bovine hoof and horn as well as human nail represent useful keratin sources. 
Moreover, we could confirm the former mentioned relationship for our extended 
database on keratin binding. It was also possible to predict the binding of ionizable 
compounds by using the pH-corrected logD. 
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8 Zusammenfassung 
Mathematische Modelle zur Simulation und Vorhersage transdermaler Absorption 
stellen eine Alternative zu ethisch problematischen in-vivo Versuchen an Mensch 
und Tier dar. Sinnvolle Konzepte zur Vorhersage stützen sich in den allermeisten 
Fällen auf vorher generierte experimentelle Daten – sei es, um die Qualität des Mo-
dells gegen ein Validierungsset zu testen oder um mit Hilfe statistischer Methoden 
Modelleingabeparameter abzuschätzen. In beiden Fällen ist eine hohe Qualität der 
erhobenen in-vitro oder in-vivo Daten von großer Notwendigkeit. Im Rahmen dieser 
Arbeit wurden verschiedene Studien zur Verbesserung und Korrektur experimen-
teller Daten erarbeitet und mathematische Modelle entwickelt, um eine bessere in-
vivo und in-vitro Vorhersage des Substanztransports durch die Haut zu ermögli-
chen. 
Zuerst wurde der Einfluss der Applikationsfläche bei finiter Dosierung auf die 
Permeationskinetik untersucht. Hierbei wurde die Absorption zweier Modellsub-
stanzen (das hydrophile Kaffein (CAF) und die lipophile Flufenaminsäure (FFA)) in 
finiter Dosierung in einem in-vitro Aufbau untersucht. Durch eine Einfärbung der 
wässrigen Substanzformulierungen konnte die Oberflächenbenetzung der aufge-
tragenen Formulierungen visuell bestimmt werden. Mit Hilfe eines automatisier-
ten, computergesteuerten Ansatzes war es möglich, die genaue Benetzung zu cha-
rakterisieren und zu quantifizieren. Mithilfe dieser Informationen konnten die ex-
perimentellen Permeationsdaten anhand der Applikationsfläche korrigiert werden. 
Es zeigte sich, dass die Permeation des  hydrophilen Koffeins stark von der Applika-
tionsfläche abhängig ist und eine Korrektur der Daten zu einer deutlichen Abnah-
me der Variabilität der experimentellen Daten führte. Eine Korrektur der experi-
mentellen Daten der lipophilen Flufenaminsäure erhöhte jedoch die Variabilität 
dieser Daten stark. Hautbiopsien nach dem Auftragen der Formulierungen zeigten, 
dass Koffein - im Gegensatz zur Flufenaminsäure - keine laterale Verteilung auf-
weist. Zusammenfassend kann somit gesagt werden, dass eine Korrektur experi-
menteller Permeationsdaten bei finiter Dosierung von den chemischen Eigenschaf-
ten (wahrscheinlich Lipophilie) abhängig gemacht werden sollte. 
Zusammenfassung 
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Im Rahmen der Untersuchung der Oberflächenverteilung von Substanzformulie-
rungen wurden außerdem erste Untersuchungen zur Auswirkung der Hauttopo-
graphie auf das Absorptionsverhalten gemacht. Hierbei wurde ein zweidimensiona-
les, numerisches Diffusionsmodell entwickelt, um die in-vivo Situation bei der Ap-
plikation von Formulierungen auf faltige Haut zu untersuchen. Es konnte gezeigt 
werden, dass Hautfalten einen Einfluss auf die Permeabilität haben könnten. Im 
Vergleich mit einer idealisierten, glatten Hautoberfläche ohne Hautfurchen konn-
ten Simulationen bei einer vollständigen Benetzung der Hautoberfläche  eine deut-
liche Erhöhung der berechneten Permeabilität für ein faltiges Hautmodell zeigen. 
Dieser Effekt war unabhängig von Lipophilie und Größe des Permeaten. Unter-
schiede in der Lag-Zeit waren aus therapeutischer Sicht unbedeutend. Bei einer nur 
teilweisen Benetzung der Hautoberfläche war die Abnahme der Permeabilität für 
das faltige Hautmodell wesentlich stärker ausgeprägt, als für das idealisierte, glatte 
Hautmodell. 
Bei finiter Dosierung ist eine vollständige Massenbilanz von großer Bedeutung, um 
ein vollständiges Bild des zugrundeliegenden kinetischen Prozesses zu erhalten. 
Bei Untersuchungen von in-vitro Penetration von FFA und CAF in finiter Dosie-
rung mit Hilfe einer Franz-Diffusionszelle wurde eine Massenbilanz in verschiede-
nen (Haut)Kompartimenten (Donor, SC, DSL, lateraler Hautteil) angefertigt. Für 
beide Substanzen wurden hohe Substanzmengen im sogenannten lateralen Haut-
teil (Teil der genutzten Versuchshaut außerhalb der Applikationsfläche) gefunden. 
Der experimentelle Versuchsaufbau wurde anschließend mit Hilfe dreier mathema-
tischer Modelle untersucht: Ein pharmakokinetisches Modell, ein mikroskopisches 
Diffusionsmodell und ein homogenisiertes Diffusionsmodell. Hierbei wurde das 
pharmakokinetische Modell an die Daten mit Hilfe einer Fitting-Routing angepasst. 
Die beiden Diffusionsmodelle nutzten experimentell bestimmte Modelleingabepa-
rameter aus Untersuchungen mit infiniter Dosierung. Alle Modelle konnten die 
experimentellen Daten zufriedenstellend beschreiben und vorhersagen. Jedoch 
konnte das mikroskopische Diffusionsmodell die Daten am schlechtesten Beschrei-
ben - das einzige eingesetzte Modell ohne modellierten Lateralteil. Dies gab Hin-
weise, dass der laterale Hautteil bei der Simulation von finiter Dosierung in-vitro 
nicht vernachlässigt werden sollte. 
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Da die Bestimmung der notwendigen Eingangsparameter für mikroskopische Dif-
fusionsmodelle einen schwierigen und arbeitsintensiven Prozess darstellt, wurde 
eine einfach anzuwendende Strategie für die Vorhersage von in-vivo Penetration 
entwickelt. Hierbei wurden in-vitro und in-vivo Haut-Penetrationsexperimente der 
Modellverbindung Flufenaminsäure, die in einer Salbe gelöst war, mittels eines 
mathematischen Modells untersucht. Hierzu wurden experimentelle stratum corne-
um Konzentrations-Schicht-Tiefenprofile (SC-CDP) für verschiedene Zeitpunkte 
unter Verwendung von zwei verschiedenen in-vitro Testsystemen (Franz-
Diffusionszelle, Saarbruecken Penetrationsmodell) untersucht  und mit Hilfe eines 
hochoptimierten, numerischen, drei-Kompartiment Diffusionsmodells simuliert. 
Diese Ergebnisse wurden anschließend mit in-vivo SC-CDPs verglichen. Hierbei 
konnten Modelleingangsparameter (Diffusionskoeffizienten und Verteilungskoeffi-
zienten) stammend aus Fittings mit in-vitro Experimenten (infinite Dosierung) ge-
nutzt werden um eine finite Dosierung in-vitro vorherzusagen. Trotz offensichtli-
cher Unterschiede in den bestimmten Verteilungskoeffizienten für den in-vivo und 
in-vitro Fall, konnte eine vernünftige Vorhersage des in-vivo-Szenarios von der Ein-
gangsparameter aus dem in-vitro Fall berechnet werden. 
Traditionelle Techniken zur Bestimmung von Konzentration-Schicht-Tiefenprofilen 
sind invasiv und bereiten Schwierigkeiten bei der Tiefenbestimmung eines extra-
hierten Hautsegments. Optische Methoden könnten diese Nachteile überwinden. 
Die konfokale Raman-Mikroskopie zeigt hierbei durch ihre nicht-destruktiven, 
markerfreien und chemisch selektiven Eigenschaften ein vielversprechendes Poten-
tial. Jedoch wird die Quantifizierung einer Substanz in der Hauttiefe durch  die 
Dämpfung des Raman-Signals behindert. Erste Ansätze zur Lösung dieses Prob-
lems wurden erarbeitet. Hierbei wurde die Signaldämpfung in einem Hautsurrogat 
mit Hilfe eines einfachen Algorithmus korrigiert und seine Anwendbarkeit durch 
die Korrektur von Humanhaut-Konzentration-Schicht-Tiefenprofilen demonstriert. 
Bei der Modellierung von Hautabsorption wird oft die reversible Bindung an Kera-
tin innerhalb der Haut vernachlässigt. Dies kann Konsequenzen für die Bestim-
mung von Verteilungs- und Diffusionskoeffizienten haben. Ein Verhältnis zwi-
schen Bindungsaffinität eines Wirkstoffes und dessen Oktanol/Wasser-
Verteilungskoeffizienten ist schon seit einiger Zeit bekannt. Jedoch wurde ein Vor-
hersagemodell zur Bindungsaffinität nur auf einem sehr limitierten Datensatz vali-
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diert. Deshalb erweiterten wir den bekannten Datensatz um Bindungsdaten bezüg-
lich verschiedenster Keratinquellen (entfettetes SC, Keratin aus Rinderhuf und 
Horn,  Keratin aus menschlichem Haar, Keratin aus menschlichem Nagel und Ke-
ratin aus Schafwolle).  Es konnte gezeigt werden, dass nur entfettetes SC, Keratin 
aus Rinderhuf und Horn und Keratin aus dem menschliches Nagel brauchbare Ke-
ratinquellen darstellen. Weiterhein konnte das bekannten Verhältnisses zwischen 
Bindungsaffinität eines Wirkstoffes und dessen Oktanol/Wasser-
Verteilungskoeffizienten bestätigt werden. Außerdem war es möglich, die Bindung 
von ionisierbaren Verbindungen durch Verwendung der pH-korrigierten logD vor-
herzusagen. 
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Appendix A 
Table A-1  Parameters for simulations with the homogenized diffusion model. A) For the 
    model with one regression parameter (HOM1), all parameters except for DSC are 
    taken from [125]. B) For the model with three regression parameters (HOM3), 
    all parameters except for DDON were optimized according to the parameteriza-
    tion provided in the text. The optimized parameters are labeled with an asterisk. 
    The regression parameters and standard errors for both models are reported in 
    Table A-3. 
 
 
 
  
 Times [min]  FFA CAF (1mg/ml) CAF (12.5 mg/ml) Reference 
A DDON [cm2/h] 2.47E-02 2.92E-02 2.92E-02 Equation 4-4 
 D!",!!∗  [cm2/h] 2.00E-05 3.70E-05 3.70E-05 Equation 4-6 
 D!",!!∗  [cm2/h] 10.43E-07 1.69E-07 2.29E-07 Equation 4-6 
 DDSL [cm2/h] 4.90E-03 2.30E-03 2.30E-03 [125] 
 KSC/DON  5.88 4.70 4.70 [125] 
 KSC/DSL   3.0 27.00 27.00 [125] 
B DDON [cm2/h] 2.47E-02 2.92E-02 2.92E-02 Equation 4-4 
 D!",!!∗  [cm2/h] 1.98E-05 3.70E-05 3.73E-05 Equation 4-6 
 D!",!!∗  [cm2/h] 7.72E-07 1.54E-07 5.97E-07 Equation 4-6 
 D!"#∗  [cm2/h] 3.26E-03 1.87E-03 10.72E-03  
 K!"/!"#∗   8.54 5.77 2.57  
 K!"/!"#∗    4.36 33.13 14.75  
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Table A-2  Rate constants and standard errors (SE) of the pharmacokinetic model 
  
 
 
 
 
Table A-3  Regression parameters for simulations with the homogenized diffusion model.   
 
 
Parameter FFA  Caffeine (1mg/ml)  Caffeine (12.5 mg/ml) 
 Mean [%/min] SE Mean [%/min] SE Mean [%/min] SE 
k1 3,70E-02 3,45E-03 3,81E-03 2,09E-04 5,92E-03 5,68E-04 
k2 4,52E-02 5,29E-03 5,73E-03 4,66E-04 2,11E-02 3,08E-03 
k3 6,78E-03 2,80E-04 2,76E-04 3,14E-04 4,35E-03 1,55E-03 
k4 2,29E-04 2,42E-04 1,52E-03 1,90E-03 2,38E-03 2,68E-03 
k5 1,00E-03 8,42E-04 1,96E-03 7,79E-04 4,52E-03 1,78E-03 
k6 7,12E-04 1,15E-04 1,50E-03 4,06E-04 5,53E-03 1,61E-03 
k7 - - 1,05E-03 4,30E-04 2,13E-03 4,37E-04 
 Parameter  FFA CAF (1mg/ml) CAF (12.5mg/ml) Reference 
A Homogenized model with one regression parameter.  
 DLIP [cm2/h] 1.10E-04 2.10E-04 2.10E-04 [125] 
 θ1  -4.91E+00 ± 9.93E-02 
-9.72E+00 ± 
1.68E+00 
-8.12E+00 ± 
6.65E-01  
 ξ  7.39E-03 ± 7.33E-04  
6.00E-05 ± 
1.01E-04 
2.98E-04 ± 
1.98E-04  
 αSC,rr  1.82E-01 1.76E-01 1.76E-01  
 αSC,zz  9.48E-03 8.06E-04 1.09E-03  
B Homogenized model with three regression parameters. 
 DLIP [cm2/h] 1.10E-04 2.10E-04 2.10E-04 [125] 
 θ1  -5.24 ±  0.11 --- 
-6.33 ±  
0.29  
 θ2  -0.41 ±  0.27 
1.08 ±  
0.37 
1.54 ±  
0.32  
 θ3  -0.37 ±  0.09 
-0.20 ±  
0.07 
0.60 ±  
0.16  
 ξ  5.31E-03 ±  5.65E-04 --- 
1.78E-03 ± 
5.21E-04  
 αSC,rr  1.80E-01 1.76E-01 1.77E-01  
 αSC,zz  7.02E-03 7.35E-04 2.85E-03  
